<SEC-DOCUMENT>0001437749-23-030502.txt : 20231107
<SEC-HEADER>0001437749-23-030502.hdr.sgml : 20231107
<ACCEPTANCE-DATETIME>20231107091944
ACCESSION NUMBER:		0001437749-23-030502
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231107
DATE AS OF CHANGE:		20231107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASSAVA SCIENCES INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29959
		FILM NUMBER:		231382027

	BUSINESS ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PAIN THERAPEUTICS INC
		DATE OF NAME CHANGE:	20000309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sava20230930_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:sava="http://www.cassavasciences.com/20230930" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>sava20230930_10q.htm</title>
  <!-- Generated by ThunderDome Portal - 11/6/2023 11:24:08 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001069530</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">CASSAVA SCIENCES INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="dei:AmendmentFlag" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
<ix:nonFraction id="c104255596" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c104255597" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c104255601" contextRef="i_2023-09-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c104255602" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c104255603" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c104255604" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c104255605" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c104255607" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c104255606" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c104255608" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c104255611" contextRef="i_2023-09-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c104255612" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c104255613" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c104255614" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c104255615" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,129,798</ix:nonFraction>
<ix:nonFraction id="c104255617" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,129,798</ix:nonFraction>
<ix:nonFraction id="c104255616" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,735,557</ix:nonFraction>
<ix:nonFraction id="c104255618" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,735,557</ix:nonFraction>
<ix:nonFraction id="c104255953" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c104255958" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c104256090" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">119,000</ix:nonFraction>
<ix:nonFraction id="c104256128" contextRef="d_2023-01-01_2023-09-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c104256210" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c104256211" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c104256216" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-07-01_2023-09-30" name="ecd:NonRule10b51ArrAdoptedFlag" id="c104256307" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2023-09-30" name="ecd:Rule10b51ArrTrmntdFlag" id="c104256308" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2023-09-30" name="ecd:NonRule10b51ArrTrmntdFlag" id="c104256309" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="sava-20230930.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2023-01-01_2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-11-02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2023-07-01_2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-01-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-09-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-09-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2023-04-26_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-09-30_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sava:StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sava:StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2023-10-01_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_LeaseContractualTermAxis-OfficeSpaceMember_StatementGeographicalAxis-AustinTexasMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-16</xbrli:startDate><xbrli:endDate>2023-03-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-09-30_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2023-11-07_PlanNameAxis-CashIncentiveBonusPlanMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-28</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasStateCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsDelawareCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-05</xbrli:startDate><xbrli:endDate>2022-07-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>
<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family: Times New Roman; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Form <ix:nonNumeric name="dei:DocumentType" contextRef="d_2023-01-01_2023-09-30">10-Q</ix:nonNumeric></b></p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 35%;">&#xa0;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>(Mark One)</b></p> </td><td style="vertical-align: top; width: 35%;">&#xa0;</td></tr>
<tr><td style="vertical-align: top; width: 35%;">&#xa0;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-09-30">&#x2611;</ix:nonNumeric>&#xa0;&#xa0;&#xa0; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</b></p> </td><td style="vertical-align: top; width: 35%;">&#xa0;</td></tr>
<tr><td style="vertical-align: top; width: 35%;">&#xa0;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td><td style="vertical-align: top; width: 35%;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Quarterly Period Ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" contextRef="d_2023-01-01_2023-09-30">September 30, 2023</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>or</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 35%;">&#xa0;</td><td style="vertical-align: top; width: 30%;">&#xa0;</td><td style="vertical-align: top; width: 35%;">&#xa0;</td></tr>
<tr><td style="vertical-align: top; width: 35%;">&#xa0;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-09-30">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td><td style="vertical-align: top; width: 35%;">&#xa0;</td></tr>
<tr><td style="vertical-align: top; width: 35%;">&#xa0;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">For the Transition Period from ___________ to ___________</p> </td><td style="vertical-align: top; width: 35%;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2023-01-01_2023-09-30">000-29959</ix:nonNumeric></b></p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>Cassava Sciences, Inc.</b></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i>(Exact name of registrant as specified in its charter)</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 20%;">&#xa0;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2023-01-01_2023-09-30">Delaware</ix:nonNumeric> </b></p> </td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2023-01-01_2023-09-30">91-1911336</ix:nonNumeric> </b></p> </td><td style="vertical-align: top; width: 20%;">&#xa0;</td></tr>
<tr><td style="vertical-align: top; width: 20%;">&#xa0;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(State</i>&#xa0;<i>or</i>&#xa0;<i>other</i>&#xa0;<i>jurisdiction</i>&#xa0;<i>of</i></p> </td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(I.R.S.</i>&#xa0;&#xa0;<i>Employer</i></p> </td><td style="vertical-align: top; width: 20%;">&#xa0;</td></tr>
<tr><td style="vertical-align: top; width: 20%;">&#xa0;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>incorporation</i>&#xa0;<i>or</i>&#xa0;<i>organization)</i></p> </td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Identification</i>&#xa0;<i>Number)</i></p> </td><td style="vertical-align: top; width: 20%;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2023-01-01_2023-09-30">6801 N. Capital of Texas Highway, Building 1; Suite 300</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2023-01-01_2023-09-30">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2023-01-01_2023-09-30">TX</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2023-01-01_2023-09-30">78731</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2023-01-01_2023-09-30">512</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2023-01-01_2023-09-30">501-2444</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Address, including zip code, of registrant</i>&#x2019;<i>s principal executive offices and</i></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>telephone number, including area code)</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p> </td></tr>
<tr><td style="vertical-align: top; width: 42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2023-01-01_2023-09-30">Common Stock, $0.001 par value</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2023-01-01_2023-09-30">SAVA</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2023-01-01_2023-09-30">Nasdaq</ix:nonNumeric> Capital Market</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2023-01-01_2023-09-30">Yes</ix:nonNumeric>&#xa0;&#x2611;&#xa0; &#xa0;No&#xa0;&#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2023-01-01_2023-09-30">Yes</ix:nonNumeric>&#xa0;&#x2611;&#xa0;&#xa0;&#xa0;No&#xa0;&#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4.1%;">&#xa0;</td><td style="vertical-align:top;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2023-01-01_2023-09-30">Large Accelerated Filer</ix:nonNumeric> &#x2611;</p> </td><td style="vertical-align:top;width:33.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accelerated Filer &#x2610;</p> </td></tr>
<tr><td style="vertical-align:top;width:4.1%;">&#xa0;</td><td style="vertical-align:top;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Non-accelerated Filer &#x2610;</p> </td><td style="vertical-align:top;width:33.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Smaller Reporting Company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-09-30">&#x2610;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:top;width:4.1%;">&#xa0;</td><td style="vertical-align:top;width:16.2%;">&#xa0;</td><td style="vertical-align:top;width:33.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Emerging Growth Company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-09-30">&#x2610;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-09-30">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;No&#xa0;&#x2611;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate the number of shares outstanding of each of the issuer&#x2019;s classes of common stock, as of the latest practicable date.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 10%;">&#xa0;</td><td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; ">Common Stock, $0.001 par value</span></p> </td><td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2023-11-02">42,174,062</ix:nonFraction></span></p> </td><td style="vertical-align: top; width: 10%;">&#xa0;</td></tr>
<tr><td style="vertical-align: top; width: 10%;">&#xa0;</td><td style="vertical-align: top; width: 40%;">&#xa0;</td><td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares&#xa0;Outstanding&#xa0;as&#xa0;of November 2, 2023</p> </td><td style="vertical-align: top; width: 10%;">&#xa0;</td></tr>
</tbody></table>
<div>
 &#xa0;
</div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    1
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="toc" title="toc" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">TABLE OF CONTENTS</span></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="text-decoration: underline; ">Page No.</span></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART I.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FINANCIAL INFORMATION</p> </td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 1.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#bs" style="-sec-extract:exhibit;">Financial Statements</a></p> </td>
      <td style="vertical-align: top; width: 7%; text-align: right;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#bs" style="-sec-extract:exhibit;">Condensed Consolidated Balance Sheets &#x2013; September 30, 2023 and December 31, 2022</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#income" style="-sec-extract:exhibit;">Condensed Consolidated Statements of Operations &#x2013;&#xa0;Three and Nine Months Ended September 30, 2023 and 2022</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#equity" style="-sec-extract:exhibit;">Condensed Consolidated Statements of Changes in Stockholders&#x2019;&#xa0;Equity - Three and Nine Months Ended September 30, 2023 and 2022</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#cashflow" style="-sec-extract:exhibit;">Condensed Consolidated Statements of Cash Flows &#x2013; Nine Months Ended September 30, 2023 and 2022</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#notes" style="-sec-extract:exhibit;">Notes to Condensed Consolidated Financial Statements</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 2.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#mda" style="-sec-extract:exhibit;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">18</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 3.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#qqd" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures About Market Risk</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">35</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 4.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#controls" style="-sec-extract:exhibit;">Controls and Procedures</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">36</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART II.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">OTHER INFORMATION</p> </td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 1.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#legal" style="-sec-extract:exhibit;">Legal Proceedings</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">36</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 1A</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#risk" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">37</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 2.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#unregistered" style="-sec-extract:exhibit;">Unregistered Sales of Equity Securities and Use of Proceeds</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">37</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 3.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#defaults" style="-sec-extract:exhibit;">Defaults Upon Senior Securities</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">37</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 4.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#mine" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">38</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 5.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#other" style="-sec-extract:exhibit;">Other Information</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">38</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 6.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#exhibits" style="-sec-extract:exhibit;">Exhibits</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">39</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#xa0;</td>
      <td style="vertical-align: top; width: 78%;">&#xa0;</td>
      <td style="vertical-align: top; width: 7%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#signatures" style="-sec-extract:exhibit;">Signatures</a></p> </td>
      <td colspan="2" style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">40</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        2
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>PART I. FINANCIAL INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 1. </b><b><i>Financial Statements</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="bs" title="bs" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Unaudited, In thousands, except share and par value data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30, 2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="8" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">ASSETS</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255560" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-4">142,350</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255561" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">201,015</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255562" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255563" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,211</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255564" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">150,184</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255565" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">211,226</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255566" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255567" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">122</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255568" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,077</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255569" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,864</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255570" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">268</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255571" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">622</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255572" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">172,529</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255573" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">234,834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="8" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">LIABILITIES AND STOCKHOLDERS' EQUITY</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255577" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,492</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255578" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,017</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued development expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255579" contextRef="i_2023-09-30" unitRef="USD" name="sava:AccruedDevelopmentExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,344</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255580" contextRef="i_2022-12-31" unitRef="USD" name="sava:AccruedDevelopmentExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,280</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued compensation and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255581" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">187</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255582" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">170</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease liabilities, current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255583" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255584" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">104</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255585" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">391</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255586" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">492</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255587" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">17,414</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255588" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,063</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities, non-current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255589" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255590" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">35</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other non-current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255591" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255592" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">197</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255593" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">17,414</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255594" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,295</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commitments and contingencies (Notes 9, 10 and 11)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c104255596">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c104255597">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders' equity:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Preferred stock, $<span style="-sec-ix-hidden:c104255601"><span style="-sec-ix-hidden:c104255602">0.001</span></span> par value; <span style="-sec-ix-hidden:c104255603"><span style="-sec-ix-hidden:c104255604">10,000,000</span></span> shares authorized, <span style="-sec-ix-hidden:c104255605"><span style="-sec-ix-hidden:c104255607"><span style="-sec-ix-hidden:c104255606"><span style="-sec-ix-hidden:c104255608">none</span></span></span></span> issued and outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255599" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255600" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c104255611"><span style="-sec-ix-hidden:c104255612">0.001</span></span> par value; <span style="-sec-ix-hidden:c104255613"><span style="-sec-ix-hidden:c104255614">120,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c104255615"><span style="-sec-ix-hidden:c104255617">42,129,798</span></span> and <span style="-sec-ix-hidden:c104255616"><span style="-sec-ix-hidden:c104255618">41,735,557</span></span> shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255609" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255610" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255619" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">514,923</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255620" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">511,049</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255621" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">359,850</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255622" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">283,552</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255623" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">155,115</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255624" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">227,539</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities and stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255625" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">172,529</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255626" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">234,834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 14pt;text-indent:-14pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     3
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="income" title="income" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Unaudited, in thousands, except per share data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development, net of grant reimbursement</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255640" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">23,603</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255641" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">18,526</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255642" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">70,692</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255643" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">50,380</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255644" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,276</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255645" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,819</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255646" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,476</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255647" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,703</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total operating expenses</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255648" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">27,879</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255649" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,345</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255650" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">83,168</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255651" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">59,083</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255652" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">27,879</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255653" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">21,345</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255654" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">83,168</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255655" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">59,083</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255656" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,005</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255657" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">878</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255658" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,254</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255659" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,223</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255660" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">223</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255661" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">210</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255662" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">616</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255663" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">748</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255664" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,651</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255665" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">20,257</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255666" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,298</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255667" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">57,112</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic and diluted</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255668" contextRef="d_2023-07-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.61</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255669" contextRef="d_2022-07-01_2022-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.51</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255670" contextRef="d_2023-01-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.82</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255671" contextRef="d_2022-01-01_2022-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.43</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Shares used in computing net loss per share, basic and diluted</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255672" contextRef="d_2023-07-01_2023-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,002</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255673" contextRef="d_2022-07-01_2022-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-4">40,050</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255674" contextRef="d_2023-01-01_2023-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,845</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255675" contextRef="d_2022-01-01_2022-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,009</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="equity" title="equity" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Unaudited, in thousands, except share data)</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Common stock</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">stockholders'</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Par value</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">paid-in capital</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">deficit</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">equity</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255691" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,016,792</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255692" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255693" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">461,181</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255694" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">207,306</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255695" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">253,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255698" contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255699" contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">471</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255700" contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255701" contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">471</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255703" contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255704" contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">24</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255705" contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255706" contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">24</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255707" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">14,488</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255708" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255709" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">211</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255710" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255711" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">211</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255713" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255714" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255715" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,527</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255716" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,527</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2022</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255717" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,031,280</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255718" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255719" contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">461,887</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255720" contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">224,833</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255721" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">237,094</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255724" contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255725" contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">462</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255726" contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255727" contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">462</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255729" contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255730" contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255731" contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255732" contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255733" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">66,637</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255734" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255735" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">119</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255736" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255737" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">119</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255739" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255740" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255741" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">19,328</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255742" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">19,328</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at June 30, 2022</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255743" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,097,917</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255744" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255745" contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">462,491</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255746" contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">244,161</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255747" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">218,370</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255750" contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255751" contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">447</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255752" contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255753" contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">447</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255755" contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255756" contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255757" contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255758" contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expiration of restricted stock Performance Awards</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c104255759" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,143</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255760" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255761" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255762" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255763" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255764" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">18,740</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255765" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255766" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">136</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255767" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255768" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">136</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255770" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255771" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c104255772" contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">20,257</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c104255773" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">20,257</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2022</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255774" contextRef="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,059,514</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255775" contextRef="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255776" contextRef="i_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">463,097</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255777" contextRef="i_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">264,418</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255778" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">198,719</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255779" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,735,557</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255780" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255781" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">511,049</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255782" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">283,552</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255783" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">227,539</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255786" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255787" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-4">650</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255788" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255789" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-4">650</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255791" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255792" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255793" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255794" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255795" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,878</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255796" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255797" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">64</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255798" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255799" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">64</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255801" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255802" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255803" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,271</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255804" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,271</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2023</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255805" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,749,435</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255806" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255807" contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">511,786</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255808" contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">307,823</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255809" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">204,005</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255812" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255813" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">812</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255814" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255815" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">812</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255817" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255818" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255819" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255820" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255821" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">170,092</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255822" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255823" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">889</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255824" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255825" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">889</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255827" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255828" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255829" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255830" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at June 30, 2023</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255831" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,919,527</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255832" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255833" contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">513,510</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255834" contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">334,199</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255835" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">179,353</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255838" contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255839" contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">926</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255840" contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255841" contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">926</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255843" contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255844" contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255845" contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255846" contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255847" contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">210,271</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255848" contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255849" contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">464</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255850" contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104255851" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">464</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255853" contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104255854" contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c104255855" contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,651</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c104255856" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,651</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2023</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255857" contextRef="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,129,798</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255858" contextRef="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255859" contextRef="i_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">514,923</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104255860" contextRef="i_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">359,850</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255861" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">155,115</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     5
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="cashflow" title="cashflow" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Unaudited, in thousands)</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended September 30,</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from operating activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255867" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,298</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255868" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">57,112</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock-based compensation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255870" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,457</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255871" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,450</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255872" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">817</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255873" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">533</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of intangible assets</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255874" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">357</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255875" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">379</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Prepaid and other current assets</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255877" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,377</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255878" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">2,790</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Operating lease right-of-use assets and liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255879" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255880" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Accounts payable and accrued expenses</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255881" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,815</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255882" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,592</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Accrued development expense</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255883" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,064</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255884" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,293</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Accrued compensation and benefits</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104255885" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255886" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,717</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Other liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255887" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">298</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255888" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">212</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash used in operating activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255889" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">59,709</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255890" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">56,194</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from investing activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Purchase of property and equipment</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255892" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">373</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255893" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,047</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash used in investing activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255894" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">373</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104255895" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,047</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from financing activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from issuance of common stock upon exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255897" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,417</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255898" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">466</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255899" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,417</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255900" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">466</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net decrease in cash and cash equivalents</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255901" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">58,665</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255902" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">58,775</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of period</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255903" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">201,015</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255904" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">233,437</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of period</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255905" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-4">142,350</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104255906" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">174,662</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     6
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a id="notes" title="notes" href="#"></a>Cassava Sciences, Inc.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Notes to Condensed Consolidated Financial Statements</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2493870" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">1.</em> General and Liquidity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#x201c;Company&#x201d;) discover and develop proprietary pharmaceutical product candidates that <em style="font: inherit;"> may </em>offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> All intercompany transactions and balances have been eliminated in consolidation. Accordingly, the condensed consolidated financial statements do <em style="font: inherit;">not</em> include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em> are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>be expected for any other interim period or for the year <em style="font: inherit;">2023.</em> For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#x2019;s Annual Report on Form&#xa0;<em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $<ix:nonFraction id="c104255917" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">359.9</ix:nonFraction>&#xa0;million at <em style="font: inherit;"> September 30, 2023</em>. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#x2019;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company <em style="font: inherit;"> may </em>seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are <em style="font: inherit;">no</em> assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2493871" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">2.</em></b>&#xa0;&#xa0;<b>Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:UseOfEstimates" id="c104257155" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#xa0;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c104257156" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#xa0;The Company maintains&#xa0;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c104257157" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> September 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c104257158" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business Segments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to <ix:nonFraction id="c104255949" contextRef="d_2023-01-01_2023-09-30" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="c104257159" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xfeff;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>,&#xa0;there were <ix:nonFraction id="c104255952" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022</em>, the Company received reimbursements totaling $<ix:nonFraction id="c104255956" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million and $<ix:nonFraction id="c104255957" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction>&#xa0;million, respectively, pursuant to NIH research grants. The Company records the proceeds from these grants as reductions to its research and development expenses.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c104257160" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b>&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xfeff;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The&#xa0;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#xa0;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c104255958">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;">&#xfeff;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xfeff;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c104257161" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xfeff;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options.&#xa0;&#xa0;There is <em style="font: inherit;">no</em> difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="c2493872" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255993" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,651</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255994" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">20,257</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255995" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,298</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104255996" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">57,112</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shares used in computing net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255998" contextRef="d_2023-07-01_2023-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,002</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104255999" contextRef="d_2022-07-01_2022-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-4">40,050</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256000" contextRef="d_2023-01-01_2023-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,845</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256001" contextRef="d_2022-01-01_2022-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,009</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104256002" contextRef="d_2023-07-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.61</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104256003" contextRef="d_2022-07-01_2022-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.51</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104256004" contextRef="d_2023-01-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.82</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c104256005" contextRef="d_2022-01-01_2022-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.43</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256006" contextRef="d_2023-07-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,780</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256007" contextRef="d_2022-07-01_2022-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,946</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256008" contextRef="d_2023-01-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,938</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256009" contextRef="d_2022-01-01_2022-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,064</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti<b>-</b>dilutive. The Company also excluded <ix:nonFraction id="c104255961" contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,143</ix:nonFraction> restricted stock awards from the calculation of net loss per share, diluted, until their expiration in <em style="font: inherit;"> June 2022 </em>because the effect of including restricted stock awards would have been anti<b>-</b>dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c104257162" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b>&#xa0; &#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c104257163" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research Contract Costs and Accruals </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="c104257164" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) <em style="font: inherit;">718</em> &#x201c;<i>Stock-based Compensation</i>&#x201d;.&#xa0;The fair value of each&#xa0;potential Plan&#xa0;award&#xa0;will be&#xa0;determined&#xa0;once&#xa0;a&#xa0;grant date occurs and&#xa0;will be&#xa0;remeasured each reporting period.&#xa0;Compensation expense associated with the Plan&#xa0;will be&#xa0;recognized over the expected achievement period for each&#xa0;Plan award, when&#xa0;a Performance Condition&#xa0;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">10</em> for further discussion of the Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c104257165" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Leases</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#xa0;assets and liabilities that arise from leases.&#xa0;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#xa0;condensed consolidated balance sheets.&#xa0;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities. As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c104257166" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#xa0;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of <ix:nonNumeric contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c104255972" format="ixt-sec:duryear">39</ix:nonNumeric> years and approximately <ix:nonNumeric contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c104255973" format="ixt-sec:duryear">10</ix:nonNumeric> years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately <ix:nonNumeric contextRef="i_2023-09-30" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c104255974" format="ixt-sec:duryear">0.6</ix:nonNumeric>&#xa0;years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c104257167" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible assets</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately <ix:nonNumeric contextRef="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c104255976" format="ixt-sec:duryear">0.5</ix:nonNumeric>&#xa0;years at <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:IncomeTaxPolicyTextBlock" id="c104257168" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b>&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method. &#xa0;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#xa0;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#xa0;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s condensed consolidated financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="sava:PrepaidExpensesAndOtherCurrentAssetsTextBock" id="c2493873" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid expenses and other current assets at <em style="font: inherit;"> September 30, 2023</em> and&#xa0;<em style="font: inherit;"> December 31, 2022</em> consisted of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="c2493874" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256015" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,136</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256016" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">874</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract research organization and other deposits</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256017" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DepositContractsAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,224</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256018" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DepositContractsAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,177</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest receivable</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256019" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,285</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104256020" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256021" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">189</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256022" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">160</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total prepaid expenses and other current assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256023" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,834</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256024" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,211</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:RealEstateOwnedTextBlock" id="c2493875" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">4.</em> Real Property</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company owns a <em style="font: inherit;">two</em>-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#x2019;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#xa0;outsourced to professional real-estate managers. The office complex has&#xa0;approximately <ix:nonFraction id="c104256027" contextRef="i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="SquareFoot" name="us-gaap:NetRentableArea" scale="0" format="ixt:num-dot-decimal" decimals="INF">90,000</ix:nonFraction> square feet of rentable space. At <em style="font: inherit;"> September 30, 2023</em>, the property was over <ix:nonFraction id="c104256028" contextRef="i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="Pure" name="sava:PercentageOfCurrentlyLeased" scale="-2" format="ixt:num-dot-decimal" decimals="1">60</ix:nonFraction>% leased. The Company also occupies approximately <ix:nonFraction id="c104256029" contextRef="i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="Pure" name="sava:PercentageOfOccupancy" scale="-2" format="ixt:num-dot-decimal" decimals="2">25</ix:nonFraction>% of the property.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company records the net income from building operations and leases as other income, net, as leasing is <em style="font: inherit;">not</em> core to the Company&#x2019;s operations. Building depreciation and amortization for space <em style="font: inherit;">not</em> occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company are&#xa0;allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="c2493876" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256045" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">583</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256046" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-4">620</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256047" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,699</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256048" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,780</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256049" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">360</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256050" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">410</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256051" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,083</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256052" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,032</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256053" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">223</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256054" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">210</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256055" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">616</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256056" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">748</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2493877" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">5.</em> Property and equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of property and equipment, net, as of <em style="font: inherit;"> September 30, 2023</em>&#xa0;and&#xa0;<em style="font: inherit;"> December 31, 2022</em> were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2493878" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256070" contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-LandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256071" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256072" contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256073" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256074" contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256075" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">470</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256076" contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,018</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256077" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,016</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256078" contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">868</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256079" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">851</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in progress</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256080" contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:fixed-zero" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256081" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">13</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256082" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,094</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256083" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,064</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256084" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,017</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256085" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-5">1,200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256086" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,077</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256087" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,864</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation expense for property and equipment was&#xa0;$<ix:nonFraction id="c104256058" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">273,000</ix:nonFraction>&#xa0;and&#xa0;$<ix:nonFraction id="c104256059" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">181,000</ix:nonFraction>&#xa0;for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>, respectively. Depreciation expense for property and equipment was $<ix:nonFraction id="c104256062" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">817,000</ix:nonFraction> and $<ix:nonFraction id="c104256063" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">533,000</ix:nonFraction> for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="c2493879" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">6.</em> Intangible assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of intangible assets, net, as of&#xa0;<em style="font: inherit;"> September 30, 2023</em> and&#xa0;<em style="font: inherit;"> December 31, 2022</em> were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="c2493880" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256101" contextRef="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256102" contextRef="i_2022-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256103" contextRef="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">293</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256104" contextRef="i_2022-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">290</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256105" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,346</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256106" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,343</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256107" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,078</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256108" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">721</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256109" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">268</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256110" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">622</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for intangible assets was&#xa0;$<ix:nonFraction id="c104256089" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">119,000</ix:nonFraction> for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>. Amortization expense for intangible assets was&#xa0;$<ix:nonFraction id="c104256093" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">357,000</ix:nonFraction> and $<ix:nonFraction id="c104256094" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">379,000</ix:nonFraction> for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for finite-lived intangible assets as of <em style="font: inherit;"> September 30, 2023</em> is expected to be as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="c2493881" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256112" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" format="ixt:num-dot-decimal" decimals="-3">97</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256113" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">167</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256114" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256115" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">268</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="c2493882" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">7.</em> Stockholders</b>&#x2019;<b> Equity and Stock-Based Compensation Expense</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><em style="font: inherit;">2022</em> Registered Direct Offering</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November&#xa0;</em><em style="font: inherit;">22,</em> <em style="font: inherit;">2022,</em> the Company completed a common stock offering pursuant to which certain investors purchased <ix:nonFraction id="c104256120" contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,666,667</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction id="c104256121" contextRef="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">30.00</ix:nonFraction> per share. Net proceeds of the offering were approximately $<ix:nonFraction id="c104256122" contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">47.3</ix:nonFraction>&#xa0;million after deducting offering expenses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>At-the-Market Common Stock Offering </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> May 1, 2023, </em>the Company entered into an&#xa0;at-the-market offering program (&#x201c;ATM&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction id="c104256124" contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="USD" name="sava:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">200</ix:nonFraction> million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on <em style="font: inherit;"> May 1, 2023 </em>and became effective immediately upon filing. The Company is obligated to pay a commission of up to <ix:nonFraction id="c104256125" contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Pure" name="sava:EquityOfferingPercentageOfCommission" scale="-2" format="ixt:num-dot-decimal" decimals="2">3</ix:nonFraction>% of the gross proceeds from the sale of shares of common stock in the offering. The Company is <em style="font: inherit;">not</em> obligated to sell any shares in the offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were <ix:nonFraction id="c104256127" contextRef="d_2023-07-01_2023-09-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> common stock sales under the ATM during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> March 2020, </em>the Company entered into an at-the-market offering program (<em style="font: inherit;">&#x201c;2020</em> Program&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction id="c104256132" contextRef="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="USD" name="sava:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">100</ix:nonFraction> million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on <em style="font: inherit;"> May 5, 2020. </em>The Company gave notice of termination for the <em style="font: inherit;">2020</em> Program on <em style="font: inherit;"> April 26, 2023, </em>which was effective <em style="font: inherit;"> May 1, 2023. </em>There were <ix:nonFraction id="c104256134" contextRef="d_2020-04-01_2023-04-26_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> common stock sales under the <em style="font: inherit;">2020</em> Program through its termination.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock Option and Performance Award Activity in <em style="font: inherit;">2023</em></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>, stock options and unvested Performance Awards outstanding under the Company&#x2019;s stock option plans changed as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="c2493883" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Stock Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256175" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,529,448</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256176" contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256177" contextRef="d_2023-01-01_2023-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">132,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104256178" contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:fixed-zero" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104256179" contextRef="d_2023-01-01_2023-09-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">495,299</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104256180" contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c104256181" contextRef="d_2023-01-01_2023-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c104256182" contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of September 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256183" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,159,007</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256184" contextRef="i_2023-09-30_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The weighted average exercise price per share of options outstanding at <em style="font: inherit;"> September 30, 2023</em> was $<ix:nonFraction id="c104256138" contextRef="i_2023-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">13.71</ix:nonFraction>. As outstanding options vest over the current remaining vesting period of <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c104256139" format="ixt-sec:duryear">2.3</ix:nonNumeric>&#xa0;years, the Company expects to recognize stock-based compensation expense of $<ix:nonFraction id="c104256140" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-6">8.0</ix:nonFraction>&#xa0;million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $<ix:nonFraction id="c104256141" contextRef="i_2023-09-30_AwardTypeAxis-PerformanceSharesMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million over the implicit service period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em>, there were <ix:nonFraction id="c104256143" contextRef="d_2023-07-01_2023-09-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">214,124</ix:nonFraction> stock options exercised. Of the stock options exercised, <ix:nonFraction id="c104256144" contextRef="d_2023-07-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,853</ix:nonFraction>&#xa0;stock options were net settled in satisfaction of the exercise price, with <ix:nonFraction id="c104256145" contextRef="d_2023-07-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> cash proceeds received. Cash proceeds to the Company for options <em style="font: inherit;">not</em> net settled totaled $<ix:nonFraction id="c104256147" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">464,000</ix:nonFraction> during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>, there were <ix:nonFraction id="c104256150" contextRef="d_2023-01-01_2023-09-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">495,299</ix:nonFraction>&#xa0;stock options exercised. Of the stock options exercised, <ix:nonFraction id="c104256151" contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">101,058</ix:nonFraction> stock options were net settled in satisfaction of the exercise price, with <ix:nonFraction id="c104256152" contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> cash proceeds received. Cash proceeds to the Company for options <em style="font: inherit;">not</em> net settled totaled $<ix:nonFraction id="c104256154" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,417,000</ix:nonFraction> during the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Subsequent to <em style="font: inherit;"> September 30, 2023, </em>there were <ix:nonFraction id="c104256156" contextRef="d_2023-10-01_2023-10-01_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">800,000</ix:nonFraction> stock options granted to officers and employees at an exercise price of $<ix:nonFraction id="c104256157" contextRef="d_2023-10-01_2023-10-01_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">17.54</ix:nonFraction> per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock-based Compensation Expense in <em style="font: inherit;">2023</em></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>, the Company&#x2019;s stock-based compensation expense was as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2493884" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256197" contextRef="d_2023-07-01_2023-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">405</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256198" contextRef="d_2022-07-01_2022-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">399</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256199" contextRef="d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,186</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104256200" contextRef="d_2022-01-01_2022-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,234</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256201" contextRef="d_2023-07-01_2023-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">544</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256202" contextRef="d_2022-07-01_2022-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">70</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256203" contextRef="d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,271</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104256204" contextRef="d_2022-01-01_2022-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">216</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256205" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">949</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256206" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">469</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256207" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,457</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c104256208" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,450</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2018</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) or a designated committee of the Board is responsible for administration of the Company&#x2019;s <em style="font: inherit;">2018</em> Omnibus Incentive Plan, as amended (the <em style="font: inherit;">&#x201c;2018</em> Plan&#x201d;) and determines the terms and conditions of each option granted, consistent with the terms of the <em style="font: inherit;">2018</em> Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the <em style="font: inherit;">2018</em> Plan, including grants of stock options and Performance Awards. Share-based awards generally expire <ix:nonNumeric contextRef="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c104256168" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant. The <em style="font: inherit;">2018</em> Plan, as amended on <em style="font: inherit;"> May 5, 2022, </em>provides for issuance of up to <ix:nonFraction id="c104256170" contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction id="c104256171" contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, subject to adjustment as provided in the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xfeff;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#xa0;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2493885" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">8.</em> Income Taxes</b><b><i> </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company did <span style="-sec-ix-hidden:c104256210"><span style="-sec-ix-hidden:c104256211">not</span></span> provide for income taxes during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>, because it has projected a net loss for the full year <em style="font: inherit;">2023</em> for which any benefit will be offset by an increase in the valuation allowance. There was also <ix:nonFraction id="c104256215" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> provision for income taxes for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:CommitmentsDisclosureTextBlock" id="c2493886" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">9.</em> Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Right-of-use Asset and Liability</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company had an operating lease for approximately <ix:nonFraction id="c104256220" contextRef="i_2023-09-30_LeaseContractualTermAxis-OfficeSpaceMember_StatementGeographicalAxis-AustinTexasMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,000</ix:nonFraction> square feet of office space in Austin, Texas with an expiration of <em style="font: inherit;"> April 30, 2024. </em>The Company and the landlord consented to early terminate this lease on <em style="font: inherit;"> February 22, 2023 </em>with <em style="font: inherit;">no</em> continuing obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There was <ix:nonFraction id="c104256222" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> rent expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em>. Rent expense for the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> September 30, 2022</em> totaled $<ix:nonFraction id="c104256225" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,000</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Rent expense for the&#xa0;<em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> totaled $<ix:nonFraction id="c104256228" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,000</ix:nonFraction> and $<ix:nonFraction id="c104256229" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="INF">123,000</ix:nonFraction>, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There was <ix:nonFraction id="c104256230" contextRef="d_2023-07-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> cash paid for operating lease liabilities during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em>. Cash paid for operating lease liabilities during the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> September 30, 2022</em> totaled $<ix:nonFraction id="c104256233" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,000</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cash paid for operating lease liabilities during the&#xa0;<em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> totaled $<ix:nonFraction id="c104256236" contextRef="d_2023-01-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,000</ix:nonFraction> and $<ix:nonFraction id="c104256237" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:num-dot-decimal" decimals="INF">124,000</ix:nonFraction>, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#x2019;s obligations under these contracts are largely based on services performed.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="sava:CashIncentiveBonusPlanTextBlock" id="c2493887" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note</b>&#xa0;<b><em style="font: inherit;">10.</em></b>&#xa0;<b> <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2020, </em>the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#x201c;at-risk&#x201d; cash bonus program that rewards&#xa0;Plan&#xa0;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The Plan is considered &#x201c;at-risk&#x201d; because Plan participants&#xa0;will&#xa0;<em style="font: inherit;">not</em> receive a cash bonus&#xa0;unless&#xa0;the Company&#x2019;s market capitalization increases&#xa0;significantly and&#xa0;certain&#xa0;other&#xa0;conditions specified in the Plan&#xa0;are met.&#xa0;Specifically, Plan participants&#xa0;will&#xa0;<em style="font: inherit;">not</em>&#xa0;be paid&#xa0;any cash bonuses unless (<em style="font: inherit;">1</em>) the Company completes a&#xa0;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a "Merger Transaction") or (<em style="font: inherit;">2</em>) the Compensation Committee of the Board&#xa0;(the "Compensation Committee") determines the Company has sufficient cash on hand, as defined in the Plan. Because&#xa0;of the inherent discretion and uncertainty regarding&#xa0;these&#xa0;requirements, the Company has concluded that&#xa0;a&#xa0;Plan&#xa0;grant date has <em style="font: inherit;">not</em> occurred&#xa0;as of <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company&#x2019;s independent directors were participants in the Plan. However, effective <em style="font: inherit;"> March 16, 2023, </em>the Board&#xa0;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#x2019; share of potential benefits under the Plan were completely forfeited to the Company and will <em style="font: inherit;">not</em> be allocated to any other participant under the Plan. The Company&#x2019;s independent directors have <em style="font: inherit;">not</em> received, and as a result of such amendment will never receive, any payments under the Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#x2019;s market capitalization for purposes of the Plan&#xa0;is&#xa0;determined based on either (<em style="font: inherit;">1</em>) the closing price&#xa0;of <em style="font: inherit;">one</em> share&#xa0;of the Company&#x2019;s common stock on the Nasdaq Capital&#xa0;Market&#xa0;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (<em style="font: inherit;">2</em>) the aggregate consideration payable to security holders of the Company in a&#xa0;Merger Transaction.&#xa0;This constitutes a market condition under applicable accounting guidance.&#xa0;&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Plan&#xa0;triggers a potential cash bonus each time&#xa0;the&#xa0;Company&#x2019;s market capitalization increases significantly, up to a maximum&#xa0;<em style="font: inherit;">$5</em>&#xa0;billion in market capitalization. The Plan specifies <ix:nonFraction id="c104256252" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">14</ix:nonFraction>&#xa0;incremental&#xa0;amounts&#xa0;between&#xa0;$<ix:nonFraction id="c104256253" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">200</ix:nonFraction>&#xa0;million and&#xa0;$<ix:nonFraction id="c104256254" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="9" format="ixt:num-dot-decimal" decimals="-9">5</ix:nonFraction>&#xa0;billion&#xa0;(each increment,&#xa0;a &#x201c;Valuation Milestone&#x201d;). Each&#xa0;Valuation Milestone&#xa0;triggers&#xa0;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#xa0;Valuation&#xa0;Milestone&#xa0;must be achieved and maintained for <em style="font: inherit;">no</em> less than <ix:nonNumeric contextRef="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" name="sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="c104256256" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days for&#xa0;Plan&#xa0;participants to be eligible for a potential cash bonus award.&#xa0;Approximately <ix:nonFraction id="c104256257" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" scale="-2" format="ixt:num-dot-decimal" decimals="2">67</ix:nonFraction>% of each&#xa0;cash bonus award&#xa0;associated with a Valuation Milestone&#xa0;is subject to&#xa0;adjustment and&#xa0;approval&#xa0;by the Compensation Committee.&#xa0;Any amounts&#xa0;<em style="font: inherit;">not</em> awarded by the Compensation Committee&#xa0;are&#xa0;<em style="font: inherit;">no</em> longer available for distribution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If the Company were to exceed a $<ix:nonFraction id="c104256260" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="9" format="ixt:num-dot-decimal" decimals="-9">5</ix:nonFraction>&#xa0;billion market capitalization&#xa0;for <em style="font: inherit;">no</em> less than <ix:nonNumeric contextRef="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" name="sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="c104256262" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days, all&#xa0;Valuation&#xa0;Milestones would be deemed achieved, in which case cash bonus awards would&#xa0;range from&#xa0;a minimum of&#xa0;$<ix:nonFraction id="c104256263" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:CashIncentiveBonusAwardExceedsMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-5">111.4</ix:nonFraction>&#xa0;million&#xa0;up to&#xa0;a hypothetical maximum of&#xa0;$<ix:nonFraction id="c104256264" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:CashIncentiveBonusAwardExceedsMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-5">289.7</ix:nonFraction>&#xa0;million.&#xa0;Payment of cash bonuses is deferred until such time as&#xa0;(<em style="font: inherit;">1</em>)&#xa0;the Company completes a Merger Transaction, or&#xa0;(<em style="font: inherit;">2</em>)&#xa0;the&#xa0;Compensation Committee determines the&#xa0;Company has sufficient cash&#xa0;on hand&#xa0;to render payment&#xa0;(each, a &#x201c;Performance Condition&#x201d;),&#xa0;neither&#xa0;of which <em style="font: inherit;"> may </em>ever occur. Accordingly, there can be <em style="font: inherit;">no</em> assurance that&#xa0;Plan&#xa0;participants will&#xa0;ever&#xa0;be&#xa0;paid a cash bonus that is awarded under the Plan, even if the Company&#x2019;s market capitalization increases&#xa0;significantly.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Plan is accounted for as a liability award.&#xa0;The fair value of each&#xa0;Valuation&#xa0;Milestone&#xa0;award&#xa0;will be&#xa0;determined&#xa0;once&#xa0;a&#xa0;grant date occurs and&#xa0;will be&#xa0;remeasured each reporting period.&#xa0;Compensation expense associated with the Plan&#xa0;will be&#xa0;recognized over the expected achievement period for each&#xa0;of the <ix:nonFraction id="c104256268" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">14</ix:nonFraction>&#xa0;Valuation&#xa0;Milestones, when&#xa0;a Performance Condition&#xa0;is considered probable of being met. &#xa0;&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> October 2020, </em>the Company&#xa0;achieved&#xa0;the <em style="font: inherit;">first</em>&#xa0;Valuation&#xa0;Milestone.&#xa0;Subsequently, the Compensation Committee&#xa0;approved&#xa0;a potential cash bonus&#xa0;award&#xa0;of&#xa0;$<ix:nonFraction id="c104256270" contextRef="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="sava:CashIncentiveBonusAward" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.5</ix:nonFraction>&#xa0;million&#xa0;in total&#xa0;for&#xa0;all Plan participants (after the <em style="font: inherit;"> March 2023 </em>Plan amendment), subject to future satisfaction of a Performance Condition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company achieved <ix:nonFraction id="c104256273" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">11</ix:nonFraction> additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $<ix:nonFraction id="c104256274" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">74.9</ix:nonFraction>&#xa0;million up to a hypothetical maximum of $<ix:nonFraction id="c104256275" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">202.3</ix:nonFraction>&#xa0;million (after the <em style="font: inherit;"> March 2023 </em>Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#xa0;<ix:nonFraction id="c104256276" contextRef="d_2023-01-01_2023-09-30_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#xa0;compensation expense was recorded&#xa0;since <em style="font: inherit;">no</em>&#xa0;grant date has occurred and <em style="font: inherit;">no</em>&#xa0;Performance Conditions are considered probable of being met.&#xa0;There is <em style="font: inherit;">no</em> continuing service requirement for Plan participants once&#xa0;the Compensation Committee approves a cash&#xa0;bonus award.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> Valuation Milestones were achieved during <em style="font: inherit;">2022</em> or the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><ix:nonFraction id="c104256283" contextRef="d_2023-10-01_2023-11-07_PlanNameAxis-CashIncentiveBonusPlanMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="sava:PaymentsForCashIncentiveBonus" scale="0" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> actual cash payments were authorized or made to participants under the Plan through the date of filing of this Form <em style="font: inherit;">10</em>-Q.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-09-30" name="us-gaap:LossContingencyDisclosures" id="c2493888" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em> Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">From time to time, the Company <em style="font: inherit;"> may </em>become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA, and <em style="font: inherit;"> may </em>receive inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company. <em style="font: inherit;">No</em> information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, <em style="font: inherit;">no</em> accrual for these matters has been recorded within the condensed consolidated financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Government Investigations</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 15, 2021, </em>the Company disclosed that certain government agencies had asked the Company to provide corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and intends to continue to cooperate with these inquiries. <em style="font: inherit;">No</em> government agency has informed the Company that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors. <em style="font: inherit;">No</em> government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em><ix:nonFraction id="c104256292" contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the <ix:nonFraction id="c104256293" contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> class action lawsuits into <ix:nonFraction id="c104256294" contextRef="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company&#x2019;s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs&#x2019; claims against&#xa0;defendant Nadav Friedmann, PhD, MD,&#xa0;our former Chief Medical Officer and a Company director, who&#xa0;is now deceased, but otherwise denied defendants&#x2019; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023. </em>The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#x2019;s alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since <em style="font: inherit;"> November 4, 2021, </em><ix:nonFraction id="c104256296" contextRef="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> additional shareholder derivative actions were filed alleging substantially similar claims, <ix:nonFraction id="c104256297" contextRef="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> in the U.S. District Court for the Western District of Texas, <ix:nonFraction id="c104256298" contextRef="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> in Texas state court (Travis County District Court) and <ix:nonFraction id="c104256299" contextRef="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the <ix:nonFraction id="c104256300" contextRef="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> federal court actions were consolidated into a single action.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#x2019;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan in <em style="font: inherit;"> August 2020. </em>The complaints seek unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023. </em>Defendants&#x2019; motion to dismiss remains pending. Although the plaintiffs in this derivative case do <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="mda" title="mda" href="#"></a>Item 2. </b><b><i>Management</i></b>&#x2019;<b><i>s Discussion and Analysis of Financial Condition and Results of Operations</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This discussion and analysis should be read in conjunction with Cassava Sciences, Inc.&#x2019;s (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) condensed consolidated financial statements and accompanying notes included elsewhere in this Quarterly Report on Form 10-Q. Operating results are not necessarily indicative of results that may occur in future periods.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This Quarterly Report on Form 10-Q contains certain statements that are considered forward-looking statements within the meaning of the Private Securities Reform Act of 1995. We intend that such statements be protected by the safe harbor created thereby. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;should,&#x201d; &#x201c;will&#x201d; and &#x201c;would&#x201d; or the negatives of these terms or other comparable terminology.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently available to us. Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Examples of such forward-looking statements include, but are not limited to statements about:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the expected safety profile or treatment benefits of simufilam for people with Alzheimer&#x2019;s disease in our on-going Phase 3 studies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our reliance on third-party contractors to conduct the clinical trials and make drug supply on a large-scale for our Phase 3 clinical program, or their ability to do so on-time or on-budget;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">limitations around data interpretation from results of our Cognition Maintenance Study (CMS) and long-term open-label study, as compared to efficacy results from a fully completed Phase 3 clinical program;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the ability of clinical scales to assess cognition or health in our trials of Alzheimer&#x2019;s disease;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any significant changes we may make, or anticipate making, to the design of any of our on-going studies of simufilam in patients with Alzheimer&#x2019;s disease;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to initiate, conduct or analyze additional clinical and non-clinical studies with our product candidates targeted at Alzheimer&#x2019;s disease and other neurodegenerative diseases;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the impact of pre-clinical findings on our ability to develop our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the interpretation of results from our pre-clinical or early clinical studies, such as Phase 1 and Phase 2 studies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our plans to further develop SavaDx, our investigational blood-based diagnostic, and to evaluate a non-antibody approach for SavaDx;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability or willingness to expand therapeutic indications for simufilam outside of Alzheimer&#x2019;s disease;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the safety, efficacy, or potential therapeutic benefits of our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to file for and obtain regulatory approval of our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our strategy and ability to establish an infrastructure to commercialize any product candidates, if approved;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the potential future revenues of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the market acceptance of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the pricing and reimbursement of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the utility of protection, or the sufficiency, of our intellectual property;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our potential competitors or competitive products for the treatment of Alzheimer&#x2019;s disease;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our need to raise new capital from time to time to continue our operations or to expand our operations;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our use of multiple third-party vendors, including a Clinical Research Organization (CRO), to conduct clinical studies of our lead product candidate;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our expenses increasing by unanticipated amounts due to inflation;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">fluctuations in our financial or operating results;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our operating losses, anticipated operating and capital expenditures and legal expenses;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">expectations regarding the issuance of shares of common stock, options or other equity to employees or directors pursuant to equity compensation awards, net of employment taxes;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the development and maintenance of our internal information systems and infrastructure;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our need to hire additional personnel and our ability to attract and retain such personnel;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">existing regulations and regulatory developments in the United States and other jurisdictions in which we operate;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our plans to expand the size and scope of our operations;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the sufficiency of our current resources to continue to fund our operations;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">potential future agreements with third parties in connection with the commercialization of our product candidates;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the accuracy of our estimates regarding expenses, capital requirements, and needs for additional financing;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">assumptions and estimates used for our disclosures regarding stock-based compensation;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the expense, timing and outcome of pending or future litigation or other legal proceedings and claims, including government inquiries; and</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">litigation, claims or other uncertainties that may arise from allegations made against us or our collaborators.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Such forward-looking statements and our business involve risks and uncertainties, including, but not limited to the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have a limited operating history in our business&#xa0;targeting Alzheimer&#x2019;s disease and no products approved for commercial sale.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development of biopharmaceutical products is a highly uncertain undertaking and involves a substantial degree of risk and our business is heavily dependent on the successful development of our product candidates.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We are concentrating a substantial portion of our research and development efforts on the diagnosis and treatment of Alzheimer&#x2019;s disease, an area of research that has recorded many clinical failures.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our clinical trials may fail to demonstrate evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and the commercialization of our product candidates.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may need to obtain substantial additional financing to complete the development and any commercialization of our product candidates.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We are a small company with no sales force and may not be successful in our efforts to commercialize any product candidates which are approved.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our CRO, contract manufacturers and other third party vendors may fail to perform as anticipated.&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be unable to protect our intellectual property rights or trade secrets.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be subject to third-party claims of intellectual property infringement.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may not succeed in our maintenance or pursuit of licensing rights or third-party intellectual property necessary for the development of our product candidates.&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Enacted or future legislation or regulatory actions may adversely affect our product pricing, or limit the reimbursement we may receive for our products.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A significant breakdown, security breach or interruption affecting our internal computer systems, or those used by our third-party vendors and research collaborators, may compromise the confidentiality of our financial or other proprietary information, result in material disruptions of our products and operations and adversely affect our reputation.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be&#xa0;unsuccessful at hiring and retaining qualified personnel.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We and certain of our directors and executive officers have been named as defendants in lawsuits that could result in substantial costs and divert management&#x2019;s attention.</p> </td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt; vertical-align: top; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-size: 10pt;">Recessionary fears, high interest rates, inflation or other macroeconomic or political factors beyond our control may reduce demand for office space in the Austin, Texas area and may cause the market value of our commercial real estate property to decline.</td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-size: 10pt;">We may fail to find new tenants to occupy office space that may become vacant and available for lease in the future.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Please also refer to the section entitled &#x201c;Risk Factors&#x201d; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as such risk factors may be amended, updated or modified periodically in our reports filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for further information on these and other risks affecting us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We caution you not to place undue reliance on forward-looking statements because our future results may differ materially from those expressed or implied by them. We do not intend to update any forward-looking statement, whether written or oral, relating to the matters discussed in this Quarterly Report on Form 10-Q, except as required by law.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This Form 10-Q may also contain statistical data and drug information received from our&#xa0;independent consultants or based on industry publications or other publicly available information. We have not independently verified the accuracy or completeness of the data contained in these&#xa0;sources of data and information. Accordingly, we make no representations as to the accuracy or completeness of such data and&#xa0;information. You are cautioned not to give undue weight to such data and information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our research programs in neurodegeneration have benefited from longstanding scientific and financial support from the National Institutes of Health (&#x201c;NIH&#x201d;). The contents of this Quarterly Report on Form 10-Q are solely our responsibility and do not necessarily represent any official views of NIH, the Department of Health and Human Services, or the United States government.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#x2019;s disease. Our novel science is based on stabilizing &#x2013; but not removing &#x2013; a critical protein in the brain. Our lead therapeutic drug candidate, simufilam, is being evaluated for the proposed treatment of Alzheimer&#x2019;s disease dementia in Phase 3 clinical studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For more than 10 years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#x2019;s disease and other neurodegenerative diseases. Our strategy is to leverage our unique scientific/clinical platform to develop a first-in-class program for treating neurodegenerative diseases, such as Alzheimer&#x2019;s.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">We currently have two biopharmaceutical assets under development:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our lead therapeutic product candidate, called simufilam, is a novel oral treatment for Alzheimer&#x2019;s disease dementia; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer&#x2019;s disease from a small sample of blood.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our scientific approach for the treatment of Alzheimer&#x2019;s disease seeks to simultaneously suppress <i>both</i> neurodegeneration and neuroinflammation. We believe our ability to improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#x2019;s disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our lead product candidate, simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer&#x2019;s brain. Published studies have demonstrated that the altered form of FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation. We are currently conducting a Phase 3 program with simufilam in patients with mild-to-moderate Alzheimer&#x2019;s disease dementia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe simufilam improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering the downstream toxic effects of altered FLNA. We have generated and published experimental and clinical evidence of improved brain health with simufilam. Importantly, simufilam is not dependent on clearing amyloid from the brain. Since simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with those of other therapeutic candidates aiming to treat neurodegeneration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam has demonstrated a multitude of treatment effects in animal models of disease, including normalizing neurotransmission, decreasing neuroinflammation, suppressing neurodegeneration, and restoring memory and cognition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. SavaDx is being developed in-house with outside collaborators. We own exclusive, worldwide rights to drug and diagnostic assets and related technologies, without royalty obligations to any third party. Our patent protection with respect to simufilam and use of simufilam for Alzheimer&#x2019;s disease and other neurodegenerative diseases currently runs through 2039&#xa0;and includes seven issued U.S. patents. In addition, we have patent protection with respect to simufilam for use in treating certain cancers that runs through 2034. Our patent estate further includes patents and patent applications for related compounds and treatments. Corresponding foreign filings have been made for each of the U.S. filings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About Alzheimer</b>&#x2019;<b>s Disease</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Alzheimer&#x2019;s disease is a progressive neurodegenerative disorder that affects cognition, function and behavior. As of 2021, there were approximately 55&#xa0;million people worldwide living with dementia, a figure expected to increase to 139&#xa0;million by 2050 according to outside sources. The annual global cost of dementia is now above $1 trillion, according to Alzheimer&#x2019;s Disease International, a charitable organization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Phase 2a Study</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In 2019, we completed a small, first-in-patient, clinical-proof-of-concept, open-label Phase 2a study of simufilam in the U.S., with substantial support from the National Institute on Aging (NIA), a division of the NIH. Treatment with simufilam for 28 days significantly improved certain key biomarkers of Alzheimer&#x2019;s pathology, neurodegeneration and neuroinflammation (p&lt;0.001). Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 2b Study</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In September 2020, we announced final results of a Phase 2b study with simufilam in Alzheimer&#x2019;s disease. In this clinical study funded by the NIH, Alzheimer&#x2019;s patients treated with 50 mg or 100 mg of simufilam twice-daily for 28 days showed statistically significant (p&lt;0.05) improvements in CSF biomarkers of disease pathology, neurodegeneration and neuroinflammation, versus Alzheimer&#x2019;s patients who took placebo. In addition, Alzheimer&#x2019;s patients treated with simufilam showed improvements in validated tests of episodic memory and spatial working memory, versus patients on placebo. Cognitive improvements correlated most strongly with decreases in levels of P-tau181, an exploratory &#x2018;research use only&#x2019; non-safety related biomarker that suggests brain changes from Alzheimer&#x2019;s disease. Materials labeled as Research Use Only are intended for products that are still under development and are not commercially distributed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Open-label Study Strategy</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Much of the value of our open-label study is to support simufilam&#x2019;s long-term safety profile in patients. We believe a well-designed, long-term, open-label study is an exercise in prudent risk-management. Clinical results serve as a tool to help inform and manage the inherent risks and uncertainties of drug development for undertaking a large, expensive Phase 3 clinical testing program.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Open-label Study Top-line Results</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In March 2020, we initiated a long-term, open-label study to evaluate&#xa0;simufilam, our lead drug candidate,&#xa0;in patients with Alzheimer&#x2019;s disease.&#xa0;This study&#xa0;was funded in part by a research grant award from NIH. The study was designed to evaluate the long-term safety and tolerability of&#xa0;simufilam&#xa0;100 mg twice daily for 12 or more months. Another study objective was to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In January 2023, we announced positive top-line Phase 2 results for our open-label study. The study enrolled over 200 patients with mild-to-moderate Alzheimer&#x2019;s disease (MMSE 16-26). Endpoints were measured at baseline (study entry) and month 12.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Alzheimer&#x2019;s is a degenerative disease of the brain. Over time, cognition progressively worsens in the mild-to-moderate stages of Alzheimer&#x2019;s as the disease takes its toll. ADAS-Cog scores that change minimally (or improve) over 1 year is a highly desirable outcome in a clinical study of patients with mild-to-moderate Alzheimer&#x2019;s disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Top-line Results </b>&#x2013;<b> mean scores, baseline to month 12 </b>(<i>lower is better, except for MMSE)</i><b>:</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ADAS-Cog11 scores changed from 19.1 (&#xb1;9.2) to 19.6 (&#xb1;13.3)</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">MMSE scores changed from 21.5 (&#xb1;3.6) to 20.2 (&#xb1;6.4)</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">NPI10 scores changed from 3.2 (&#xb1;4.6) to 2.9 (&#xb1;4.6)</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">GDS scores changed from 1.8 (&#xb1;1.8) to 1.4 (&#xb1;1.9)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Response Analysis </b>&#x2013;<b> baseline to month 12</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">ADAS-Cog scores improved in 47% of patients; this group had a mean change of -4.7 (&#xb1;3.8) points (lower is better).</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In an additional 23% of patients, ADAS-Cog declined less than 5 points; this group had a mean change of 2.5 (&#xb1;1.4) points.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Patients with an NPI10 score of zero increased from 42% to 54%, indicating reduced dementia-related neuropsychiatric symptoms after 1 year on simufilam.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Analysis of Efficacy Endpoints</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Efficacy outcomes were analyzed by an independent, outside biostatistical consulting firm led by Suzanne Hendrix, PhD. The pre-specified primary efficacy endpoint was change in baseline on ADAS-Cog11, a cognitive scale widely used in Alzheimer&#x2019;s clinical research. Exploratory endpoints included the Mini-Mental State Examination (MMSE) to assess disease stage by cognitive impairment; the Neuropsychiatric Inventory (NPI10) to assess dementia related behavior; and the Geriatric Depression Scale (GDS). The Full Analysis Set (FAS) population (N=216) was used for the statistical analysis of efficacy endpoints.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Alzheimer&#x2019;s is a progressive disease. Severity of disease is typically assessed by MMSE score. In this study, mild patients are MMSE 21-26; moderate patients are MMSE 16-20. Mild and moderate sub-groups showed notable differences on changes in ADAS-Cog mean scores, baseline to month 12 (lower is better):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In the <i>mild</i>&#xa0;sub-group, ADAS-Cog scores improved, from 15.0 (&#xb1;6.3) to 12.6 (&#xb1;7.8)</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In the <i>moderate</i>&#xa0;sub-group, ADAS-Cog scores worsened, from 25.7 (&#xb1;9.2) to 30.1 (&#xb1;13.1)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe the improvement in ADAS-Cog over 1 year in mild patients taking simufilam is well outside the expected range of historic placebo decline rates from numerous other studies. Figure 1 presents a model of historical declines on ADAS-Cog in early disease (MCI + mild) and mild disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <div style="text-align: center;">
   <div>
    <img alt="a1.jpg" src="a1.jpg" /></div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Figure 1:</i></b><i> Statistical model of simufilam versus historical 1-year placebo declines on ADAS-Cog in early disease and mild disease.</i><i><sup style="vertical-align:top;line-height:120%;">1</sup></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Safety Data</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam 100 mg twice daily was generally safe and well tolerated in this open-label study. There were no drug-related serious adverse events. Three treatment-emergent adverse events (TEAEs) occurred in 7% or more of study patients: COVID-19 (12%), urinary tract infection (10%) and headache (9%). Reported TEAEs are based on all study patients who received at least one dose of drug. The top three reasons for patient discontinuations were withdrawal of informed consent (N=14), adverse events (N=13) and patient non-compliance (N=7).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Biomarker Data</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Exploratory biomarkers were analyzed from cerebrospinal fluid (CSF) collected from 25 patients in the open-label study who agreed to undergo a lumbar puncture at baseline and again after 6 months of treatment. CSF samples were analyzed blind by our academic collaborator at City University of New York. All CSF biomarkers were &#x2018;research use only&#x2019;, non-safety-related exploratory biomarkers. We previously announced results of this bioanalysis in a press release dated July 29, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">P-values shown below are baseline vs. 6-month levels by paired t-test:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">CSF biomarkers of disease pathology, t-tau and p-tau181, decreased 38% and 18%, respectively (both p&lt;0.00001)</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">CSF biomarkers of neurodegeneration, neurogranin and neurofilament light chain (NfL), decreased 72% and 55%, respectively (both p&lt;0.00001)</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">CSF biomarkers of neuroinflammation, sTREM2 and YKL-40, decreased 65% and 44% (both p&lt;0.00001)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Limitations of Open-label Study and Top-line Results</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Data results from our open-label safety study do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for simufilam in Alzheimer&#x2019;s disease. Rigorous evidence for drug safety and efficacy is derived from one or more large, randomized, placebo-controlled studies. The open-label design and size of this study may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our open-label study add complexity or limitations to the scope of data interpretation. In addition, &#x2018;top-line data&#x2019; is a summary of the clinical data prior to the completion of a full and final audit or quality-control of the clinical database. We communicated top-line data so that stakeholders had timely access to a summary of the study&#x2019;s findings prior to us receiving the final dataset. Final data may change from initial top-line data.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">1 </sup>Figure 1: Forest plot model by our independent consultant, Pentara Corporation. Data was sourced from non-randomized studies (i.e., ADNI) and randomized, controlled trials conducted by other sponsors in patients with early (i.e., MCI + mild) and mild Alzheimer&#x2019;s disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Cognition Maintenance Study&#xa0;(aka, Randomized Withdrawal Study)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In May 2021, we initiated a Cognition Maintenance Study (CMS). The CMS is a randomized, withdrawal study design. ICH<sup style="vertical-align:top;line-height:120%;">2</sup> defines this type of study design as follows: &#x201c;<i>In a randomized withdrawal trial, subjects receiving a test</i>&#xa0;<i>treatment for a specified time are randomly assigned to continued treatment with the test treatment or to placebo (i.e., withdrawal of active therapy) </i>&#x2026;&#xa0;<i>Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment</i>.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CMS study design is intended to evaluate simufilam&#x2019;s effects on cognition and health outcomes in Alzheimer&#x2019;s patients who continue with drug treatment versus patients who discontinue drug treatment. It is a double-blind, randomized, placebo-controlled study of simufilam in patients with mild-to-moderate Alzheimer&#x2019;s disease. Study patients are randomized (1:1) to simufilam or placebo for six months. To enroll in this study, patients must have previously completed 12 months or more of open-label treatment with simufilam. Final enrollment was 157 patients. See Figure 2.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Figure 2. Cognition Maintenance Study Design</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="cass02.jpg" src="cass02.jpg" style="width:623;height:193;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Top-line Results</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam treatment for 6 months slowed cognitive decline by 38% compared to placebo in mild-to-moderate Alzheimer&#x2019;s disease (MMSE 16-26). The placebo arm declined 1.5 points on ADAS-Cog, and this arm declined at all measured timepoints. The simufilam arm declined 0.9 points on ADAS-Cog, a 38% difference in favor of drug at month 6 (95% CI, &#x2013; 2.1 to 1.0; not significant for sample sizes). See Table 1 and Chart 1.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Table 1: Results of Randomized Withdrawal Study </i></b>&#x2013;<b><i> cognitive change, full analysis set (FAS)</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 10%; margin-right: 10%; border-left: 1px solid black; border-right: 1px solid black; border-top: 1px solid black;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i>Full Analysis Set</i></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Simufilam 100 mg</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(N = 78)</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Placebo</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(N = 77)</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Numerical</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Difference</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent Difference</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6-month Change in</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">ADAS-Cog</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">0.9 point</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Decline</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1.5 point</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Decline</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#x2013;&#xa0;0.6</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">38% in favor of drug</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">2 </sup>International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), Topic E10, Choice of Control Group in Clinical Trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="a03.jpg" src="a03.jpg" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Upon randomization into the CMS, mean baseline MMSE scores were 18.6 and 18.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores were 19.3 and 21.9 for the simufilam and placebo arms, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Simufilam Drug Effects Favored Patients with Mild Alzheimer</i></b>&#x2019;<b><i>s Disease.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam treatment for 6 months slowed cognitive decline &gt; 200% compared to placebo in mild Alzheimer&#x2019;s disease. CMS patients with mild Alzheimer&#x2019;s (MMSE 21-26) on placebo declined 0.6 points on ADAS-Cog over 6 months as a group. CMS patients with mild Alzheimer&#x2019;s on simufilam improved 0.6 points over 6 months as a group, a 205% difference in favor of drug (95% CI, &#x2013; 2.6 to 0.4; not significant for sample sizes). See Table 2 and Chart 2.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Table 2: Results of Randomized Withdrawal Study </i></b>&#x2013;<b><i> cognitive change, mild patients</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 10%; margin-right: 10%; border-left: 1px solid black; border-right: 1px solid black; border-top: 1px solid black;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i>Mild Patients</i></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Simufilam 100 mg</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(N= 40)</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Placebo</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(N= 36)</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Numerical</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Difference</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent Difference</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6-month Changes in</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">ADAS-Cog</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">0.6 point</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Improvement</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">0.6 point</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Decline</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#x2013;1.1</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">205% in favor of drug</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div style="text-align: center;">
   <div>
    <img alt="chart_2.jpg" src="chart_2.jpg" /></div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Upon randomization into the CMS, mean baseline MMSE scores for mild patients were MMSE 24.0 and MMSE 24.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores for mild patients were 11.0 and 11.2 for the simufilam and placebo arms, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Simufilam for 18 months stabilized cognition in mild Alzheimer</i></b>&#x2019;<b><i>s disease.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">After taking open-label simufilam for 12 months, 76 patients with mild Alzheimer&#x2019;s disease (MMSE 21-26) enrolled in the CMS and were randomized to receive either simufilam (N=40) or placebo (N=36) for 6 months. Mild patients randomized to simufilam in the CMS showed no material decline in ADAS-Cog scores over 18 months as a group, indicating stable cognition. Mild patients randomized to placebo in the CMS (and therefore withdrawn from simufilam treatment for 6 months) declined by 0.8 points in ADAS-Cog as a group. See Figure 3.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="a04.jpg" src="a04.jpg" /></p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Figure 3. Historical declines on ADAS-Cog over 18 months in Alzheimer's disease (MMSE 20-30), placebo arms vs simufilam treatment.</i></b><b><i><sup style="vertical-align:top;line-height:120%;">1</sup></i></b><b><i> </i></b><i>Notes: results shown for CLARITY P3 trial of lecanemab; EMERGE and ENGAGE P3 studies of aducanumab; and TRAILBLAZER P3 trial of donanemab; in this figure, the CMS is referred to as the </i>&#x2018;<i>PTI-125-04</i>&#x2019;<i> study; </i>&#x2018;<i>Simufilam100mg-Simufilam100mg</i>&#x2019;<i> refers to patients who received simufilam in both the open-label phase and the CMS; </i>&#x2018;<i>Simufilam100mg-Placebo</i>&#x2019;<i> refers to patients who received simufilam in the open-label phase and placebo in the CMS.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">1</sup> Figure 3: Forest plot by our independent consultant, Pentara Corporation. Data was sourced from the placebo groups in randomized, controlled trials of monoclonal antibodies conducted by other sponsors in Alzheimer&#x2019;s disease (MMSE 20-30).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Safety Data</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam 100 mg twice daily was safe and well tolerated in this study. There were no drug-related serious adverse events. No treatment-emergent adverse events (TEAEs) occurred in 5% or more of study participants in the CMS, except for COVID-19 which was reported in 6% of patients on drug vs 5% of patients on placebo, and falls, which was reported in 5% of patients on placebo vs 1% of patients on drug.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Discussion</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CMS was a randomized withdrawal study. Patients who completed 12 months of open-label simufilam treatment were all invited to participate in the CMS. It is not known how long a washout period may be needed to remove lingering drug effects, if any, from prior treatment with open-label simufilam for 12 months.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In this small study of oral simufilam in patients with mild-to-moderate Alzheimer&#x2019;s disease, the pre-specified cognitive endpoint showed a 38% decline in ADAS-Cog over six months in favor of simufilam&#xa0;(not statistically significant), with good drug safety. Effects were pronounced in mild patients. Mean baseline MMSE and ADAS-Cog scores were approximately balanced given the small size of each arm.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Analysis of Efficacy Endpoints</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The pre-specified cognition endpoints were analyzed by Pentara Corporation, an independent consulting firm that specializes in complex statistical analysis of clinical trial results. Suzanne Hendrix, PhD, CEO of Pentara, has over 150 peer-reviewed publications of clinical trial results and statistical approaches for clinical trials, many focusing on statistical methodology for Alzheimer&#x2019;s disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Chain of Custody for Clinical Data</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Investigator sites collected clinical data from study participants. Sites entered their clinical data directly into an electronic data capture system managed by an independent, outside data management vendor. The data management vendor also maintains the clinical database. The data management vendor transmitted the clinical database directly to Pentara Corporation for analysis.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Study Limitations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CMS is a proof-of-concept study involving a small number of patients and limited data. Top-line clinical CMS results do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for simufilam in Alzheimer&#x2019;s disease. Rigorous evidence for drug safety and efficacy is derived from one or more large, randomized placebo-controlled Phase 3 studies. The limited size of the CMS may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our CMS study add complexity or limitations to the scope of data interpretation. In addition, &#x2018;Top-line data&#x2019; is a summary of the clinical data prior to the completion of a full and final audit or quality-control of the clinical database. We are communicating top-line data so that stakeholders may have timely access to a summary of the CMS findings prior to us receiving the final dataset. Final data may change from initial top-line data.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>End-of-Phase 2 (EOP2) Meeting with FDA</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In January 2021, we held an End-of-phase 2 (EOP2) meeting for simufilam with the U.S. Food and Drug Administration (FDA). The purpose of this EOP2 meeting was to gain general agreement around key elements of a pivotal Phase 3 program to treat Alzheimer&#x2019;s disease dementia. FDA attendees included Robert Temple, MD, Deputy Center Director for Clinical Science and Senior Advisor in the Office of New Drugs; Billy Dunn, MD, Director, Office of Neuroscience; Eric Bastings, MD, Director, Division of Neurology, and others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In February 2021, we announced the successful completion of our EOP2 meeting. Official meeting minutes confirm that we and FDA are aligned on key elements of a Phase 3 clinical program for simufilam. FDA has agreed that the completed Phase 2 program, together with an ongoing and well-defined Phase 3 clinical program, are sufficient to show evidence of clinical efficacy for simufilam in Alzheimer&#x2019;s disease. There is also agreement that the use of separate clinical scales to assess cognition (ADAS-cog<sup style="vertical-align:top;line-height:120%;">1</sup>) and function (ADCS-ADL<sup style="vertical-align:top;line-height:120%;">2</sup>) are appropriate co-primary endpoints of efficacy. A clinical scale that combines cognition and function, such as iADRS<sup style="vertical-align:top;line-height:120%;">3</sup>, is a secondary efficacy endpoint.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Special Protocol Assessments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In August 2021, we announced that we had reached agreement with FDA under a Special Protocol Assessment (SPA) for both Phase 3 studies. These SPA agreements document that FDA has reviewed and agreed upon the key design features of our Phase 3 study protocols of simufilam for the treatment of patients with Alzheimer&#x2019;s disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">An SPA agreement indicates concurrence by the FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, etc.). These elements are critical to ensure that our planned Phase 3 studies of simufilam in Alzheimer&#x2019;s disease can be considered adequate and well-controlled studies in support of a future regulatory submission and marketing application.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The first clinical study protocol under the SPA is titled &#x201c;<i>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of One Dose of Simufilam in Subjects with Mild-to-Moderate Alzheimer's Disease.</i>&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The second clinical study protocol under the SPA is titled &#x201c;<i>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects with Mild-to-Moderate Alzheimer</i>&#x2019;<i>s Disease.</i>&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 3 Drug Supply</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik supplies and is expected to continue to supply us with large-scale, clinical-grade quantities of simufilam. Evonik is one of the world&#x2019;s largest contract development and manufacturing organizations for pharmaceutical ingredients. Other vendors supply excipients, the finished dosage form (i.e., simufilam tablets), drug packaging, package labeling and other critical steps in the supply chain for Phase 3 drug supply.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Phase 3 Clinical Program Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our Phase 3 program consists of two large, double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer&#x2019;s disease dementia. Both studies are designed to measure changes in cognition and function during their treatment period. Highlights of this clinical program are summarized in Figure 4.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In June 2021, we announced the selection of Premier Research International as our CRO to help conduct our Phase 3 clinical program.&#xa0;Phase 3 clinical sites are located in the United States, Canada, Puerto Rico, Australia, and South Korea.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><sup style="vertical-align:top;line-height:120%;">1</sup></i><i> ADAS-Cog = The Alzheimer</i>&#x2019;<i>s Disease Assessment Scale </i>&#x2013;<i> Cognitive Subscale, a measure of cognition </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><sup style="vertical-align:top;line-height:120%;">2</sup></i><i> ADCS-ADL = Alzheimer</i>&#x2019;<i>s Disease Cooperative Study </i>&#x2013;<i> Activities of Daily Living, a measure of health function</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><sup style="vertical-align:top;line-height:120%;">3</sup></i><i> iADRS =</i> <i>integrated Alzheimer</i>&#x2019;<i>s Disease Rating Scale, a composite measure of cognition and health function</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Figure 4. Summary of Our Phase 3 Clinical Program</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -171pt; text-indent: 126pt;"><img alt="cass01.jpg" src="cass01.jpg" style="width:622;height:121;" /></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RETHINK-ALZ and REFOCUS-ALZ</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In Fall 2021, we announced initiation of our two Phase 3 studies of simufilam in mild-to-moderate Alzheimer&#x2019;s disease dementia. By early November 2023, we had announced the completion of patient enrollment in both Phase 3 studies. A total of approximately 1,900 patients have enrolled in these studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg over 52 weeks. Details of the RETHINK-ALZ Phase 3 study include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Enrollment completed&#xa0;&#x2013; approximately 800&#xa0;patients with mild-to-moderate Alzheimer&#x2019;s disease&#xa0;dementia.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Patients are&#xa0;randomized (1:1) to simufilam 100 mg or placebo twice daily.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Patients are&#xa0;treated for 12 months.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The co-primary efficacy endpoints are ADAS-Cog12<sup style="vertical-align:top;line-height:120%;">1</sup>, a cognitive scale, and ADCS-ADL<sup style="vertical-align:top;line-height:120%;">2</sup>, a functional scale; both are standard clinical tools in trials of Alzheimer&#x2019;s disease.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A secondary efficacy endpoint is iADRS<sup style="vertical-align:top;line-height:120%;">3</sup>, a standard clinical tool in trials of Alzheimer&#x2019;s disease that combines cognitive and functional scores from ADAS-Cog &amp; ADCS-ADL.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Other secondary endpoints include plasma biomarkers of disease and NPI<sup style="vertical-align:top;line-height:120%;">4</sup>, a clinical tool that assesses the presence and severity of dementia-related behavior.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our second Phase 3 study, called REFOCUS-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 76 weeks. Details of the REFOCUS-ALZ Phase 3 study include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Enrollment completed&#xa0;&#x2013; approximately 1,100&#xa0;patients with mild-to-moderate Alzheimer&#x2019;s disease dementia.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Patients are&#xa0;randomized (1:1:1) to simufilam 100 mg, 50 mg, or placebo BID.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Patients are&#xa0;treated for 76 weeks.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The co-primary efficacy endpoints are ADAS-Cog12<sup style="vertical-align:top;line-height:120%;">1</sup>, a cognitive scale, and ADCS-ADL<sup style="vertical-align:top;line-height:120%;">2</sup>, a functional scale; both are widely used clinical tools in trials of Alzheimer&#x2019;s disease.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A secondary efficacy endpoint is iADRS<sup style="vertical-align:top;line-height:120%;">3</sup>, a widely used clinical tool in trials of Alzheimer&#x2019;s disease that combines cognitive and functional scores from ADAS-Cog &amp; ADCS-ADL.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;">&#x25ba;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Other secondary endpoints include CSF, plasma and imaging biomarkers of disease and NPI<sup style="vertical-align:top;line-height:120%;">4</sup>, a clinical tool that assesses the presence and severity of dementia-related behavior.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><sup style="vertical-align:top;line-height:120%;">1</sup></i><i> ADAS-Cog = The Alzheimer</i>&#x2019;<i>s Disease Assessment Scale </i>&#x2013;<i> Cognitive Subscale, a measure of cognition </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><sup style="vertical-align:top;line-height:120%;">2</sup></i><i> ADCS-ADL = Alzheimer</i>&#x2019;<i>s Disease Cooperative Study </i>&#x2013;<i> Activities of Daily Living, a measure of health function</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><sup style="vertical-align:top;line-height:120%;">3</sup></i><i> iADRS = integrated Alzheimer</i>&#x2019;<i>s Disease Rating Scale, a composite measure of cognition and health function</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><sup style="vertical-align:top;line-height:120%;">4</sup></i><i> Neuropsychiatric Inventory (NPI)</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     29
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 3 Entry Criteria Includes a Plasma Assay for Phosphorylated Tau (pTau)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe plasma levels of pTau proteins can provide independent confirmation of Alzheimer&#x2019;s neuropathology. RETHINK-ALZ and REFOCUS-ALZ studies use a &#x2018;research use only&#x2019;, non-safety related exploratory P-tau181 plasma assay to qualify mild-to-moderate Alzheimer&#x2019;s patients. The plasma assay we use does not rely on age, APOE-gene status or complex algorithms to provide a result.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Data and Safety Monitoring Board (DSMB)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">In September 2023, we announced a&#xa0;positive interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer&#x2019;s disease. A&#xa0;scheduled meeting of a DSMB&#xa0;recommended that both of our&#xa0;Phase 3 studies of simufilam continue as planned, without modification. This DSMB only reviewed&#xa0;patient safety. It did&#xa0;not assess drug efficacy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt; text-align: justify;"><b>Interim MRI Safety Data&#xa0;</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">In October&#xa0;2023, we announced&#xa0;a potentially significant safety finding based on interim magnetic resonance imaging (MRI) brain data from Alzheimer&#x2019;s patients who are enrolled in a Phase 3 clinical trial of simufilam. These MRI data suggest simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities, or ARIA. MRIs were all analyzed for ARIA by independent, board-certified neuroradiologists.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">ARIA is a medical term used to describe a spectrum of brain MRI imaging abnormalities, such as brain swelling&#xa0;and brain bleeds. ARIA is also a known risk factor for Alzheimer&#x2019;s patients taking the class of drugs known as monoclonal antibodies directed against&#xa0;amyloid. In contrast to such class of drugs, simufilam is a&#xa0;small-molecule (oral) drug candidate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">The new safety finding is based on an independent, interim neuroradiological evaluation of brain MRIs taken at week 40 in a blinded sub-study of 180 Alzheimer&#x2019;s patients enrolled in our&#xa0;on-going 76-week Phase 3 clinical trial of simufilam in mild-to-moderate Alzheimer&#x2019;s (NCT#05026177). Final MRI data is expected at the conclusion of this Phase 3 study.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Open-label Extension Study for the Phase 3 Program</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In October 2022, we announced the initiation of an open-label extension study for our Phase 3 program. This study is designed to provide no-cost access to oral simufilam for up to one year to Alzheimer&#x2019;s patients who have successfully completed a Phase 3 study of simufilam and who meet other entry criteria.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The open-label extension study is expected to generate long-term safety and tolerability data for (oral) simufilam 100 mg twice daily over 52 weeks. There is no obligation for a patient or a physician to participate in the open-label extension study. Each clinical investigational site and each patient chooses whether to participate in this open-label extension study. Patient enrollment for this study began November 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Publication Confirming Mechanism of Action of Simufilam</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">In September 2023, we&#xa0;announced the publication of new research that confirms the biological activity of simufilam. Researchers at the Cochin Institute (Paris, France) used a highly precise cell-based assay to show that simufilam interrupts amyloid binding to the &#x3b1;7 nicotinic acetylcholine receptor (&#x3b1;7nAChR). We&#xa0;believe&#xa0;this protein interaction underlies simufilam&#x2019;s mechanism of action in Alzheimer&#x2019;s disease. The research appears in a special<i> </i>issue of <i>International Journal of Molecular Sciences, </i>a peer-reviewed scientific publication.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt; text-align: justify;"><b>Publication Showing Simufilam Suppresses Overactive mTOR</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In June 2023, we&#xa0;announced the publication of new research that showed the effects of simufilam on mTOR. Scientific literature shows overactive mTOR plays a key role in aging, Alzheimer&#x2019;s disease and other conditions. When functioning normally, mTOR monitors cellular needs and is activated by insulin. The new published research shows mTOR is overactive in lymphocytes isolated from blood collected from Alzheimer's patients versus healthy controls. After oral administration of simufilam 100 mg twice daily to Alzheimer's patients for 28 days, lymphocytes showed normalized mTOR activity and restored mTOR sensitivity to insulin. These data suggest a meaningful impact of simufilam on mTOR signaling. The research appeared in <i>Frontiers in Aging</i>, a peer-reviewed scientific publication.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>SavaDx</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our investigational product candidate, called SavaDx, is early-stage program focused on detecting the presence of Alzheimer&#x2019;s disease from a small sample of blood. For business, technical and personnel reasons, we continue to prioritize the development of simufilam, our novel drug candidate, over SavaDx, our novel diagnostic candidate. SavaDx is a research-use only, non-safety related exploratory biomarker.&#xa0;SavaDx accounts for 1% or less of our research budget.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The regulatory pathway for SavaDx may eventually include formal analytical validation studies and clinical studies that support evidence of sensitivity, specificity and other variables in various healthy and diseased patient populations. We have not conducted such studies and do not expect to conduct such studies in 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">SavaDx is currently designed as an antibody-based detection system for altered filamin A (FLNA). Working with third parties, we are evaluating the use of mass spectrometry to detect FLNA, i.e., without the use of antibodies. These evaluations are on-going.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Financial Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have yet to generate any revenues from product sales. We have an accumulated deficit of $359.9&#xa0;million at September 30, 2023. These losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related costs and general corporate expenses. Research and development activities include costs of clinical and preclinical trials as well as clinical supplies associated with our product candidates. Salaries and other personnel-related costs include stock-based compensation associated with stock options and other equity awards granted to employees and non-employees. Our operating results may fluctuate substantially from period to period as a result of enrollment rates of clinical trials for our product candidates, timing of preclinical activities and our need for clinical supplies.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">We expect to continue to use significant cash resources in our operations for the next several years. Our cash requirements for operating activities and capital expenditures may increase in the future as we:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">continue our ongoing Phase 3 program with simufilam;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">manufacture large-scale supplies for simufilam;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">conduct other preclinical and clinical studies for our product candidates;&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">seek regulatory approvals for our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">develop, formulate, manufacture and commercialize our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">implement additional internal systems and develop new infrastructure;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">acquire or in-license additional products or technologies, or expand the use of our technology;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">maintain, defend and expand the scope of our intellectual property;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">incur costs related to legal proceedings and claims, including U.S. government inquiries; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">hire additional personnel.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. If our development efforts result in regulatory approval and successful commercialization of our product candidates, we expect to generate revenue from direct sales of our drugs and/or, if we license our drugs to future collaborators, from the receipt of license fees and royalties from sales of licensed products. We conduct our research and development programs through a combination of internal and collaborative programs. We rely on arrangements with universities, certain collaborators, contract development and manufacturing organizations (CDMOs), CROs and clinical research sites for a significant portion of our product development efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We focus substantially all of our research and development efforts in the development of simufilam. Research and development expenses for our investigational diagnostic product candidate, SavaDx, represented less than 1% of total research and development expenses for the periods presented. The following table summarizes expenses by category for research and development efforts (in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Three months ended</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Nine months ended</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>September 30,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>September 30,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Clinical trials</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">19,532</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">14,778</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">57,018</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">39,592</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Pre-clinical projects</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,290</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,022</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,464</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,411</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Chemical, Manufacturing and Controls costs (&#x201c;CMC costs&#x201d;)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">602</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">668</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,834</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,080</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel related</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,450</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,365</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,273</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,278</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock-based compensation</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">405</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">399</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,186</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,234</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Other</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">324</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">294</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">917</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">785</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">23,603</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">18,526</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">70,692</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">50,380</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical trial costs include the costs of our CRO. CMC costs include&#xa0;costs related to our contract development and manufacturing organizations. Research and development expenses include compensation, contractor fees and supplies as well as allocated common costs such as facilities.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the three and nine months ended September 30, 2023, we did not receive reimbursement from NIH research grants. During the three and nine months ended September 30, 2022, we received $0.4 million and $0.9&#xa0;million from NIH research grants, respectively. These reimbursements were recorded as a reduction to our research and development expenses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Estimating the dates of completion of clinical development, and the costs to complete development, of our product candidates would be highly speculative, subjective and potentially misleading. Pharmaceutical product candidates take a significant amount of time to research, develop and commercialize. The clinical trial portion of the development of a new drug alone usually spans several years. The cost and pace of our future research and development activities are linked and subject to change.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Accounting Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with&#xa0;U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses and net loss incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">There have been no material changes to our critical accounting estimates during the&#xa0;nine months ended September 30, 2023 from those described in &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on&#xa0;February 28, 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Results of Operations </b>&#x2013;<b> Three and Nine Months Ended September 30, 2023 and 2022</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and Development Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses consist primarily of costs of drug development work associated with our product candidates, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">clinical trials,</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">pre-clinical testing,</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">clinical supplies and related formulation and design costs, and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">compensation and other personnel-related expenses.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses were $23.6&#xa0;million and $18.5&#xa0;million during the three months ended September 30, 2023 and 2022, respectively. This 27% increase was due primarily to increasing enrollment and costs to conduct the ongoing Phase 3 clinical program and open-label studies in simufilam compared to the prior year.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses were $70.7&#xa0;million and $50.4&#xa0;million during the nine months ended September 30, 2023 and 2022, respectively. This 40% increase was due primarily to increasing enrollment and costs to conduct the ongoing Phase 3 clinical program and open-label studies in simufilam as well as higher preclinical costs compared to the prior year.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect research and development expense to continue to increase in 2023 compared to&#xa0;2022 as we conduct a Phase 3 clinical program and other clinical studies with simufilam, continue to hire new personnel, manufacture drug supply, and continue our development efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>General and Administrative Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. Allocated expenses consist primarily of facility costs for our Company owned office complex in Austin, Texas. Depreciation and amortization for office space leased but not occupied by the Company is included in general and administrative expense. Depreciation and amortization for office space occupied by the Company is allocated between general and administrative expense and research and development expense. We also incur expenses associated with operating as a public company, including additional legal fees, expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance and audit expenses, investor relations activities, Sarbanes-Oxley compliance expenses and other administrative expenses and professional services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">General and administrative expenses were $4.3&#xa0;million and $2.8&#xa0;million during the three months ended September 30, 2023 and 2022, respectively. The 52% increase was due primarily to $1.0&#xa0;million in higher legal expenses due to ongoing legal matters as well as a $0.5&#xa0;million increase in stock-based compensation expense due to new grant awards compared to the prior year.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">General and administrative expenses were $12.5&#xa0;million and $8.7&#xa0;million during the nine months ended September 30, 2023 and 2022, respectively. The 43% increase was due primarily to $2.2&#xa0;million in higher legal expenses due to ongoing legal matters, a $1.1&#xa0;million increase in stock-based compensation expense due to new grant awards as well as an increase in headcount and personnel costs compared to the prior year.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect general and administrative expense for 2023 will continue to increase compared to&#xa0;2022 due primarily to stock-based compensation increases due to new grant awards during the period and higher legal and professional fees related to ongoing securities class action and derivative lawsuits, governmental investigations as well the Company&#x2019;s lawsuit against a hedge fund and certain individuals who we believe executed a &#x201c;short and distort&#x201d; campaign against the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Interest Income </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Interest income was $2.0&#xa0;million and $0.9&#xa0;million during the three months ended September 30, 2023 and 2022, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Interest income was $6.3&#xa0;million and $1.2&#xa0;million during the nine months ended September 30, 2023 and 2022, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The increase in interest income was due to increases in interest rates compared to the prior periods.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect interest income to continue to increase&#xa0;in 2023 compared to&#xa0;2022 due to increases in interest rates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other income, net </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We record the activities related to leasing office space to third parties in buildings we own as other income, net, as leasing is not core to the Company&#x2019;s operations. Other income, net, was $223,000 and $210,000 during the three months ended September 30, 2023 and 2022, respectively. Other income, net, was $0.6&#xa0;million and $0.7&#xa0;million during the nine months ended September 30, 2023 and 2022, respectively. Other income, net, was lower in the three and nine months ended September 30, 2023 as occupancy related expenses were higher in 2023 compared to the prior year periods as the Company began occupying approximately 25% of the property beginning late August 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation and amortization for the office complex is included in general and administrative and research and development expense, and thus not reflected in other income, net.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity and Capital Resources</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Since inception, we have financed our operations primarily through public and private stock offerings, payments received under collaboration agreements and interest earned on our cash and cash equivalents balances. We intend to continue to use our capital resources to fund research and development activities, capital expenditures, working capital requirements and other general corporate purposes. As of September 30, 2023, cash and cash equivalents were $142.4 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>2022 Registered Direct Offering</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On November 22, 2022, we completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#xa0;million after deducting offering expenses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At-the-Market Common Stock Offering </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On May 1, 2023, we entered into an&#xa0;at-the-market offering program (&#x201c;ATM&#x201d;) to sell, from time to time, shares of our common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the SEC on May 1, 2023 and became effective immediately upon filing. We are obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock in the offering. We are not obligated to sell any shares in the offering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were no common stock sales under the ATM during the three and nine months ended September 30, 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In March 2020, we entered into&#xa0;an at-the-market offering program (&#x201c;2020 Program&#x201d;) to sell, from time to time, shares of our common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on May 5, 2020. We gave notice of termination for the 2020 Program effective on April 26, 2023, which was effective May 1, 2023. There were no common stock sales under the 2020 Program through its termination.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>2020 Cash Incentive Bonus Plan Obligations</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In August 2020, the Company's Board of Directors (the "Board") approved the 2020 Cash Incentive Bonus Plan (the "Plan"). The Plan was established to promote the long-term success of the Company by creating an &#x201c;at-risk&#x201d; cash bonus program that rewards&#xa0;Plan&#xa0;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The Plan is considered &#x201c;at-risk&#x201d; because Plan participants&#xa0;will&#xa0;not receive a cash bonus&#xa0;unless&#xa0;the Company&#x2019;s market capitalization increases&#xa0;significantly and&#xa0;certain&#xa0;other&#xa0;conditions specified in the Plan&#xa0;are met.&#xa0;Specifically, Plan participants&#xa0;will&#xa0;not&#xa0;be paid&#xa0;any cash bonuses unless (1) the Company completes a&#xa0;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a "Merger Transaction") or (2) the Compensation Committee&#xa0;determines the Company has sufficient cash on hand, as defined in the Plan. Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of December 31, 2022, the Company&#x2019;s independent directors were participants in the Plan. However, effective March 16, 2023, the Board&#xa0;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#x2019; share of potential benefits under the Plan were completely forfeited to the Company and will not be allocated to any other participant under the Plan. Our independent directors have not received, and as a result of such amendment will never receive, any payments under the Plan.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#x2019;s market capitalization, including all outstanding stock options, was $89.4&#xa0;million at the inception of the Plan in August 2020. If the Company were to exceed a $5&#xa0;billion market capitalization&#xa0;for no less than 20 consecutive trading days, and conditions noted above for payment are met, all&#xa0;Plan milestones would be deemed achieved, in which case total cash bonus awards would&#xa0;range from&#xa0;a minimum of&#xa0;$111.4&#xa0;million&#xa0;up to&#xa0;a hypothetical maximum of&#xa0;$289.7&#xa0;million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#x2019;s potential financial obligation to plan participants at September 30, 2023 totaled $6.5&#xa0;million (after the March 2023 Plan amendment), based upon the achievement of one Plan milestone in the Company&#x2019;s market capitalization in 2020. No actual cash bonus payments have been made to any Plan participant, as the Company has not yet satisfied all the conditions necessary for amounts to be paid under the Plan. During the year ended December&#xa0;31, 2021, the Company&#x2019;s market capitalization increased substantially. These increases triggered the achievement of 11 additional Plan milestones. Collectively, the achievement of such milestones could trigger potential Company obligations to Plan participants ranging from a minimum of $74.9&#xa0;million up to a hypothetical maximum of $202.3&#xa0;million, with exact amounts to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No Valuation Milestones were achieved during the 2022 or the nine months ended September 30, 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No actual cash payments were authorized or made to participants under the Plan as of September 30, 2023, or through the filing date of this Form 10-Q.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Cash</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in operating activities was $59.7&#xa0;million for the nine months ended September 30, 2023, resulting primarily from the net loss of $76.3&#xa0;million, partially offset by an increase in accounts payable and accrued expenses of $5.8&#xa0;million, an increase in accrued developmental expenses of $5.1&#xa0;million, a decrease in in prepaid and other current assets of $2.4&#xa0;million and stock-based compensation expense of $2.5 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Net cash used in operating activities was $56.2&#xa0;million for the nine months ended September 30, 2022, resulting primarily from the net loss reported of $57.1 million, a decrease in accounts payable of $3.6 million and accrued compensation and benefits of $1.7 million, partially offset by a decrease in in prepaid and other assets of $2.8 million, an increase in accrued developmental expenses of $1.3 million and stock-based compensation expense of $1.5 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in investing activities during the&#xa0;nine months ended September 30, 2023 was $0.4 million as final payment was made on renovations and fixtures for our corporate headquarters.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in investing activities during the&#xa0;nine months ended September 30, 2022 was $3.0&#xa0;million related to renovations and fixtures for our corporate headquarters.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities during the nine months ended September 30, 2023 was $1.4&#xa0;million, from the exercise of stock options.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities during the&#xa0;nine months ended September 30, 2022 was $0.5&#xa0;million, from the exercise of stock options.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and Leases</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We own an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. This property is intended to accommodate our anticipated growth and expansion of our operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are outsourced to professional real-estate managers. Our office complex has&#xa0;approximately 90,000 square feet of rentable space. At September 30, 2023, the property was over 60% leased. We occupy approximately 25% of the property since&#xa0;late August 2022. Virtually all&#xa0;tenant&#xa0;leases will expire&#xa0;in 2024. We believe tenant leases that expire in 2024 may&#xa0;not be extended, renewed or re-leased beyond their expiry date, in which case we will no longer receive rental payments or reimbursement for shared expense for such office space.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We previously leased a different location with approximately 6,000 square feet of office space pursuant to an operating lease in Austin, Texas expiring in April 2024. We and the landlord consented to early terminate this lease on February 22, 2023 with no continuing obligations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Other Commitments</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have an accumulated deficit of $359.9&#xa0;million as of September 30, 2023. We expect our cash requirements to be significant in the future. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our drug candidates, the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products and other corporate needs. We believe that our current cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months. We may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to us. However, there are no assurances that additional financing will be available on favorable terms, or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><a id="qqd" title="qqd" href="#"></a>Item 3. </b><b><i>Quantitative and Qualitative Disclosures About Market Risk</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate sensitivities and, to a lesser extent, currency fluctuations related to our clinical operations outside the U.S.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Interest Rate Sensitivity</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents of $142.4 million as of September 30, 2023, which consisted primarily of U.S. Treasury securities and money market accounts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain investment vehicles with high credit quality and short-term duration, in accordance with our Board-approved investment policy. Such interest-earning instruments carry a degree of interest rate risk. However, due to the generally short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point increase or decrease in interest rates during any of the periods presented would increase or decrease our annual net loss by less than $2 million in our condensed consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="controls" title="controls" href="#"></a>Item 4. </b><b><i>Controls and Procedures</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Evaluation of disclosure controls and procedures. </i>Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer (as Principal Executive Officer) and our Chief Financial Officer (as Principal Financial Officer) have concluded that our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Changes in internal control over financial reporting. </i>There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified during the three months ended&#xa0;September 30, 2023 that has materially affected, or is reasonable likely to materially affect, our internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>PART II </b>&#x2013;<b> OTHER INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="legal" title="legal" href="#"></a>Item 1. </b><b><i>Legal Proceedings</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">From time to time, we may become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA, and may receive inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to us. No information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, no accrual for these matters has been recorded within the condensed consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Government Investigations</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On November 15, 2021, the Company disclosed that certain government agencies had asked the Company to provide corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and intends to continue to cooperate with these inquiries. No government agency has informed the Company that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors. No government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against the Company or others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Between August 27, 2021 and October 26, 2021, four putative class action lawsuits were filed alleging violations of the federal securities laws by us and certain named officers. The complaints rely on allegations contained in Citizen Petitions that were submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On June 30, 2022, a federal judge consolidated the four class action lawsuits into one case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of our securities between September 14, 2020 and July 26, 2022. On May 11, 2023, the court dismissed with prejudice plaintiffs&#x2019; claims against&#xa0;defendant Nadav Friedmann, PhD, MD, our former Chief Medical Officer and a Company director, who&#xa0;is now deceased, but otherwise denied defendants&#x2019; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on July 3, 2023. We believe the claims are without merit and intend to defend against these lawsuits vigorously. We are unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s Board. This complaint relies on allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#x2019;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, four additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, one in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On July 5, 2022, the three federal court actions were consolidated into a single action.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#x2019;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On January 6, 2023, the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on March 10, 2023, and moved to partially dismiss the amended complaint on March 14, 2023. Defendants&#x2019; motion to dismiss remains pending. Although the plaintiffs in this derivative case do not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="risk" title="risk" href="#"></a>Item 1A. </b><b><i>Risk Factors</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>There have been no material changes to our risk factors from those disclosed under </i>&#x201c;<i>Risk Factors</i>&#x201d;<i> in Part I, Item 1A of our&#xa0;2022 Annual Report on Form 10</i>&#x2011;<i>K. The risks and uncertainties described in our&#xa0;2022</i> <i>Annual Report on Form 10</i>&#x2011;<i>K are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition or results of operations.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="unregistered" title="unregistered" href="#"></a>Item 2. </b><b><i>Unregistered Sales of Equity Securities and Use of Proceeds</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="defaults" title="defaults" href="#"></a>Item 3. </b><b><i>Defaults Upon Senior Securities</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="mine" title="mine" href="#"></a>Item 4. </b><b><i>Mine Safety Disclosures</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2023-09-30" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c2493889" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="other" title="other" href="#"></a>Item <em style="font: inherit;">5.</em> </b><b><i>Other Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the quarter ended <em style="font: inherit;"> September 30, 2023</em>, <ix:nonNumeric contextRef="d_2023-07-01_2023-09-30" name="ecd:Rule10b51ArrAdoptedFlag" id="c104256306" format="ixt:fixed-false">none</ix:nonNumeric> of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) of the Exchange Act) informed us of the adoption or termination of a &#x201c;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#x201d; or &#x201c;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement,&#x201d; as those terms are defined in Regulation S-K, Item <em style="font: inherit;">408.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     <em style="font: inherit;">38</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="exhibits" title="exhibits" href="#"></a>Item 6. </b><b><i>Exhibits </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 122pt;text-indent:-111pt;">The following exhibits have been filed with this report:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 8%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td colspan="5" style="vertical-align: middle; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporated by</b></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Reference</b></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#xa0;Description</b></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filing</b></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filed</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>No.</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>No.</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Herewith</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm" style="-sec-extract:exhibit;">Amended and Restated Certificate of Incorporation.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/29/2005</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm" style="-sec-extract:exhibit;">Certificate of Amendment of Restated Certificate of Incorporation.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/8/2017</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm" style="-sec-extract:exhibit;">Certificate of Amendment of Restated Certificate of Incorporation.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/29/2019</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000009/sava-20221231xex3_4.htm" style="-sec-extract:exhibit;">Amended and Restated Bylaws of Cassava Sciences, Inc.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/13/2023</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.4</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/ex1-1.htm" style="-sec-extract:exhibit;">Capital On Demand<sup style="vertical-align:top;line-height:120%;">TM</sup>&#xa0;Sales Agreement, dated as of May 1, 2023, between Cassava Sciences, Inc. and JonesTrading Institutional Services LLC</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/1/2023</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.1</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.2*&#x2020;</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000039/sava-20230630xex10_2.htm" style="-sec-extract:exhibit;">Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan&#xa0;(As Amended March 16, 2023).</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%; text-align: center;">10-Q</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%; text-align: center;">8/3/2023</td>
     <td style="vertical-align: middle; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%; text-align: center;">10.2</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.3*</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000039/sava-20230630xex10_3.htm" style="-sec-extract:exhibit;">Cassava Sciences Non-Employee Director Compensation Plan</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%; text-align: center;">10-Q</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%; text-align: center;">8/3/2023</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%; text-align: center;">10.3</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.1</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_566477.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.2</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_566478.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.1+</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_566479.htm" style="-sec-extract:exhibit;">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Instance Document - (the instant document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104.</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File &#x2013;(formatted as Inline XBRL and contained in Exhibit 101).</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 9%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#x2020;Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and the type of information that the Company treats as private or confidential.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">* Management contract, compensatory plan or arrangement.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">+The certification furnished in Exhibit&#xa0;32.1 hereto is deemed to accompany this Quarterly Report on Form&#xa0;10-Q and will not be deemed &#x201c;filed&#x201d; for purposes of Section&#xa0;18 of the Exchange Act of 1934. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     39
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="signatures" title="signatures" href="#"></a>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cassava Sciences, Inc.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Registrant)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ REMI BARBIER</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Remi Barbier,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chairman of the Board of Directors,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">President and Chief Executive Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Date: November 7, 2023</p> </td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Executive Officer)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td style="vertical-align: top; width: 40%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ERIC J. SCHOEN</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Eric J. Schoen,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Date: November 7, 2023</p> </td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Financial and Accounting Officer)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex_566477.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_566477.htm</title>
	<!-- Generated by ThunderDome Portal - 10/27/2023 3:12:42 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 11pt;text-indent:-11pt;">Exhibit 31.1</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER&nbsp;PURSUANT TO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#65279; </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I, Remi Barbier, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Cassava Sciences, Inc.;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:36.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ REMI BARBIER</p>
			</td>
			<td style="vertical-align:top;width:19.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Remi Barbier,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chairman of the Board of Directors,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:&nbsp; November&nbsp;7, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex_566478.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_566478.htm</title>
	<!-- Generated by ThunderDome Portal - 10/27/2023 3:13:25 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 11pt;text-indent:-11pt;">Exhibit 31.2</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER&nbsp;PURSUANT TO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#65279; </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I, Eric J. Schoen, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Cassava Sciences, Inc.;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:36%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ERIC J. SCHOEN</p>
			</td>
			<td style="vertical-align: top; width: 18%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 36%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Eric J. Schoen,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 36%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 36%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:&nbsp; November&nbsp;7, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex_566479.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_566479.htm</title>
	<!-- Generated by ThunderDome Portal - 10/27/2023 3:14:28 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Exhibit 32.1</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER&nbsp;AND CHIEF FINANCIAL OFFICER&nbsp;PURSUANT TO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(18 U.S.C. Section 1350)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Cassava Sciences, Inc. (the &#8220;Company&#8221;), hereby certifies that to the best of such officer&#8217;s knowledge:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended September&nbsp;30, 2023, and to which this certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13-(a) or 15-(d) of the Securities Exchange Act of 1934, and</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 180pt;text-indent:36pt;">Date:&nbsp; November&nbsp;7, 2023</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 288pt;text-indent:36pt;">&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:36.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ REMI BARBIER</p>
			</td>
			<td style="vertical-align:top;width:19.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Remi Barbier,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chairman of the Board of Directors,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 55.7%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ERIC J. SCHOEN</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Eric J. Schoen,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sava-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:37PM UTC 2023-11-06--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sava="http://www.cassavasciences.com/20230930" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cassavasciences.com/20230930">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-unaudited" roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-general-and-liquidity" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - General and Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-expenses-and-other-current-assets" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Real Property</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-2020-cash-incentive-bonus-plan" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-contingencies" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995463 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-tables" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995464 - Disclosure - Note 2 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-expenses-and-other-current-assets-tables" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995465 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-tables" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995466 - Disclosure - Note 4 - Real Property (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-tables" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995467 - Disclosure - Note 5 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-tables" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995468 - Disclosure - Note 6 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995469 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-general-and-liquidity-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995470 - Disclosure - Note 1 - General and Liquidity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995471 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995472 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995473 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995474 - Disclosure - Note 4 - Real Property (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-components-of-other-income-net-details" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995475 - Disclosure - Note 4 - Real Property - Components of Other Income, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995476 - Disclosure - Note 5 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-components-of-property-and-equipment-details" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995477 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995478 - Disclosure - Note 6 - Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-components-of-intangible-assets-details" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995479 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995480 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995481 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995482 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995483 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995484 - Disclosure - Note 8 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995485 - Disclosure - Note 9 - Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-2020-cash-incentive-bonus-plan-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995486 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-contingencies-details-textual" roleURI="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995487 - Disclosure - Note 11 - Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sava_AccruedDevelopmentExpenseCurrent" name="AccruedDevelopmentExpenseCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_AtthemarketCommonStockOfferingMember" name="AtthemarketCommonStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_AustinTexasMember" name="AustinTexasMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CashBonusIncentiveIncrementalAmounts" name="CashBonusIncentiveIncrementalAmounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_CashIncentiveBonusAward" name="CashIncentiveBonusAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_CashIncentiveBonusAwardExceedsMaximum" name="CashIncentiveBonusAwardExceedsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_CashIncentiveBonusPlanMember" name="CashIncentiveBonusPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CashIncentiveBonusPlanTextBlock" name="CashIncentiveBonusPlanTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_EquityOfferingMaximumAmount" name="EquityOfferingMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_EquityOfferingPercentageOfCommission" name="EquityOfferingPercentageOfCommission" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_IncreaseDecreaseInDevelopmentExpense" name="IncreaseDecreaseInDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_LeasingCommissionsAndOtherMember" name="LeasingCommissionsAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_OfficeSpaceMember" name="OfficeSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_PaymentsForCashIncentiveBonus" name="PaymentsForCashIncentiveBonus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_PercentageOfCurrentlyLeased" name="PercentageOfCurrentlyLeased" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PercentageOfOccupancy" name="PercentageOfOccupancy" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" name="PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" name="PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_PerformancePlanValuationMilestoneAmount" name="PerformancePlanValuationMilestoneAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" name="PrepaidExpensesAndOtherCurrentAssetsTextBock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsDelawareCourtMember" name="ShareholderDerivativeActionsDelawareCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsMember" name="ShareholderDerivativeActionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsTexasCourtMember" name="ShareholderDerivativeActionsTexasCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsTexasStateCourtMember" name="ShareholderDerivativeActionsTexasStateCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" name="StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_The2018EquityIncentivePlanMember" name="The2018EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_The2022RegisteredDirectOfferingMember" name="The2022RegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ViolationsOfFederalSecuritiesLawsMember" name="ViolationsOfFederalSecuritiesLawsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" name="statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-significant-accounting-policies-tables" name="statement-statement-note-2-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" name="statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" name="statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-4-real-property-components-of-other-income-net-details" name="statement-statement-note-4-real-property-components-of-other-income-net-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-4-real-property-tables" name="statement-statement-note-4-real-property-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" name="statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-5-property-and-equipment-tables" name="statement-statement-note-5-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" name="statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" name="statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-tables" name="statement-statement-note-6-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sava-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:37PM UTC 2023-11-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="sava-20230930.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20230930.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="sava-20230930.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details" xlink:href="sava-20230930.xsd#statement-note-4-real-property-components-of-other-income-net-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sava-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:37PM UTC 2023-11-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets" xlink:href="sava-20230930.xsd#statement-note-3-prepaid-expenses-and-other-current-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information" xlink:href="sava-20230930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity" xlink:href="sava-20230930.xsd#statement-note-1-general-and-liquidity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies" xlink:href="sava-20230930.xsd#statement-note-2-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property" xlink:href="sava-20230930.xsd#statement-note-4-real-property" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RealEstateOwnedTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes" xlink:href="sava-20230930.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments" xlink:href="sava-20230930.xsd#statement-note-9-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AustinTexasMember" xlink:label="sava_AustinTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_OfficeSpaceMember" xlink:label="sava_OfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sava_OfficeSpaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinTexasMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan" xlink:href="sava-20230930.xsd#statement-note-10-2020-cash-incentive-bonus-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies" xlink:href="sava-20230930.xsd#statement-note-11-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LossContingencyDisclosures" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies" xlink:href="sava-20230930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables" xlink:href="sava-20230930.xsd#statement-note-2-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:href="sava-20230930.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables" xlink:href="sava-20230930.xsd#statement-note-4-real-property-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual" xlink:href="sava-20230930.xsd#statement-note-1-general-and-liquidity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual" xlink:href="sava-20230930.xsd#statement-note-2-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual" xlink:href="sava-20230930.xsd#statement-note-4-real-property-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfCurrentlyLeased" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfOccupancy" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingMaximumAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingPercentageOfCommission" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual" xlink:href="sava-20230930.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual" xlink:href="sava-20230930.xsd#statement-note-9-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AustinTexasMember" xlink:label="sava_AustinTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_OfficeSpaceMember" xlink:label="sava_OfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sava_OfficeSpaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinTexasMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:href="sava-20230930.xsd#statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanValuationMilestoneAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAward" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual" xlink:href="sava-20230930.xsd#statement-note-11-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20230930.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sava_LeasingCommissionsAndOtherMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details" xlink:href="sava-20230930.xsd#statement-note-4-real-property-components-of-other-income-net-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20230930.xsd#statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sava-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:37PM UTC 2023-11-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="sava-20230930.xsd#sava_DocumentAndEntityInformation" xlink:label="sava_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="sava_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DocumentAndEntityInformation" xlink:to="sava_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="sava_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="sava_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-significant-accounting-policies-policies" xlink:label="sava_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-significant-accounting-policies-policies" xlink:to="sava_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:to="sava_statement-statement-note-2-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:to="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-4-real-property-tables" xlink:label="sava_statement-statement-note-4-real-property-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-4-real-property-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Real Property</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-4-real-property-tables" xlink:to="sava_statement-statement-note-4-real-property-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-5-property-and-equipment-tables" xlink:label="sava_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-5-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-5-property-and-equipment-tables" xlink:to="sava_statement-statement-note-5-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-6-intangible-assets-tables" xlink:label="sava_statement-statement-note-6-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-tables" xlink:to="sava_statement-statement-note-6-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:to="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:to="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-4-real-property-components-of-other-income-net-details" xlink:label="sava_statement-statement-note-4-real-property-components-of-other-income-net-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-4-real-property-components-of-other-income-net-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Real Property - Components of Other Income, Net (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-4-real-property-components-of-other-income-net-details" xlink:to="sava_statement-statement-note-4-real-property-components-of-other-income-net-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment - Components of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:to="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets - Components of Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:to="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:to="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatements" xlink:label="sava_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="sava_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NotesToFinancialStatements" xlink:to="sava_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetUsefulLife</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="sava_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="sava_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="sava_AccruedDevelopmentExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label xlink:label="sava_AccruedDevelopmentExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued development expense, classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AccruedDevelopmentExpenseCurrent" xlink:to="sava_AccruedDevelopmentExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 120,000,000 shares authorized; 42,129,798 and 41,735,557 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, performance awards (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, performance awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasePayments</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Performance awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Performance awards forfeited/canceled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAssetsCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyNewClaimsFiledNumber</link:label>
    <link:label xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_IncreaseDecreaseInDevelopmentExpense</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in development expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInDevelopmentExpense" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in operating lease right of use assets and liabilities, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:label xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Bock]</link:label>
    <link:label xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasesAcquiredInPlaceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Acquired-in-Place [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAcquiredInPlaceMember" xlink:to="us-gaap_LeasesAcquiredInPlaceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConstructionInProgressMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageOfCurrentlyLeased-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageOfCurrentlyLeased</link:label>
    <link:label xlink:label="sava_PercentageOfCurrentlyLeased-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Currently Leased</link:label>
    <link:label xlink:label="sava_PercentageOfCurrentlyLeased-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of currently leased.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfCurrentlyLeased" xlink:to="sava_PercentageOfCurrentlyLeased-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:label xlink:label="stpr_TX-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TEXAS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_TX" xlink:to="stpr_TX-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageOfOccupancy</link:label>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Occupancy</link:label>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of occupancy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfOccupancy" xlink:to="sava_PercentageOfOccupancy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LandMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNonoperatingExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsNet</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositContractsAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract research organization and other deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsAssets" xlink:to="us-gaap_DepositContractsAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Notes 9, 10 and 11)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyDisclosures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the cash incentive bonus plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTextBlock" xlink:to="sava_CashIncentiveBonusPlanTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AustinTexasMember" xlink:label="sava_AustinTexasMember" xlink:type="locator"/>
    <link:label xlink:label="sava_AustinTexasMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Austin, Texas [Member]</link:label>
    <link:label xlink:label="sava_AustinTexasMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Austin, Texas.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AustinTexasMember" xlink:to="sava_AustinTexasMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Violations of Federal Securities Laws [Member]</link:label>
    <link:label xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the violations of federal securities laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_OfficeSpaceMember" xlink:label="sava_OfficeSpaceMember" xlink:type="locator"/>
    <link:label xlink:label="sava_OfficeSpaceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Space [Member]</link:label>
    <link:label xlink:label="sava_OfficeSpaceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents office space.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_OfficeSpaceMember" xlink:to="sava_OfficeSpaceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount" xlink:type="locator"/>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PerformancePlanValuationMilestoneAmount</link:label>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Plan, Valuation Milestone Amount</link:label>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of valuation milestone for performance plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanValuationMilestoneAmount" xlink:to="sava_PerformancePlanValuationMilestoneAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="locator"/>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashBonusIncentiveIncrementalAmounts</link:label>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Bonus Incentive, Incremental Amounts</link:label>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of incremental amounts for cash bonus incentive.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashBonusIncentiveIncrementalAmounts" xlink:to="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="locator"/>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</link:label>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)</link:label>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum number of days valuation milestone must be achieved and maintained in performance plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cash incentive bonus plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanMember" xlink:to="sava_CashIncentiveBonusPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Texas Court [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Texas Court</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsMember" xlink:to="sava_ShareholderDerivativeActionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Delaware Court [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Delaware court.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Texas State Court Member</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Texas State Court.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="sava_AtthemarketCommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-market Common Stock Offering [Member]</link:label>
    <link:label xlink:label="sava_AtthemarketCommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the At-the-Market Common Stock Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AtthemarketCommonStockOfferingMember" xlink:to="sava_AtthemarketCommonStockOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="sava_The2022RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2022 Registered Direct Offering [Member]</link:label>
    <link:label xlink:label="sava_The2022RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2022 Registered Direct Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_The2022RegisteredDirectOfferingMember" xlink:to="sava_The2022RegisteredDirectOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission" xlink:type="locator"/>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_EquityOfferingPercentageOfCommission</link:label>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Percentage of Commission</link:label>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of commission in equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EquityOfferingPercentageOfCommission" xlink:to="sava_EquityOfferingPercentageOfCommission-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_EquityOfferingMaximumAmount</link:label>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Maximum Amount</link:label>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount to be issued in the equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EquityOfferingMaximumAmount" xlink:to="sava_EquityOfferingMaximumAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashIncentiveBonusAwardExceedsMaximum</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Award, Exceeds Maximum</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash incentive bonus award if the maximum milestone is exceeded.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</link:label>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment</link:label>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">the percentage of valuation milestone cash bonus award subject to approval and adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" xlink:type="locator"/>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PaymentsForCashIncentiveBonus</link:label>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Cash Incentive Bonus</link:label>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payments for cash incentive bonus.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsForCashIncentiveBonus" xlink:to="sava_PaymentsForCashIncentiveBonus-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashIncentiveBonusAward</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Award</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash incentive bonus award.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAward" xlink:to="sava_CashIncentiveBonusAward-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:label xlink:label="sava_LeasingCommissionsAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing Commissions and Other [Member]</link:label>
    <link:label xlink:label="sava_LeasingCommissionsAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents leasing commissions and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasingCommissionsAndOtherMember" xlink:to="sava_LeasingCommissionsAndOtherMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="sava_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="sava_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2018 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_The2018EquityIncentivePlanMember" xlink:to="sava_The2018EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Net Settled in Satisfaction of the Exercise Price [Member]</link:label>
    <link:label xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock options were net settled in satisfaction of the exercise price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RealEstateOwnedTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate Owned [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateOwnedTextBlock" xlink:to="us-gaap_RealEstateOwnedTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceAmount</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmount" xlink:to="us-gaap_GovernmentAssistanceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetRentableArea-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetRentableArea</link:label>
    <link:label xlink:label="us-gaap_NetRentableArea-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Rentable Area (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseCost</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:label xlink:label="srt_OfficeBuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive common stock options excluded from net loss per share, diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation for stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing net loss per share, basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expiration of restricted stock Performance Awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expiration of restricted stock Performance Awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options forfeited/canceled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RetainedEarningsAccumulatedDeficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development, net of grant reimbursement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sava-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:37PM UTC 2023-11-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets" xlink:href="sava-20230930.xsd#statement-note-3-prepaid-expenses-and-other-current-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information" xlink:href="sava-20230930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity" xlink:href="sava-20230930.xsd#statement-note-1-general-and-liquidity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies" xlink:href="sava-20230930.xsd#statement-note-2-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property" xlink:href="sava-20230930.xsd#statement-note-4-real-property" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RealEstateOwnedTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes" xlink:href="sava-20230930.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments" xlink:href="sava-20230930.xsd#statement-note-9-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AustinTexasMember" xlink:label="sava_AustinTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_OfficeSpaceMember" xlink:label="sava_OfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="sava_OfficeSpaceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="sava_AustinTexasMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan" xlink:href="sava-20230930.xsd#statement-note-10-2020-cash-incentive-bonus-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies" xlink:href="sava-20230930.xsd#statement-note-11-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LossContingencyDisclosures" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies" xlink:href="sava-20230930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-significant-accounting-policies-policies" xlink:label="sava_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables" xlink:href="sava-20230930.xsd#statement-note-2-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:href="sava-20230930.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables" xlink:href="sava-20230930.xsd#statement-note-4-real-property-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-4-real-property-tables" xlink:label="sava_statement-statement-note-4-real-property-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-4-real-property-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-5-property-and-equipment-tables" xlink:label="sava_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-5-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-6-intangible-assets-tables" xlink:label="sava_statement-statement-note-6-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual" xlink:href="sava-20230930.xsd#statement-note-1-general-and-liquidity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual" xlink:href="sava-20230930.xsd#statement-note-2-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual" xlink:href="sava-20230930.xsd#statement-note-4-real-property-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfCurrentlyLeased-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfOccupancy-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingMaximumAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingPercentageOfCommission-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual" xlink:href="sava-20230930.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual" xlink:href="sava-20230930.xsd#statement-note-9-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AustinTexasMember" xlink:label="sava_AustinTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_OfficeSpaceMember" xlink:label="sava_OfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="sava_OfficeSpaceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="sava_AustinTexasMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:href="sava-20230930.xsd#statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashBonusIncentiveIncrementalAmounts-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanValuationMilestoneAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAward-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual" xlink:href="sava-20230930.xsd#statement-note-11-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20230930.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20230930.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20230930.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="sava_LeasingCommissionsAndOtherMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:href="sava-20230930.xsd#statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details" xlink:href="sava-20230930.xsd#statement-note-4-real-property-components-of-other-income-net-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-4-real-property-components-of-other-income-net-details" xlink:label="sava_statement-statement-note-4-real-property-components-of-other-income-net-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-4-real-property-components-of-other-income-net-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:href="sava-20230930.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20230930.xsd#statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20230930.xsd#sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a1.jpg
<TEXT>
begin 644 a1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ !@$2  ,
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***,YH **** "BBB@ HHHH **,YHH **** "BBB@ HHHH ****
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M=(_^,T ?95%?&O\ PVA^U]_T93;?^'ATC_XS1_PVA^U]_P!&4VW_ (>'2/\
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MFV_\/#I'_P 9H ^RJ*^-?^&T/VOO^C*;;_P\.D?_ !FC_AM#]K[_ *,IMO\
MP\.D?_&: /LJBOC7_AM#]K[_ *,IMO\ P\.D?_&:/^&T/VOO^C*;;_P\.D?_
M !F@#[*HKXU_X;0_:^_Z,IMO_#PZ1_\ &:/^&T/VOO\ HRFV_P##PZ1_\9H
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M10 4444 %%%% !1110 4444 %%%% !1103B@ HHSFB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *:7PV*=4<GW_H* .3^+_P 6
M]#^!W@W^WO$5S+:Z=]NL]/\ -CA:4B:[N8K6 849P99HP3T&<FNFMY/,B5@V
M>QS^M>&_\%&+IK3]FCS5NM)L_P#BJ/#0$NHVWVFW.=<L0%V".3YV)"HP7Y79
M6W)C>ON%N2(E^7;QG'I41E[[CV1UU,/&.&A66\FUY:)?YG@?_!0;]KNX_9-^
M'.CW>EQI-KFLZD$BB.F7>I9M;:-KFZ/DVJ/+EHH_)5L;4DN(V8@=?,_CY_P4
MOU[X?ZXVN^&_">FZK\-]#NKZ#4]0FU7R]0U">#P^^L""* IMBC8/"@G\R0E@
MP\E4VRGZ]N/".FW7B2'6);.&35+:VDLHKEAF2.&1D>2,?[+-&A([[1Z5YE_P
MP9\&V\0V.J-\/?#SWFG:=)I-L7B9XXK:2W:U=!&6V9:W=H"Q7<8CY9.S"T*+
M7WG)IU.2\3_ML:PWQBUSP%X5\#6^M^*-'UB:T,6H:ZFFVUS:6VFZ;?7$RR^3
M(1,/[3@CCB90K$,S2Q* :XSQ%_P5&DT/X@^)/#=KX)L=7O[66UBT-++Q#YJ7
MIFUBSTAA=SBV^S0ND][&Q6VFNRJQRK)Y4J&.O6(O^"?7P=@\%1^'U\#Z>VEQ
MZB-593<W#3SW/D1V[/+.9/-EWPQ1QNLCLKI&JL&  JUI/["?PCT'Q5/K-IX&
MT>&]N)UN1@R&"!UNH;T&&$MY4(^U6\,Y$:J#)&K$$\UKHY7Z%:'E^F_\%)3_
M &9J"ZAX):UU;1(K=-1AMM5$]O%=OXFG\/S1Q2-"ADC2:!YE=D0NF 41LXS/
M$O\ P4F\4>%[;4M2F^%EJWAVPM[W5/M8\4H;AM/LM3&G73^0+?\ X^#(ZR0Q
M!BDB(_F2P.%5_:_$?[$/PF\7:SI^H:AX(T6XN]*O)K^!]KK^_EO?M[O(%8"3
M_2R9P) P60E@ 36WJ?[,/P_UG19M-NO"FCS6-Q9W&GRP-%\CV]Q<"ZFC(S]U
MYP)#_M &CW>B#0^=OB=_P4AUK3_&'CSPGX?\-Z#=:YX?LY+_ $6=-7:Z@U!(
M-4M-/GBN7,,=M!(SW2X$-Q<F+#"<0R+Y9N_M _MD^,K7]EF'7O#]@/#OC&'Q
M[;^"-7ATZP;Q8MK(+W[/<M9(OD-=97E"R(PR0\2NI4>LW7["/PBOM>\1:E/X
M(TF:Z\61W$6I^8\S1S+<3I<7 2,OLB\V>..5_+5=\B!SEN:T-;_9!^&NN_!V
MU^'MUX6LY/"=C=1WT%D)YD>*YCD\U;D3*XF\\2?/YN_>6.2Q)K'X=7Y Y*Z/
M!?#/[7OQ \ _$SP+8^*)EU;PC?>&]1UGQ)=ZQX8E\.ZSIV-1MK6"Y^S^:RQV
M\7G'S0PW%'$H.$VMR.@?MX_$+QG\%K7QU=>+_ _@G3?!_A30-=U[[9X>N]0M
M=;N+^W:YD:1[=W>PL5C3:)PDA0^:[;E0 _5_@+]E3X??#:U\O2_#L'S6-SI3
M27UU-J$IM+EUDGMC)</(QB=T0E"=ORC K)U;]A'X/ZYI7A6QF\"Z*+#P;IT&
MCZ3:P^9!!%80X,5G(B,%GMEQQ#,'CY;Y?F;.W,2>$_$;_@IQ+X8^*'Q<T;3K
M:QO[?PGHLO\ 80GT^\CM9;^U>VCNGFNRJPR0![Z/]W&_F!+&Z/'48/QE_:U^
M)WP>O/\ A";?XA:1XN\6KXLTC3KJ?1_A_=2:OIUG=VNI22>7IS2K'<1F2QQ%
M<Q2N,&X#+F'+?7NI? +P3JWAO2]&O?#.CWFDZ////9VD\ D@B>>*>&;Y6R&$
MD=Q.C*V0PE8$&N$3_@G;\&/^$3ET;_A";5K.:^@U(2-J%VUW%- )%MS'<F7S
MXTB$LH2-'5$\V3:HWMF0.N_9JUC6M<^$>BW7B*^U34-8ND>6:;4M!_L.[(WD
M 26>YO*(&._/7O7HO>N9^%WPHT+X,^#;;0?#MK<6>EVI9HHY[V>\<%CDYDF=
MW//JQQVKIJ<M1+0****0PHHHH *1_N'Z4M!&10!\C^+/VK?&'PA_::\47GC]
M-4\(_!G1YI;/3KZ;1]/.GZHT.F"\D<W7VTW:-E;@#-H(B8"OF L"?+]!_P""
M@?Q4^/WPPFUCP''H>L+I_C#6;75[_P $+I7B3_A'='MK>.>T$YN-1@A:9UD&
M]HY&)96"(PP3]CVG[,W@6P^+=YX[A\.V:^*M00I<7>^1DD8H(VD\DMY0E* (
M90GF%/E+$<5E^+_V-?A?X^M%@U+P?I<D:ZG+K&8&DMG>YE"K,[-$RLRRJBB1
M"2D@4!U;%9J+T#K<[7X>Z_#XK\(Z3JEO<?;+?4K*&ZBF\KR3,KH&W[/X2=V2
M.V[%;T=5K*RALH(X88TAAC0)&D8VK&HP J@<  #H*M@8%:$QT04444%#7&%K
MSC]I"X\46GPSU";PAJ\.AZM;K]H,XT,ZU=2Q1J7>.VM!)'YL[;0JY; #'@G&
M/2:Y'XN_!3PO\=/"O]B^*=,&I:>LZ7,86>6VFMIDSMDBFB99(G )&Y&4[689
MPQ!F4;@>(7GQH^(7Q)_83\,>._#VH:?H_BZ[TF/4-5ATKPY)X@N)IE0B:UL[
M0RQ[I//7:RLS% KC)(#5P7PX_;D\>^*/VD/AOI]\NDQ^'?'3Z=90Z98Z'=36
MMQ#<>'FU.;4X-79O*?RKR*2U$&T,8UW$ D,/H/Q3^QG\,?&7A*W\/WWA6V72
MK$0BS@M;F>S^PB)'C00-"Z-""CNK",KY@=@^[)K3T/\ 9>^'OA;XE6_C#3/"
M6CZ;X@L[)-/M[BUB\F.WA2/R4"1*1$K+"/*#A0XB^0-L^6C[5PZ6/08N!^ I
M](JA1Q2U0!1110!ROQI\?0_"CX2^)O%5Q;M=6_AG2[K5I8$.&F6"%Y2H/8G;
MU[=>U?/>G?%WXN0?''X>Z5-KG@O6&\006MQJOAS2=(F:>TT][9I+C5+FZ:3_
M $,)<8@@C(<3!>"S%_*^G/%'AZS\5Z#>Z;J%K#>:?J4#VMS!*NZ.>.12CHP]
M&4E3[&O'_!7[ /PU\'^*;?Q)_9>I7WBI;6"SN-:EU:YBNM0C@@:V@,ZPO''(
MT<#>6&9"P ')(S1'X@>JL>?^+_VI?%WPF_:D\377Q _M3PC\&=%DFMM.U*?1
M[!M/U,Q:4+V20W?VTW:,KI<@ V@C)A">9N;!9^RU_P %%-'^(W[.7Q0^)/B_
M7O Z:+X$\0W]NY\/ZM;WL6GV""-K6.>996C:Y99 &;<J;S@?*NX^VZ#^RSX
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M)M"KIB2.,;V..<=37Z >4*9Y<8]-W3.>?SH \?\ @/\ %GXB>-/@=X-UK7/
M8AU[6-"L+[4HOMZV7E74MK%),ODR O%MD=UV.2RXP:ZW_A-O&/\ T(__ )6X
M?\*[1($7.WUR><T[RA0!Q/\ PFWC'_H1_P#RMP_X4UO&OC+'_(CC\=<AP?\
MQVNX\H4&-<4 5=)GFGL(9+B%;6>1 TD(</Y38Y7<.#CUJY30BYS3J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *C?_6?A4E1S<#/\5 '@_P#P
M4=F^S?LR,WVG3;/_ (JCPVIDO;7[3#AM<L5*[/+D^=@2J-L.UV5LKMW#VZS'
M[OZ]3ZG/X_2O$?\ @HO<M;?LR,WVK3['_BJ/#:B6]MOM$.6URQ4+LV/\S$[5
M.WY693E<;A[A:YV+D;=P!(K*/\1^B_4]2M_N%+_%+\H'@/\ P4&_:HU+]F7X
M>Z+)X>L[V^\0:U?DQP6VA7>M/]DM8VN;H^1:QR28D1%MQ(0$C:Y5F8 <^3_M
M"_\ !2WQ-X(UK_A)/"OAW0;[X:Z+<W\-[/<ZH8]5UB:'PX^LK'' 8BD4#"2%
M?.5Y'R3F()AC]G3^&=/GU^#5FM8'U*W@DM8KDKF2.*1E9T!_NLR(2/\ 9'I7
MG*_L2_"*+Q19ZROPY\'_ -J:?IKZ1;7!TV,O#:/$\#Q+D8VM#(\1[E&VYV\5
M?-K<\Q6ZGGGBW]M?Q!>?&37/A_X1\'Z'J/B30]9GMO\ B;:\=.M9K*UTS3+Z
MXEWK#(Z3_P#$SCCCC*["(V9I(QBN*\0?\%/M6T;XA>(M!L_!.@ZU,9+5/#MQ
M9ZU=?8[[S-9LM'?[3>&S^RDQS7JLPLY;K88I8Y/*E7:?;H?V"_@S#X%M_#*_
M#7PA_8-OJ"ZLEF;%63[6L20B8D\LQBC2,DD[D15.0,5=TK]BSX2Z+XNOM=M?
MA]X3@U;4;B.ZN+@6*EC*D\=RC*#PA$T,4OR@?/&K=1FJYH\U^G4>AXMI/_!2
M:^CTK5%U3P780:MH,5O%J"6NKNUI]L;Q1/X>E6&1X49H0]NTR.R*SJP4JASB
MAXK_ ."CGCKPO:ZEK#_#/PS)X;L;>^U<7*^)Y6NVTRQU5=.GS$+3 NG9Q)%&
M'*%5<.\; *???$/['?PL\6:]I>I:EX!\*WU_H=Y-J%G++8HQ@N)KK[7))CH6
M:Y_??-G]YEA@\UKWG[/7@/5-'DT^X\)Z#-9W%I/8/"]FC));SSBYFB([H\P$
MC#NPR>:.9/8/=/F?XJ?\%$_%%CXW\?>%O#OA_P -MJ>CVLUYX=U!+^YN+._^
MRZK9:=/#=3R6T=H)"]V 5MI[@VY1UF\N1=AN_';]KGQT_P"RC;:MH=K-X=\<
M1_$&U\#ZM#X<C@\0M'(+_P"S7!L?M*Q)+N7E3.B%>0RAEQ7MES^Q/\(;SQ#X
MBU23X=^$YM2\6Q31:Q,]BC-?I-(DLJOGC$DL:.V,;G4,<GFKVL_LF_#3Q%\&
M+7X=WW@KP_<^";.2.6#2)+<?9XI8Y/,24=_-$GS^9G>6)).234J+NV]@ZJW0
M^8M6_:\^)'P8^(W@O3_$.H:U=:/JW@_6[Z[C\3:!96&LMJOVNWATQ-EH_E*I
M8R)L4EI#+'W(%<Y^RK^U-\:OV@/&_@^/5=8\7+:KH?A2YU=O"OA/2[C1FN;R
MRCGO6N9[B3SX59V) @!\N,J1N)S7UOX5_8U^%/@K3[&UTWP'X9@ATV9+FTWV
M@F:WD6ZANT9&?+#;<V\$JX. \2$8(%9UY^P/\&;WQ5I.O-\._#4>K:+#:6]C
M<PVYA:WBM?\ CV4!" 5B'"@@X''3BM+Q!VZ'Q_\  _\ X*!_%:_UNWU+6+KQ
M'KWVKP]XC\4W.BZMX9L=,T:ZT_3OM 0Z3>0.UQ<3K<)9Q&.3<?*N'E8+A,]'
M\3_VM?B5\+_!GV&/XG0^+/%GBS3/#NLV-KIO@K;<64=_K&G6=PVD22*ME?VZ
MQWZ+&)99)8Y3$9'97.W[,C_9_P# \5CX<M8_"FA1V_A"];4=#B2U15TFX=95
M>6$ ?(S+/,&(^\)6!R#7(1?L"?!6VT;Q%IR?#/PBEEXL=7U6+[ NVZ*SB=!_
ML*LRK(%3:JLJD $#$WOL2I*^I<_9*U/Q1JWPM:3Q==>,+S56OYMI\2Z-8Z3?
M+&-F!Y-FS1%,DD/G<<G.,"O6@,5Q?P:^!'A']G[PS)HO@W0[70=+FN&NWMK=
MG*-*P52YW$G.$4>VVNR20,.M!,;VU'44W>I_B'YT>:H/WE]>M!0ZBF[U'\0_
M.G4 %-?E#]*=01D4 ?(?C/\ :0\;?"#]J#Q1K7CQ]>\/_!G2)YK#2)+>VTNY
ML-1:'2C>2.Y4M?H^4N5'1-T(4KALGPW4O^"H'C[XB_"'4-4\+^)O!M[JUGXC
M\2,T?A6WM]<:RT_3[:"XMHYM\WE^4JSJ+N=29 2OE+R*^\M,_9R\!Z-\7;SQ
M[:^%=%M_&6H0^1<:LEN%N)EP 23TW%0 7QN(&"<<5G_$#]DOX8_%;338>)/
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MN SO 8$'FLW2?V*OA+H+>&6M/ /AH2>#YI;C1'>V\QM.>5Q(YC+$G!=5?!.
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M:[)_^"?'P)FM-+MW^$/PYDAT1WDT]7T&W;[(9&5WV97Y0S(K$#@E0>HK7?\
M8X^$S_%&3QN?AOX)_P"$PDNUOFUD:1 +UIU*$2F7;N+@QH=V<Y0>E3NFB3Y6
MMOVD_B;\=O@AHNA>'?%OC3P;\:6URY\.BR'A&TLXY@8XIUU6_M-0LWF@L;>U
MFC)9!%YLA$:G,J$)HGQ_^,$UO\:/$=QKGQ,N--^']UXKMM/NQI'AA/"A.FPS
MB#S?^8F7$L8+8 4OQ]P$U]2_%/\ 8J^#_P <_&*^)/&GPR\!^*/$*VR68U34
M]%M[F\$*L62,3,I<(&)(4' )XJ.T_89^#-IXRN/$</PL\ QZ[=+(DU^NB6XG
ME#Q&%]S;<G=&2K9Z@G.<T+8(Z'S7^R3^U_XXM?B-K5IXZN/BKK&FZ3X/T_6-
M0TS7O"VEW&ORW-Y*@M[C3+?08W-Q8LBW2RR.&,<D<:Y!WBH?C)_P41\6:;XW
M^)5GH\>L:7I=K);67A>\OO#$\5E+<6FHV<&H!+J:(17$DJW4X$:,QC^PRMQ@
MX^TH/A=X;M?$NFZTFAZ4FL:/8R:987PM4^T65I(8R]O')C<L3&*,E =N47C@
M5E^-_P!GGP'\2/ D7AGQ!X-\,ZYX;MW:2/2[[38KBSC9E=681,I4$K)("<9P
M[>M'5,.IY#^VIJ7CC4?%W@_PG\,_'WB#PQXV\22N([2STK3;ZPM;*-T-SJ=\
M+JWED$,*L(T2*2,RRS1)D99T^A]-5EMUW,S,H&XL &)]2!QGZ<5XV?\ @FS^
MS_)%!&WP9^&[+:[A#G0+?]T&(8A3MR!N .!QGGK7M=O:1V4"Q1*L<<:A%51@
M*H& !]*%%(5M2:@]***!GS]^WK\0_&/P^\$>'6\)ZEK>BQZAJ\D&J:CHFB0Z
MUJ=I"EG<RQ^3:RJX96GCA61A%(4C9V^0 RIX]\"/VQ_B'\4/B%\.=6U34K6U
ML?%&IZ-X;U'PK'96_E1M=^%O[;DOQ+\T_F";**HD\KR5;*E_FKZT^*GP<\'_
M !S\,+HOC3PWH/BK25G2Z2SU:RCNX5E3[L@5P0&&2,CL2.A-"?!?P='\2(?&
M*^&?#Z^++>Q_LN/6191_;DM=V?LXFQO$>?X<X]JF,;%2LU:QU:?T%/IJ !?E
MIU42%%%% #77<*\W_:3@UVX^'-U;^'?$FJ>&]7D<&%M)M-/NM5U#:CO]FLUU
M _91/)MP#,&4 -T^\OI5<M\5/A+X5^-GA2;0/&7A_1/%&BSNDDECJEI'=0,Z
MG*ML<$;@>AZBIE&X(^:?BC^T?\3KO_@E)>?%#PGK/A.Q\>:?X/N-9O\ 4;S3
MY9[.VFMH)3<F*W^4/*)(F4*Y$8.3\RX%:<OQ2^)6F_MQ+%KDVK6?PMDU&TT'
M2$L+S2+BWO;V;3/M#_:H/L[WT>)3( PGB $*'RV1BY]^'P9\'CP_J6DGPWH/
M]D:M8QZ9?61LHS;75K'&8D@DCQM:-8R4"D8"DCI4,?P'\$0_%C_A.H_"?AU?
M&GV7[$-<6PB&H>0 %\OSL;]H7Y<9Z<=.*KFU#[/R.QB_I3ZCCX?\*DH ****
M .1^.'CW_A5'P>\5>*OLIO#X9T>\U409(\XP0/)LR.1G;C/H37A-I\2_BEH7
M[1?P+T35->\,W?A7QIHE_)JJPZ8RZAJ%_%9+<A]^?+@@C9L*B L^<LW!!^EM
M;TNUUW2KBQOK>*ZL[R)X)X95#)+&ZE65@>"""01Z&N7\/? [PSX?\*Z#I,FF
MPZI#X;M)-/TV;4P+RYMH)$\IXQ*XW8:/$9R<E0 <T%)GSI?_ +1?CS_AL;Q%
MH=YJK>%/ XU"\\*Z)/<6UE=6/VZ+18]36[GCPETFW=,WF-/Y+"-8S&K2"4;O
MP:_:7UOX5_"CXPWGQ*U#7M;F^%.L21"2^TZTCUBZLVM()H6FCL%^S?O7E<QM
M$ 1"8_-"N'%>T#]G3P /%,NN?\(7X8_M>;21H4MZVG1--+IX4J+5F(RT.W*[
M#QMXZ<57\ ?LT> OA,VBKX3\*Z+X9M_#[7;65OI5LMI#$UR$$YV)@%F\M<D@
MGY14_9Y0ZGS3\)_VV?&?Q-_X)]^(/'&GZMX?\5>.+?QC<>&%GT1$@L;8R:TE
MG'Y;7 "$PP2J5DE!5F0&13\R4RR^)GQ,^)'AKX9:?H_Q0\6:/XTOO%%YX6UN
MQ?0M&N+5ETRZE?4KBY?[(=^V&+[.LEN;>.1YHF$498@?5>H? [P9JUA>6EYX
M7T&ZM]2@N[6[BFLXY%N8KN0272N"/F$T@#OG.YN3DU)X5^#OA'P#9:';Z'X9
MT'28?"]I)8:1':64<2Z9!)L\R*$*!L5]B$A<;MHSTJH]E_6A+['/?L[^.]4\
M77'C;3=9FAN[KPIXFNM*CNHHA&+F I%<1%E  WK'.L;$#!,>>I.?38SE:Y?X
M7?#/2_A=HUY9Z4DVW4+^XU2ZFFD\R:[N9Y&DDE=_XB<JH]%50. *ZI1M%3&]
MM0"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH \1_X* ?\D,T/_LH/@K_U
M*-+KVZO$?^"@'_)#-#_[*#X*_P#4HTNO;J "BBB@ HHHH **** (;LGR6V_,
M<'C.W=[9KC#K?C\GY?#OAO;VSK$N<?\ ?FNX9=U)Y2F@#A_[9^(7_0N^&?\
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MB@ K$\73ZU;6:_V':Z;<7#/A_MMP\,:K[;58DUMTFP9H X;[5\0O^@?X._\
M ^X_^-T?:OB%_P! _P '?^!]Q_\ &Z[G8*3:O^30!P_VKXA?] _P=_X'W'_Q
MNC[5\0O^@?X._P# ^X_^-UW&U?\ )HVK_DT </\ :OB%_P! _P '?^!]Q_\
M&Z^-?^"K'[2O[:WP)\3_  OA_9\^%_A?QQ8ZU->IXI>.RFU'^SU22U$!+&6'
MR]RO<'HV=A)QC!_0+:O^336A1LY .<9SWH XN:Y\?"XD$-CX1:/>=I:^N Q7
M/&0(_2F_:OB%_P! _P '?^!]Q_\ &Z[@(H__ %T;5_R: .'^U?$+_H'^#O\
MP/N/_C='VKXA?] _P=_X'W'_ ,;KN-J_Y-&U?\F@#A_M7Q"_Z!_@[_P/N/\
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M_:9\5>+?VCO$7@G7-?\ "?BC3[C4_$IT]+!3_:GA^+3=3CMEBOMK>6RNLX5
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M_P!Y>OK0 ZB@'-!.!0!XC_P4 _Y(9H?_ &4'P5_ZE&EU[89,#\<5XG^W^<_
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MPJX 90W49KJY?!VB-XN_X2!M+TUM>6S.G?VE]F0W?V8OO,'FXW>7O ;9G;N
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MBX^\OYTUI1N^\,8SUI@245#YF1PU'FY_B7\Z5T!-146_/\7ZU(GW:8"T444
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MY0J>67<KVT/^?:_'_,\L_P"%E?%(_P#-,=%_\*Y/_D:E_P"%D_%+_HF.C?\
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M:LNFG4EC78@%.HHKH/)"BBB@ HI"X'>@.#WH 6BBB@ HHHH **** "B@'-%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5'-\PVU)4<WW?]J@#P;_@H
MO?\ ]D_LU?:#J$FE[?%7AM//CA\UB'UNQC,>W/\ RT#&//4!\@$@ ^XZ?^[M
MU'S;L<DCDUX;_P %%]4;2/V9&F;4KC2?^*H\-Q?:((A*^7URQ01[21P^[83G
MA7)YQ7N5L#@;MN2!D#I64?XC]%^IZE;_ '"E_BE^4#YS_;[\5^*M$3P7IOAG
MQ5-H;:E=W3W>GZ?JMII&KZTD<0VI9W5Y&]JAB9_,DCDVM)&I*ME"K>3^'_\
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MICB%I%#*24=PN_C]$KWP!X>O[>XCN-%T::.ZAN+:=9;2-UFBG(-Q&^1\RR$
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M0$@^6[D;F3(!VDXR/:J=G\)O"-EIBV-OX9\.16*W NQ;QZ= L(F P)-@7&\
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M7@\4>1:6F(8AY'V?/VZ3(SF;_5<\=N*_0(RJ!]Y?SIFV//\ #EN@S]3_ (T
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M&-CN^578X.,'W"TC_=JV[KSS4.M:+::_9_9[ZUANH=Z2>7-&'7<K!E;!XRK
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MPO%H?@_P[X=\)Z'#(TL>GZ+8PV%HCN=S,(HE5,L3DG&230!TX;)I::I^:G4
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M_>X_V8/AK#X;_L9?AWX%71_MBZE]A&@VHMOM2YVS^7Y>WS1N;#XW#)YYJ_\
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M&ZT6'7;K4=+DU:&W#P-"C7FPV4MPZRK&)8TPAEC0CS8V->1Z)^T+XV\8^%/
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M,!@51,0HHHH*"BBB@ HHHH **** "BBB@ HHHH **** /$?^"@'_ "0S0_\
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MP% '& , 8XP* ZZ&A131,I_B%.!S0 4444 %%%% !1110 4V3_5-GI@YIU%
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M3G '8"NC7O\ 6J 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q'_ (*
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MME7QM=67]DVT@(>/[/9QP'$09O+G7($<9%>P+^VU^UP!_P F:P^O_)4M-_\
MC5*O[;'[6Q'_ "9K#G@?\E3TT$_^0J)9A1=O=E_X#+_Y$J7"^-:^*E_X.H__
M "9:_:^^(WBQ/CM=Z;I>N:UH<>CZKX*LM.2SD98WCU+59H[J9T7 F4F"*(A\
MH '7^,UYK^Q7^V-X]U#_ (47X:U+QM9^*;[5M!T*VO-+O+..35?$-O/IDDU]
MKAF1MR?9;M#9R @J)+>3S&\R90.NE_:O_:B_X2N/6O\ ABG3QK$-L]A'=?\
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M/_X3_P#]OKH?".GZIINF-'JVHVNJ77FDB:"T^RJ%XPNS>W(P><\YZ"MC;10
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M17$S[BJ\3#_P6N_9&@URZU)-49=2U# NKL>";\3W.,8WO]FW-C ZD]!5Y?\
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M&3?\%K_V1[B]T^ZDU622XTF62XL9F\$WYDLI),[WB;[-E&;)R5P3DYJI=?\
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M#=\"?_"1U;_Y94 =]Y'Q"_Y_/!G_ (#W/_Q='D?$+_G\\&?^ ]S_ /%UP/\
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M_P!IS_H;O@3_ .$CJW_RRH_X1_\ :<_Z&[X$_P#A(ZM_\LJ />**\'_X1_\
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M?_3G0![S17@__"/_ +3G_0W? G_PD=6_^65'_"/_ +3G_0W? G_PD=6_^65
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MR,$"ERA=6]9TRW>TL88V9I&C0(78 %\<9(  &>N  !VXH NT444 -=]E<?\
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M\0[J&W\/:C.FF-'-:FZ6Z:7(\LQ!6W@J&+ C& <UZ)I\Z7-E')&08Y%5D(&
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M3S2C8&1N/+8Y&X\G&:U<5U'STE:3"BBB@04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4S^/\
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3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>a03.jpg
<TEXT>
begin 644 a03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @  @$2  ,
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAEM>\GP2OQ2N_#FJW.JW=R=.^R)''-;VU]) PE6S#R2LZ1G.V$;<%5!^OO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444;J
M"B@'-% !1103B@ HHS10 44$XHS0 449H)Q0 449XH!S0 444%MM !11FC-
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M-_PAL)?V3?C[K?@[Q%JWB]=?MO#UK=6>F^%/[(TMKJ"_B.^"!!EK@0E/-95
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M]OF^\3?%"QU-_!/B+P;!;Z;>0?;/)AO+6X<R02?9OFWE)0Z@_*06QD]/8O\
M@GEIOBG2/V2O#%OXN_M<:DC7?V9-48M>Q6'VJ4V22D_,76V\D'=\V1SS0![9
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !4.H:E;Z383W5U<0VMK:QM---*X2.)%!+,S'@* "23P *E?E#CTKY
MD_;S\1>++CX=W5CJ?A6UMOA[:^(-%DUG5UU83-<Z8-3M3=":V$898?++F0[S
MB-7R-I. #Z*\*^,]'\=:3_:&B:MINL6.\Q_:;&Z2XAW#J-R$C([C/%4;/XL^
M%=0\6MH%OXF\/SZZKO&=.CU&%KL.@)=?*#;\J%8D8X /I7SI\#?BEX&^&7QG
M^/7BZQU;0]/^%UM)H0.H6!#:6M^;?RIS&8@48D/:(Q3/S @X937->%)-"^#W
M[6&C_P#" ^,M#\:7GQ#\?ZJ=<\//IEHVI:$&AN7O+@3HJW$*020+'^]^5O.5
M1DNF0#[0H5@XR#D>HH/2O,OCI\:KOX3_ !%^$6@V.GVMTWQ.\77'AJ6>9F'V
M!(]!U?51*JK]XEM,2/!(P)2W)7! /3:*RMNM?\]-+_[]2?\ Q5&W6O\ GII?
M_?J3_P"*H U:*RMNM?\ /32_^_4G_P 51MUK_GII?_?J3_XJ@#5HK*VZU_ST
MTO\ []2?_%4;=:_YZ:7_ -^I/_BJ -6BLK;K7_/32_\ OU)_\51MUK_GII?_
M 'ZD_P#BJ -6BLK;K7_/32_^_4G_ ,51MUK_ )Z:7_WZD_\ BJ -6BLK;K7_
M #TTO_OU)_\ %4;=:_YZ:7_WZD_^*H U:*RMNM?\]-+_ ._4G_Q5&W6O^>FE
M_P#?J3_XJ@#5HK*VZU_STTO_ +]2?_%4;=:_YZ:7_P!^I/\ XJ@#5HK*VZU_
MSTTO_OU)_P#%4;=:_P">FE_]^I/_ (J@#5HK*VZU_P ]-+_[]2?_ !5&W6O^
M>FE_]^I/_BJ -6BLK;K7_/32_P#OU)_\51MUK_GII?\ WZD_^*H U:*RMNM?
M\]-+_P"_4G_Q5&W6O^>FE_\ ?J3_ .*H U:*RMNM?\]-+_[]2?\ Q5&W6O\
MGII?_?J3_P"*H U:*RMNM?\ /32_^_4G_P 51MUK_GII?_?J3_XJ@#5HK*VZ
MU_STTO\ []2?_%4;=:_YZ:7_ -^I/_BJ -6BLK;K7_/32_\ OU)_\51MUK_G
MII?_ 'ZD_P#BJ -6BLK;K7_/32_^_4G_ ,51MUK_ )Z:7_WZD_\ BJ -6BLK
M;K7_ #TTO_OU)_\ %4;=:_YZ:7_WZD_^*H U:*RMNM?\]-+_ ._4G_Q5&W6O
M^>FE_P#?J3_XJ@#5HK*VZU_STTO_ +]2?_%4;=:_YZ:7_P!^I/\ XJ@#5HK*
MVZU_STTO_OU)_P#%4;=:_P">FE_]^I/_ (J@#5HK*VZU_P ]-+_[]2?_ !5&
MW6O^>FE_]^I/_BJ -6BLK;K7_/32_P#OU)_\51MUK_GII?\ WZD_^*H U:*R
MMNM?\]-+_P"_4G_Q5&W6O^>FE_\ ?J3_ .*H U:*RMNM?\]-+_[]2?\ Q5&W
M6O\ GII?_?J3_P"*H U:*RMNM?\ /32_^_4G_P 51MUK_GII?_?J3_XJ@#5H
MK*VZU_STTO\ []2?_%4;=:_YZ:7_ -^I/_BJ -6BLK;K7_/32_\ OU)_\51M
MUK_GII?_ 'ZD_P#BJ -6BLK;K7_/32_^_4G_ ,51MUK_ )Z:7_WZD_\ BJ -
M6BLK;K7_ #TTO_OU)_\ %4;=:_YZ:7_WZD_^*H U:*RMNM?\]-+_ ._4G_Q5
M&W6O^>FE_P#?J3_XJ@#5HK*VZU_STTO_ +]2?_%4;=:_YZ:7_P!^I/\ XJ@#
M5HK*VZU_STTO_OU)_P#%4;=:_P">FE_]^I/_ (J@#5HK*VZU_P ]-+_[]2?_
M !5&W6O^>FE_]^I/_BJ -6BLK;K7_/32_P#OU)_\51MUK_GII?\ WZD_^*H
MU:*RMNM?\]-+_P"_4G_Q5&W6O^>FE_\ ?J3_ .*H U:*RMNM?\]-+_[]2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !FD#@GJ*-P_7%?EIXC_P"#@G2=&_X+Y:?^SH+RR;X:_8SX
M9NK]5'R^)9661#Y@SF-<"WZA0TKDC*B@#]3**0NH[TM !1110 4444 %%%%
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M&VBMWOKK;]HNV1 IEDV@+O<C<=H R3@ <#4HHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>E
M"%@*^8/$4P'_  64\%?-]_X-:YCW_P")UI->'_\ !=W_ (+8ZM_P1^\/_#^Z
MT7P+I/CB3QE<W4,T=YJ<EG]D$2J1@HC;LEL<^E?D[K'_  =Z^+]5_:UT'XL?
M\*3\+K>:'X4O_"HL!X@G,<\=U=VER9M_DY!4VH4+@YWDY&!0!_3CN -+7P#_
M ,$)/^"R6L?\%@_AAX]\0:UX'TGP3)X-U:UTZ*WLM2DO1=^="\A9BZ)M(V8
M&<\U]_4 %%%% !1110 4444 %"MN'%(Y^4_2OA+5=:U">+4_B@-8U[_A.-+^
M.\7A2UM_[3E^SMIG]LQ:6;$6NX0E7L9'FR4+AG\S=P#0!]V%U ZU\_?MB,!^
MT3^R?ST^*M]_Z@_BJO?SF,-QZMQ7Y:_$3[)JOQ!\;-_:M]?VMCXLUN8RRZG*
MS:9<FYNX)?)?=FV*1RS0_NRA\MV7)#-GY+BSBN&14J=6=-SYVUH[6LK]F?:<
M&\'RSZ=6*J\GL^7[/-?F;\U;;3O][/U,,RK_ !#IF@RJ/XATS^%?!OP!_;.\
M:>(_!&E^%/ 8TOQ4_A33[73&F$GV^^D6&)4\R4[P6=@F2W<G/>I_'W[47Q^T
M=GW>"?B(V >-)\*-< GVP37GT?$#"UX*6'P]:?\ AIMK[[H[L?X<XW!5Y4<7
M7I4[/[<^65NC<=6KK6Q]UF10V,\]:'D6-<LP4>I.*_*WQS^VU^T&#(MO\(_V
MF=:ZC9!X0:U&?9FVUY+XM_;$_:@O1)]E_93_ &G=0DP0INU$2$_19#Q6O^M6
M95/]WRVJ_P#$XP_-LY/]5<NI_P ?,J2_PJ4_R2/VCN-?L;0$RWMI&%Y.Z95Q
M^M8.L_&SPAH087GB;1;;:.=]V@Q^M?A1XG_:5_;2O+[-I^Q%\1KZ'NVH23^8
M?R0BIM'_ &G?VQ+156\_8 \=77KY>J74.?\ R :/[6XFJ_P\#"'G*JG^$4']
ME<,T_P")CIS\HTFOQDS]K-4_:[^'.EYW>*]/F*\_N&,N?^^:YW5/V]_AW9[O
M*O=1O"O.([&1?R+ "OR7TS]L[]J_3-H;_@F[XNNL?\]];O3GZ[8!6UIW_!03
M]K32FS#_ ,$R]4SVWZA>R?\ H41HY>+JG6A#Y3D_T0D^$J?2O/YPBOU9^EVI
M_P#!2+PK;-MM=$UZ[]#^[0'\"V?TK'O/^"C%Y=/_ ,2WP/=7$?8RW#*?_'4-
M?!>F_P#!5G]M#2(PMO\ \$U+J,+TPTQ(_$V^:V++_@L]^W?IJ;;?_@G;KUNO
MI%=W*?R@I?V-Q+4_B9A&/^&DG^;*_MCANG_#P$I?XJLE^2/M8_MB?%#Q)\VC
M^ U56^[F"68_^RTB?$S]H3Q,W[GP^NFJW0?V?Y7ZNQKXR_X?9?M\$?\ */7Q
M-_X,+O\ ^,4-_P %L/V^"?\ E'KXFX_Z?[O_ .,4O]4<?4?^T9E5?^'EA^"0
M?ZV8"G_N^74E_BYI_FS[./@?]H[Q$?\ 2-7^PQR=EN;9-OX*I-#?LD?%WQ'^
M\U#Q\]NS=5&HW'_L@"U\8_\ #[/]OC_I'KXF_P# ^[_^,4?\/L_V^/\ I'KX
MF_\  ^[_ /C%5_J#@Y_[Q7K5/\567Z6%_KYC(?[O0HT_\-./ZW/M2'_@G3J6
MLD'6?'%U,S<MMC>;/XNPK4TW_@FMX;M &NM<U2X/?RH4AS^'-?"__#[/]OC_
M *1Z^)O_  /N_P#XQ1_P^S_;X_Z1Z^)O_ ^[_P#C%:4_#W((N[PZD^[E)_FS
M.IX@9_)65?E7:,8K\D?H3IO_  3]^']@/GAUB[]1+= ;O^^5%=#8?L;?#FPC
M7_BE[:8KWEFD8G_Q['Z5^:O_  ^S_;X_Z1Z^)O\ P/N__C%'_#[/]OC_ *1Z
M^)O_  /N_P#XQ7JT>%<FI?!A:?\ X"G^:9Y5;BC.*OQXFI_X$U^31^I>E_ ;
MP9H\:K;^%=#55Z;[1)/U8&MZQ\+:;I*JMKIMC:JO00VZ)C\A7Y+?\/L_V^/^
MD>OB;_P/N_\ XQ1_P^S_ &^/^D>OB;_P/N__ (Q7JT<#AZ7\*$8^B2_)'EUL
M;B*O\6I*7JV_S/UV*.3_ /7IZ [N]?D-_P /L_V^/^D>OB;_ ,#[O_XQ1_P^
MS_;X_P"D>OB;_P #[O\ ^,5U'*?KY17Y!_\ #[/]OC_I'KXF_P# ^[_^,4?\
M/L_V^/\ I'KXF_\  ^[_ /C% 'Z^4V92R\>M?D*/^"V7[?!/_*/7Q-S_ -/]
MW_\ &*\_^ 7_  <M_M9?M36&MW7P[_8GN/&-OX;U!M*U233-7NIA8W2C+0R?
MN.' (R* /V3^('PHT'XGZ?\ 9]<TJWU 8PLC)ME3_=<<CZ9Q7SYXO_8?\1?#
M34Y=8^'.O7D<H.\6TDPBF]=N[[C@>CBOB_\ X?9_M\?](]?$W_@?=_\ QBD/
M_!;']OAB/^->OB7CG_C_ +O_ .,5\[G'"V79DU4KPM46TX^[->DE^MT?091Q
M/F&6KDH3O![PE[T'_P!NO3[K,^TO!G[;OB#X;ZG'HOQ(T&XAN8CL:[AC\N0^
M[(>&[G*G)]*^A?AY\4_#_P 3K'[5H>K6VH1X&55\21Y[,O4=.]?DCXQ_X*Z?
MMO?$#3/L>L_\$X]:U&V[+->71*_[K>1E3]#7#_";]J3]J27XH?:M<_8L^,7@
M'2I,>7=: 9]0FMF)Y+!U1F0>BY/;!KP_9\193\#^N45T?NU4O7:7SU9[CGP_
MFS]Y?5*KZKWJ3?IO'\D?N49E'\0ZXI5=6Z'-?"_B']M_XT?"KX:QJ_@W3K[Q
M)<0I+8Q^*?M&D[EP?EE:*.0A^G\('7/2OF2Z_P""YO[;/_"67VE:3^PZ/$TE
MB0K7.B^()[VVD'JLBPX;^G>O:R?BS+\PE[&$G"JMX37+-/M9[_*YXN;<*YAE
M\?;5(J5)[3@^:+^:V^=C]A**_(+_ (?9_M\?](]?$W_@==__ !BE_P"'V?[?
M'_2/7Q-_X'W?_P 8KZ0^=/U\HK\@_P#A]G^WQ_TCU\3?^!]W_P#&*/\ A]G^
MWQ_TCU\3?^!]W_\ &* /U\HK\@_^'V?[?'_2/7Q-_P"!]W_\8H_X?9_M\?\
M2/7Q-_X'W?\ \8H _7RBOR#_ .'V?[?'_2/7Q-_X'W?_ ,8H_P"'V?[?'_2/
M7Q-_X'W?_P 8H _7RBOR#_X?9_M\?](]?$W_ ('W?_QBC_A]G^WQ_P!(]?$W
M_@?=_P#QB@#]?**_(/\ X?9_M\?](]?$W_@?=_\ QBC_ (?9_M\?](]?$W_@
M?=__ !B@#]?**_(/_A]G^WQ_TCU\3?\ @?=__&*/^'V?[?'_ $CU\3?^!]W_
M /&* /U\HK\@_P#A]G^WQ_TCU\3?^!]W_P#&*/\ A]G^WQ_TCU\3?^!]W_\
M&* /U\HK\@_^'V?[?'_2/7Q-_P"!]W_\8H_X?9_M\?\ 2/7Q-_X'W?\ \8H
M_7RBOQ7^-_\ P<3_ +9'[-?PPU/QIX^_87U+PGX3T;ROMVJZCJEU#:VOFRI#
M'O;R,#=+)&@]2X%;'@C_ (+S_MQ?$GP7H_B/0?V!=<U;0O$%C!J>FWUMJ5T\
M-Y;31K)%*C>1RK(RL#Z&@#]D**_(/_A]G^WQ_P!(]?$W_@?=_P#QBC_A]G^W
MQ_TCU\3?^!]W_P#&* /U\HK\@_\ A]G^WQ_TCU\3?^!]W_\ &*/^'V?[?'_2
M/7Q-_P"!]W_\8H _7RBOR#_X?9_M\?\ 2/7Q-_X'W?\ \8H_X?9_M\?](]?$
MW_@?=_\ QB@#]?**_(/_ (?9_M\?](]?$W_@?=__ !BC_A]G^WQ_TCU\3?\
M@?=__&* /U\HK\@_^'V?[?'_ $CU\3?^!]W_ /&*/^'V?[?'_2/7Q-_X'W?_
M ,8H _7RBOR#_P"'V?[?'_2/7Q-_X'W?_P 8H_X?9_M\?](]?$W_ ('W?_QB
M@#]?**_(/_A]G^WQ_P!(]?$W_@?=_P#QBC_A]G^WQ_TCU\3?^!]W_P#&* /U
M\HK\@_\ A]G^WQ_TCU\3?^!]W_\ &*/^'V?[?'_2/7Q-_P"!]W_\8H _7RBO
MR#_X?9_M\?\ 2/7Q-_X'W?\ \8H_X?9_M\?](]?$W_@?=_\ QB@#]?**_(/_
M (?9_M\?](]?$W_@?=__ !BC_A]G^WQ_TCU\3?\ @?=__&* /U\HK\@_^'V?
M[?'_ $CU\3?^!]W_ /&*/^'V?[?'_2/7Q-_X'W?_ ,8H _7RBOR#_P"'V?[?
M'_2/7Q-_X'W?_P 8H_X?9_M\?](]?$W_ ('W?_QB@#]>FD5<Y/3K3J_+/]C#
M_@O=\5OB%^WGX-^!/[0'[.6J?!/6_B-:2S>'9)+N6:2X>-97+.DD:XB(AD7<
M"3N XQR/U*B.Y,XQGF@!U%%% !1110 4444 %!Z444 >0_M"?LO^'_C^D*^(
M/#OA_7X[8DP#5-,@O1 3U*"5&VD]RN*^(?&'_!.?P'#_ ,%/?A[HB>"/!:V=
MQ\-]>O9;<:#9K!(\>H:>JN8_+VE@'(!(R 3CJ:_3KRU]*^7?B,A'_!8/X62!
MF"_\*O\ $:,OK_Q,-+/]* /3/V>OV;_#_P  [&:W\.^']#\/P73AYXM+T^&S
M69QP'<1*H8@$@$Y(S7K%- "=%IU !1110 4444 %%%% "/RC=^.E>?M^S!X$
ME^+/_";-X;L_^$E:Z%\;HO)L-PL/DB?RMWE>=Y?R"39OQCFO0:* $<;D(]17
MQ5_P4*_8T^'GQ6_:4_99FU3P^D"ZE\3-3M=4M["5[*WUF.7PUK.J2"[2$JMQ
MNN]*LW)DW$A7'21L_:U?/O[8?_)Q/[)__95;[_U!_%59U*-.HK5(IKS5SHP^
M,KX>7/0FXO35-K5:K;L]NQ\=_M2_\$(-8^&?BMO'W[-?B;4/#.N6+&=-&EO&
MB9>^VWN.N">/+DRN!C)Z5G_LX?\ !<+QA\ /&$?P^_:;\):II6I69$+:Y'9F
M.X3_ &YX>DB\??BSG).*_527/EMCKCBO,OVCOV2? /[6/A"31?'GAJSUJWVD
M03E=EU9GGF*8?.IYS@'&>H-?,5N'9X>;Q&43]G+K%ZPE\NGJMC]WRWQFPV<8
M:&4^(F%^O48JT:\;1Q5)=XU-/:);\L]]VV=#\)_C%X7^.7A.U\0>$M=TWQ!H
M]TH9+FSG$BCV8#E6]F -=8)5./FZ]*_(OXK_ /!*CX[?\$Y_&ESXZ_9R\5:I
MKNB1DRSZ1N'VH1C!*R0G]W<+QC(&_ KV+]B__@O;X7^(>JP>%/C)IK_#OQ=
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M^)ZLO_!7OX3R+]UOAOXB1O\ P-TXU]15\M_%=V7_ (*Z?!W _=R?#_Q(A/\
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MX"7PXBB^>FU_>M=TWW4M$]$VSW6BF^<O]Z@2*>]>\?E ZBBB@ HHHH ****
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M_P"3B?V3_P#LJM]_Z@_BJOH*OGW]L/\ Y.)_9/\ ^RJWW_J#^*J /H*BBB@
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M_P"&?$G@W43I/B3PSKT$5OJN@W6T.J3+#++"RO&0Z/%+)&RGAB00/B_X _\
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MMTT^@ZBBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(<U]#_L._P#!>7X=_'NZM?#OQ*BA^&?C$D0^;=2'^Q[R3H=LS<VYR#\LV .
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M^K?^"VX_^(H UJ*R?^$RM?\ GWU;_P %MQ_\11_PF5K_ ,^^K?\ @MN/_B*
M-:BLG_A,K7_GWU;_ ,%MQ_\ $4?\)E:_\^^K?^"VX_\ B* -:BLG_A,K7_GW
MU;_P6W'_ ,11_P )E:_\^^K?^"VX_P#B* -:BLG_ (3*U_Y]]6_\%MQ_\11_
MPF5K_P ^^K?^"VX_^(H UJ*R?^$RM?\ GWU;_P %MQ_\11_PF5K_ ,^^K?\
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M1>F#E1V!KD_UAS;*O=SJASTU_P O:2;5N\H;KS:T[(Z?]7\JS1<V2U^2H_\
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M (3*U_Y]]6_\%MQ_\10!K45D_P#"96O_ #[ZM_X+;C_XBC_A,K7_ )]]6_\
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MQJK2;7RS90=:]P_+SU3QE^U?#I7QBG\$^'O".O>--6TM[1=;>PO=/M8=&-R
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MV!G_ -NRC+_(/^(3\'XC_D7\4X=]E5I5:7WMW2/UC,R@]S]!2^:M?DR?"?\
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M@F53XHU;3V8#_C[T>>-1_P " (KLI<3954^&O'YNWYV/FL=X(<?83^-E-?\
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M_'7B[2U[!X8;@#\\5^E%%>?4X7RF?Q4(_)6_*Q]E@?'GQ!PG\+-JS_Q24_\
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M3+L4 ?4E%%% !1110 4444 %%%%  3@4U9-_3UIQY%>,VOQG\96_[;UG\/\
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MX_\ XJ@#6HK)_P"$]T7_ *"VE_\ @7'_ /%4?\)[HO\ T%M+_P# N/\ ^*H
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M_@7'_P#%4?\ ">Z+_P!!;2__  +C_P#BJ -:BLG_ (3W1?\ H+:7_P"!<?\
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M +1I:* $V_[1HV_[1I:* $V_[1HV_P"T:6B@!-O^T:-O^T:6B@!-O^T:-O\
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M[8?_ "<3^R?_ -E5OO\ U!_%5 'T%1110 4444 %%%% !1110 4444 %%%%
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M$XHE#!9M9*&+2M2KO91Q$5I&3V5167>R2@_U2CD\U<BG5\'?\$VO^"TOA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8[74W7@^26^Z_!S&W.>F:^W3<X)^7I[U\._\%(/^"-7AK]JQKKQAX(:'P?\
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M?@C^SSH/P$LM671Y-6OM0\07O]H:KJFK7KWVH:E,(TB0RS2$LP2..-%'150
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MU% &3_P@^D_] ^U_[]BC_A!])_Z!]K_W[%:U% &3_P (/I/_ $#[7_OV*/\
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M:F7B/VB2UFMXCI@P\\<D"$()-BA1LS7V=4:P[3GY=W?Y?SJ2@ HHHH ****
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M'V==^[:N[&,@<X^M "Q?,S-N+;OR_"GTBKM%+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7S/_P4G\"V'Q/T[X5^&]2_X]==\:6]IUQM<V\Y
M1_JCA6'NM?3%,>'<?KZC- 'YR>,/&FJ?M#Q>#=9\0K-:?\*I\4:-X1D29-AF
MU@S%;V900=P\I8E!&.2W%>@>!OB[>:U\6O#<EKXZURZ^+MQXVNK'7?!CZU,\
M-MHH:56,FEES';PQQK"R70C5F++^\?S,'[:\GC[VWZ"@0<CI[G'6@#X3^'DV
MN>(+CP?KUYX\^(%U<>+OB1KGA&[M/^$ENH[3[ L=_P"7%%&D@6.1&MHV65<2
M+E@'"\#BOV?/"_ASQ?\ !']F/0=+\6:P]V?%5W:ZW]A\3SW%]I%RFF7)DM%9
MI&DLB4508X_+*B0L-I8-7Z0K;[&RK<=P1G-'V?@<@,.<XZ\8H ^?OV9-=\0:
MY^R'XG@M]6U;7M>T'4O$VAZ9>7ETUQ?2&TO;NWM5>8DN\@6.,%V)9B,DYKR;
M_@F]\1)HM?\ A_X5\->./^$Z\/\ _"#/<^*=-:PT^&3P-JB26H@@E>VACE22
M8O>*8;HO,QMBY;[Q/VTL.T=1ZCCH:580GW=J_04 +&<H,]>].I%7:/QS2T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>a04.jpg
<TEXT>
begin 644 a04.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M2/\ @J-\#?VW_&^J>%_AUXT_M+Q-H]I]ON='O]+O-*OOLVX)YZ0W44;21[B
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MCXT>-/A_H&M)J'BSX=Q6$^NVB0R!;2.^B:6V82%=CAT0M\A.,<UZ)0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444UVVB@!U>#_ /!33PK9^-_V#_BC
MI.I?#S6OBMINH:')#=>%='NQ::CJL19=XMY,';*BYD7 )+(  217:>+OVM_A
M9\/_ !%<Z/KWQ*\ Z'J]DP6YLK_Q!:V]Q Q .&1W#*<$=166_P"W+\%6;/\
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MT@B.4%>4M^W)\%&QGXP?#'_PJ++_ ..4Y?VY_@HJX_X6_P#"_P#\*BR_^.4
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MQP,XK[LKR?\ X;E^"F/^2P?#'_PJ++_XY3O^&Z?@K_T5_P"%_P#X5%E_\<H
M]6HKRG_ANGX*_P#17_A?_P"%19?_ !R@_MU?!-?^:O?##_PJ++_XY0!ZM17E
M/_#=/P4_Z*_\,/\ PJ++_P".4?\ #=/P4_Z*_P#"_P#\*BR_^.4 >K45Y3_P
MW5\%#_S5[X8?^%19?_'*/^&Z?@K_ -%?^%__ (5%E_\ '* /5J*\I_X;I^"O
M_17_ (7_ /A467_QRC_ANGX*_P#17_A?_P"%19?_ !R@#U:BO*3^W3\%0/\
MDKWPO/\ W-%E_P#'*!^W3\%<?\E>^&'_ (5%E_\ ': /5J*\I_X;I^"O_17_
M (7_ /A467_QRC_ANGX*_P#17_A?_P"%19?_ !R@#U:BO*?^&Z?@K_T5_P"%
M_P#X5%E_\<H_X;I^"O\ T5_X7_\ A467_P <H ]6HKRG_ANGX*_]%?\ A?\
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MEW]DG_HW'X-_^$M:?_$4?\.7?V2?^C<?@W_X2UI_\17TW10!\R?\.7?V2?\
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M-T4 ?,9_X(M_LDDY_P"&<?@Y_P"$M:?_ !%+_P .7?V2?^C<?@W_ .$M:?\
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M;C\&_P#PEK3_ .(I/^'+?[).<_\ #./P;X_ZE:T_^(KZ<HH ^9/^'+G[)/\
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M]&X_!O\ \):T_P#B*^FZ* /F3_AR[^R3_P!&X_!O_P ):T_^(H_X<N_LD_\
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M+6=UXRU8ZWJ[F=Y!<W9AB@,@#$A?W<,8VK@<9ZUU5% !1110 4444 ?.K_\
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M?:FK,K=*/.4_SQ0 Z@#%0P7T-U$)(I%EC;(#(0P/;@C\?RJ17#']: '4444
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M%-"=<9J2B@!$X6EHHH **** "BBB@ HZT$X%-,@'_P!:@!V**;Y@_/I0) U
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M:2N +$VL?V88;</W>-O!YZ=:T8K=8455^55& HZ >E $E%%% !1110 4444
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M-_R-/[0'_95M2_\ 2.QH ^B**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH H^)/[0_L.Y_LK['_:.W_1_M180AL_Q;><?2N)0_% .I=? C+N
M&<27/3_OG_.:]$(R*:8P: /Q:_8MNO\ @HU)_P %G-53QZOCIO@7_P )!X@\
MG^UHXU\._8]MT;+:57S/+SY/EX^;.W/>OUCQ\5"./^$#_P"^[KC_ ,<KT$P*
M3WI0F!WH CLS,+6'[1Y?VC:/-\O.W=CG&><9]:FI H!S2T %%%% !1110 45
MPG[0VF^-]0\ 2-X"\3:#X5UFS8W,EUJNA-K$,L*HQ:,1+<0%68X^?><8/RG-
M?+W[-?\ P4 \;:-^R7\%?B'\3H)/B'KW[1":</"WASP)X92QGTVYN-+N-1EA
MEDN[_9)&D5O*?.+1XV?=.<@ ^W**^1_B;_P57\-^"O$?B+PS?>&?'G@_5$TG
MQ#>Z+JNL:9:36]]+I%I-<W#"R2\%YY82%GC,T<"3JOR2896;SGP?_P %6/'5
MY\:M#T.+P'J7CS2M5UKQ-IRVGA738UU6:#3M.T6ZMYL7-W'!%N_M&?>'EZ^4
MBY;[S2N!]_45\=> /^"I=OXZO_%VNZ/X9USQIX+6+PW+X9CT2SBAU!QJ=C/=
M2/?/=SPP6J1F$HS321A'^0DN54VM6_X*_>#['X!^%_B18_#GXM>(/"_BV[;2
M;632M/T^XF34UU.72SIWE&]#37/VF%U MQ*CH ZNR\A ?7=%?+=M_P %9_AC
M<?&.7PB+/Q&+?^U;[P];:W_H1L;W5;*&26XL4C%S]J#J(I$$CP+"[QLHD) S
MZI^RC^TE:_M=?!K2?'NE^%?%WA?0O$$$-_I \0P6\%QJ=G-#'-%=(D,TNR-U
M<8$A5^.4'% 'J%%%% !1110 4444 %%%% !110WW: "BOB_]MK]M[Q!\'OVT
M/#_PUM_BC\,_A'X?O_ \_B=M7\5Z*^IO?W2:A';"VB'VRV"A8W+GEB>.@R:R
M?V;?^"HWC+QMX8U#5_&7P]U"X:U\+Z/J<6F>&;%Q>:A/>:IJ5DMVGVR2)8+&
M:&S@NE:Y:/R8IOG8X!(!]S4$9KY2\,?\%8/"/Q#\,:3)X4\!_$WQ;XGU*]UJ
MRF\+:1:Z?-J6G'2)TAOY9)3=BT:-7DC5&BN'\XRH$W$D!Y_X*V?#&'XL:?X7
MFT_Q5:QW.JZ;X?OM5NX+6TM]&U74(XI+:PN8);A;P2_OXD=D@>.*25%=U).
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M\"^+[CP/I^F75YK_ (1L+BQL--U*Z\XSZ-(LTLOF2P+''('5PQCG3S(XV(%
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M(,,;MH /6:*:ARM.H **** "BBB@ KYW_8&_Y&G]H#_LJVI?^D=C7T17SO\
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M=PH6:ZCM;9(%D<+P&8(&('&2<5SO_#4,'_0G^.O_  3R4?\ #4,'_0G^.O\
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M>6C]J&W_ .A/\=?^":2E_P"&H;?_ *$_QU_X)I*/];<I_P"?R^Y_Y!_8./\
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M:]XPU)M/L[V^@TNRAAM9+N[U*\F8B*VMX(@TLTSX8A$4G",W"J2.[/2OG_\
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M_&C_ (7SX*_Z&K0/_ Z/_&D'P;\'L>/#.B'/_3E'_A3O^%,^#_\ H6=$_P#
M*/\ PH_X7?\ IU_Y.'_";_?_ /)1/^%\^"_^AJT#_P #H_\ &D/QY\%_]#5H
M'_@='_C4G_"E?"'_ $+.A_\ @%'_ (4G_"E?"'_0LZ'_ . 4?^%'_"[_ -.O
M_)P_X3?[_P#Y*,_X7MX+QQXJ\/\ '_3]'_C1_P +V\%D?\C5H'_@='_C3_\
MA2OA#_H6=#_\ H_\*7_A2O@__H6=#_\  )/\*FV>_P#3K_R<7_";_?\ _)2/
M_A>W@O\ Z&KP_P#^!T?^-'_"^/!>?^1J\/\ _@='_C3F^#7@\''_  B^B?\
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M>"",\_C4K?!KP>O_ #+&A\<_\>4?^%'_  IKP>?^99T3_P  H_\ "G_PN_\
M3K_R<7_"=_?_ /)3D?AB_P %_@JFH+X/7X>^%EU243W@TI+6T^TN.C/L W$<
MXSTS76+\>?!8'_(U>'__  .C_P :4_!KP>/^99T/_P  H_\ "E_X4SX/[^&=
M%'ULX_\ "C_A=_Z=?^3C_P"$W^__ .2B'X\^"O\ H:M _P# Z/\ QI#\>?!1
M_P"9JT#_ ,#H_P#&G'X,^#P?^19T3_P#C_PI1\&/!Y_YEC0__ ./G]*+9[_T
MZ_\ )Q?\)O\ ?_\ )1A^/'@K_H:M _\  Z/_ !H_X7QX+'_,U>'_ &_TZ/\
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M27Z!103@4PS8'3\*]0XQ]%1FX4-CFE\\?GZT /HJ,3@GH:439?;M- #Z***
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MR+\K;EXKUCP5X,TGX=>$]-T'0=-L='T71[:.TL;&SA6&WM(4&U(T10 J@#
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M?_\  VT_^.5W46CVD%PTT=K;QRMG+K&%8YZ\]:L4 >>_\+<\4?\ 1-]?_P#
MVT_^.4?\+<\4?]$WU_\ \#;3_P".5Z%10!Y[_P +<\4?]$WU_P#\#;3_ ..4
M?\+<\4?]$WU__P #;3_XY7H5% ' VGQ7\37%U%&_P\UR%)'"M(UY:E8P3R3A
M\\=>*[Q6R:<1D4!<&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #&:*** "BBB
M@ Q1THHH 3:/0?E2XQ110 4444 %&*** #%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8Q1110 48HH
MH **** "C%%%  !BBBB@ ;I7QO\ LZ:;\=?VJ_ NK>,K?X^OX6LYO%?B+2;3
M2K/P7IMU#906&LWMA$HED!=SLME+,W)9CVQ7V-(V(\U1T+3M.T%6L=/@L;-5
M9[EK:V18PIED=VD*+CEW+L6_B;<>3F@#P/\ X9B^/7_1SNI?^$#I'_Q-'_#,
M7QZ_Z.=U+_P@=(_^)KZ,HH ^<S^S'\>E&?\ AIS4O_"!TC_XFO#?V+?@%\9-
M:\1_&Z/2_P!HJ_TV2S^)>H07C#P/I4OVN<6ED3*<YVY!4;1@?+G'-??S?=K%
M\*7&AR7FJ)HTFDO,MXQU(631EENBHW>=LY\W 7.[YL 4 >&_\,Q?'K_HYW4O
M_"!TC_XFC_AF+X]?]'.ZE_X0.D?_ !-?1E% 'SG_ ,,Q?'K_ *.=U+_P@=(_
M^)KS?X7>&/V@/B%\?/BAX-D_:1N8(?A_-ID44R> M),EQ]KM//)?@@8/ P!Q
MZU]J5FV&GZ=9ZY>R6\-C%J%UY<EXT:(L\V 51I"!N; ! )],"@#P7_AF+X]?
M]'.ZE_X0.D?_ !-'_#,7QZ_Z.=U+_P ('2/_ (FOHRB@#YS_ .&8OCU_T<[J
M7_A Z1_\37F>FZ!^T!??MC:]\+S^TA.+71_!FF^*8[H>!-)^T/)=7U]:M&PQ
MMV 6:D8 .7;G@"OMBL)+O0)/'5U'%-HY\3+9QK<HCQ?;Q:AV*!P/WGEAG<@'
MY<N2.2: /$/^&8OCU_T<[J7_ (0.D?\ Q-'_  S%\>O^CG=2_P#"!TC_ .)K
MZ,HH ^<_^&8OCU_T<[J7_A Z1_\ $UYIKOA[]H#2/VP_#/PQ'[2%PUKKO@W5
MO$\EVW@/2?.CDL[W3;=$48QL9;URW&<HN#@FOM?/-8EW>:%_PG-O'))I!\2+
M9R"!&:/[<+5F0R!1_K/+++&6Q\I*KGH* /#E_9C^/3*/^,G-2_\ "!TC_P")
MH_X9B^/7_1SNI?\ A Z1_P#$U]&+PHHH ^<_^&8OCU_T<[J7_A Z1_\ $UY?
M\6M%_:"^&W[1_P )? T?[1TUQ;_$>35TGN)/ FDB6U%E9_:%,8 P=QX.0>/0
MU]ML^P<UFZQ9Z7+JVG7EY#IYOK5WCL9YXT,T3NA#+$S<AF13D+R0.>* /!A^
MS'\>B/\ DYS4OQ\ Z1_\31_PS%\>O^CG=2_\('2/_B:^BH_N#_.*=0!\Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP7/. *W*;''Y8]:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cass01.jpg
<TEXT>
begin 644 cass01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Y FX# 2(  A$! Q$!_\0
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M6+_OAO\ "JOQ%_Y$ZX_ZZ1_^A"O&:]'"8.%:GS2;W.6O7E3E9'N'_"<>&O\
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M +Y;_"O)/^$<U#[*LY$ WPM.L1F'F,BYW$+UXP:HWEG-8RI%<!5D:-9-H;.
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MXC!Y=C&BP+<(B@MP)<Y_+/%7K'Q21>PM=6,<>^6 W-R@<LPC(P=O3H.U0?\
M">>(_P#H(C_ORG^%'_">>(_^@B/^_*?X5#I2?V5][_R*4TNK^[_@B2>)95F,
M=OI\*V.9@\'SXF$A^8DGD=!C'2D3Q3=QNI2RB6..2!HHANPBQ9VKZG.3DT[_
M (3SQ'_T$1_WY3_"GR>-O%$/^MO2G./F@0<_E1[)[<J^]_Y!SKN_N_X)7M_$
M=S!&D9LD>,&?<I+#<)?O#(Z8[5#=ZW-=Z0FG?8DCC0J=V7;&/[H8G;G/..M6
M_P#A//$?_01'_?E/\*<GCCQ-('*7Q8(-SD0(=HZ9/'N*?LY)WY5][_R%S+:[
M^[_@G.;6_N-^1HVM_<;\C71#QSXE*,XO\JN,L($P,].U+'XX\32R+''?;W<X
M55@0DGT'%:<U7LOO_P" 3:'=_=_P3G-K?W&_(U[1\/01X,LP01\TG7_?-><_
M\)UXD!P=0&1_TQ3_  KT_P &ZA=:IX8MKN\D\R=V<,VT#.&(' KAS!S=)<R6
M_?\ X!T851Y]&;]%%%>.=X4444 %%%% !1110 5Q'Q0_Y%NW_P"OI?\ T%J[
M>N(^*'_(MV__ %]+_P"@M71A/X\?4RK_ ,-GDM%:VG06ATB]NK@0[XI8D1I@
MY4!MV>%YSP*F@T2&\AAD2Y*O.IE"K'\BKYPCXR<]\\U] ZD4]3S%!O8PZ*Z"
M/0+=KJ*-;B5RYD=0T8 *1R;6!(/!.#C\/6KEWX:L6N(5CEDMQ(WE*JKO&[$C
M9.3Z)C J77@F/V<CDZ*W_P#A'8C:PW"WA5+E0T&\*#]S?\PS]!\N?6I/[ LX
M/MC///*MO'*I^0+^\$8<$<\CG]*?MH"]G(R--_U\W_7M+_Z :I]JN:;_ *^;
M_KVE_P#0#51<;EW9VYYQUQ5KXF+H=,;_ $]K7?/>0SR>3&D;K"\=P""ORR$?
M*R  ]<Y %2W/B"%8[E+2ZVJ;>;R@L>/WIG+*1QUVG@]JHR:3I\ZV:63W,<MS
M;M<;[F1=D:J6W9VKDG"&H3X;O/[/%ZLD)A*B0$EA^[+8#9(QCOC.<=JYN6GU
M9K>?0U9-2TN>\^T?:XXQ%)</M,39D\R( 8P/[P/7%/DUZQE,C2W1=C$BJ2I)
M_P"/=D(Z?WS68/#;1PS2SWD8C%O)+&RJXW,A (P5!Q\PY[YI&\+W"R&/[=9F
M02&'8&;/F!=VW[OIWZ4N6EW'>?8VO[:TJ*&,"]$KQ.6B9T)(7RF4<;0%^;'R
MC([UDWVLQWFDRP2W'F.;:VV@K_RU4_.<XZXZGO4:^%=1:&WD)B4S&,;6)&P2
M'"DG&.XS@G&:C_L)5L[FY>^@:-(#+$T>XAR'"%3D9&"?U%.,:2=TQ-S?0S+7
M_C\M_P#KJO\ ,4Z]_P"/^Z_Z[/\ ^A&FVO\ Q^6__75?YBG7O_'_ '7_ %V?
M_P!"-=/VC'H:-DUK/X?GLI;Z&VF-VLR^:K$%0A'\(/<UKV^LZ=%:V4/FVWDQ
M"%7C,<A8.K@LX_A&<$YZD'&*RK6PTR?1C=$7OV@3QV^T2)M+N#@],XXZ4^+P
MI>SO*L,]O+Y<IAW)NVM(.J@XXQQR<#FN>:@V^9V-8\RV1?M=0?48'V3L=16*
M<+<"$L85,BE?N@G!7<!@'&:NW^L1VFI31M?;7@GD;:%/):W"@@8Q]_/';-85
MAX?GE^S3B[1(WECCD:(MNC#G'7&">Q )QWIC>'V\N2;^T;01JKRY<OGRU<H6
M/R^O;K4N%/FW_IE<T[;#EU*U?6M*O;H^<(X8Q=,4R2XR,D?Q8^4^^*O3:S"N
MCW=L^H?:;R2V*-.BL!+F4$+R!G"[N3ZXJD/"FHE)FS%^[9U7!)\S:,D@XP.#
MQG&:?:^&&DO(89KZW"L\:RB,L6CWJ67MCD#\*I^R>M]B5S]MS KW3P9_R)VE
M_P#7 ?S->&, '8!@P!(##H?>O<_!G_(G:7_UP'\S7/F7\->IKA/C91^(O_(G
M7'_72/\ ]"%>0VEH]V\@#K&D2&221^B*._')Z@8]Z]>^(O\ R)UQ_P!=(_\
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M))"T)5(&X4R>8<9/K^E>MT4EC6MHH?U=/J>4S1>);E'6XT%Y<EF0O:L?++
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MQ-KJA+=?E;GK_B?S->P44?7Y?RH?U5=V>.-I7B=XQ&UEJ90(4"E&QM( (^F
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M*X2XC,Z2JI7<)FY!.XYYY)/4]Z8$=[KUI87AMIPX8,HSQC!4G=].,?7%5O\
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M?<FZ@21E"N)&1@#D95B#CVXJR_\ K'_WC_.CD0[E_P"TP?\ /3_QTT?:8/\
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MN0F?D^Z1]=Q7\*KR:QJL)G4QH\L6]3&%'& /GP.<9)//'I72T9H Y;^T[_\
MM&%R_P"X 9'G4!@$W)\V!\I.3C(Z#FM72;V>Y>>.X=9'CP=T8&SDG@$?3H1D
M5J9HH *Z&Q_X\8?]VN>KH;'_ (\8?]VLJNQ42/4_^/%OJ/YUA5NZG_QXM]1_
M.L*G3V"6YS]Q<W(U9[X++]BBD^R$A_EP1@MMZY#D#/H*K6]X;6PLYK1FEG-J
MWGKO+9D. F[/0[C_ #KJ:*T).97SX+?^S[F?RY()@Z_:78I,C*3AG4\?-N[]
MA5HW,YT%?+AN8\8WR;]^$WX;:WWC\N2#CI6Y10!A27D-O)LL;EH[9W/F3L#)
M&A"$@*3ZGK_B:;9ZI>W%Y:Q3NMN\SLC6_E_,JB/<'!/OZ_3UK?J$6ENMR;D1
M#SCGYLGOUXZ"@#G6D5=*A@EN9FO'DF2&264J%Q(?WC'CH,8_("NH'0<YXZ^M
M%% #Q_J&_P!X?UIE/'^H;_>']:92&86L37C7H:T21EL$$\@1]H8D_=(_B^0-
MQZD5#%.CR/):RL]ZU^=B[R<Q$]QG 7;_ $KHZ*8CG4DA-@/]+N8[]X'^T.NY
MS&W<NO;!Z8Q[59TVZ$"7.Z(O%&03);2&2+&.2-QR#QR.:V<FB@#D9)[R*VD-
MX)8UOC'.I,F0O[P;E&/NC85X]C5W[0D&JQF.<KIXN,*Q<[,^4VX GJ,X_&NA
MHH 165T#HP96&00<@U-;_P#'U%_OC^=15+;_ /'U%_OC^=)[#.DK&U?_ (^8
M_P#<_K6S6-J__'S'_N?UK"G\1<MC/HHHKH($;A&/H#7,6U]>226NI%)!;0+'
M#+M;"_,/G.WJ<%EY[8-=110(Y+S<:-"UK+(UR;28W.V1B1\IP6YX.[&._6K#
MB2.2YA>06(V0E4+O)'(,\L3P0#]TXQCO72T4 9^CN7LFRFW;*RC;*9$/NC'G
M;_\ 7K0HHH *?%_K4_WA3*?%_K4_WA2&-/WC]:2E/WC]:2@ HHHI@9VN+(^E
M,D4LD3O+$HDC/S+EP,UBK+>76L>5<1,SI<".2(R,D;$1'D$=CP:ZNB@1D:7%
M<6^HSP3RM)M@C(^8E5RSG )ZX&!GKQ6O110 4444#"M[3/\ CP3ZG^=8-;VF
M?\>"?4_SK.IL..Y;HHHK L**** "BBB@ HHHH *BGMX[E DF< YX-2T4 4O[
M+MO1O^^J/[+MO1O^^JNT57,^XK(I?V7;>C?]]4?V7;>C?]]5=HHYGW"R*7]E
MVWHW_?5']EVWHW_?57:*.9]PLBFNF6RG(#<C'WJ3^R[;T;_OJKM%',^X612_
MLNV]&_[ZH_LNV]&_[ZJ[11S/N%D4O[+MCU#_ /?5']EVWHW_ 'U5VBCF?<+(
MI?V7;>C?]]4?V7;>C?\ ?57:*.9]PLBD-+M@0<-Q_M4ITRV))(;DY^]5RBCF
M?<+(I?V7;>C?]]4?V7;>C?\ ?57:*.9]PLBE_9=MZ-_WU1_9=MZ-_P!]5=HH
MYGW"R*7]EVWHW_?5']EVWHW_ 'U5VBCF?<+(I?V7;>C?]]5:CC6*-8T^ZHP,
MT^BDVWN.Q'-"D\9C?.T^AJM_9=MZ-_WU5VBA-K8+%+^R[;T;_OJC^R[;T;_O
MJKM%/F?<5D4O[+MO1O\ OJC^R[;T;_OJKM%',^X612_LNV]&_P"^J/[+MO1O
M^^JNT4<S[A9%+^R[;T;_ +ZH_LNV]&_[ZJ[11S/N%D4_[,MMI7#8)S]ZD_LN
MV]&_[ZJ[11S/N%D4O[+MO1O^^J/[+MO1O^^JNT4<S[A9%+^R[;T;_OJC^R[;
MT;_OJKM%',^X612_LNV]&_[ZH_LNV]&_[ZJ[11S/N%D4O[+MO1O^^J<FFVZ.
MK@-E3D?-5NBCF?<+(*KSV<-RX:0'(&!@U8HI)V&4O[+MO1O^^J/[+MO1O^^J
MNT4^9]Q612_LNV]&_P"^J/[+MO1O^^JNT4<S[A9%+^R[;T;_ +ZH_LNV]&_[
MZJ[11S/N%D4O[+MO1O\ OJC^R[;T;_OJKM%',^X612_LNV]&_P"^J4:9;*P(
M#9!S]ZKE%',^X612_LNVST;_ +ZH_LNV]&_[ZJ[11S/N%D4O[+MO1O\ OJC^
MR[;T;_OJKM%',^X612_LNV]&_P"^J/[+MO1O^^JNT4<S[A9%+^R[;T;_ +ZH
M_LNV]&_[ZJ[11S/N%D4O[+MO1O\ OJC^R[;T;_OJKM%',^X612_LNV]&_P"^
3JLPPI!$(TSM'J:DHI-M[CL?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cass02.jpg
<TEXT>
begin 644 cass02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #! F\# 2(  A$! Q$!_\0
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M]TS_ ,!7_P#CE'E>(O\ G]TS_P !7_\ BZ.1?S(.9]C8HK'\KQ%_S^Z9_P"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1K#G_EVB_P#0!6L5'ENT0V[V,O\ X3.;_H5?$7_@(O\ \51_PF<W_0J^(O\
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M5?$7_@(O_P 55.7XG:19736VIV.IV$P4,$N+?D@^P)]*ZO?[UXE\5#GQL?\
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M4.@SP<H3W-$DG@AV"0:W+;VCI$D]K&&V3B/[F[*Y[<X(SWKRY:G0$D  DGH
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MW.GW GA#;=X4CGKW'O4EQJ$%K*D4ID,CJ6"QQ,YP, GY0<=17(_"O_D5)/\
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M.SBK-?\  .JE"2NI.Z?_  ?TL=)-N'B'4W3/G+9YC(Z@X'3WILS3BRDG3?\
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M\I?_ $$U3TU_^)39?]>\?_H(JYXT_P"1(UO_ *\I?_0369IS?\2JR_Z]X_\
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M36IK&O3;MU,=GD_YZ/\ ]]&H6DD_YZO_ -]&NAC\.M-:1R&5Q)+&70A/W8]
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M?[I_E74:1_R!K'_KWC_]!%8UMD;4=V9_C3_D2-;_ .O*7_T$UBZ?'_Q*[/\
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MM^,;&TM/!NNRV]M%')/$7E=5P78D<D]Z\)6OH7Q;9S:AX5U"SMPIFFBV(&;
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MC2Y\E2!^]B_^*K>TZ)[?3;6&48DCA1&&>A  -959)I&M*+3+-%%%8&P4444
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M+F)%MK6W$T<H)RY"[F4_@1C\:KZ9XN\_2TN+ZTE6=59[E;==RVZAV4%LG/\
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>chart_2.jpg
<TEXT>
begin 644 chart_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P =M5^ /Q,^ FK>!=?TW2?#OCJ\\.:G\5/%7Q%\4K8:QX1BTO[)+:+X$O\
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MO%,-_97FF7NL7,%L]E=07,LD43@U]C MDCWQQC _3_ZXZD'I0!)17YV>+O\
M@J1^R%X&\0^._#OB'Q9XXAG^%OQ!D^&_Q.U6Q^%7C[5?#/P\UI;VVTZ#4/&7
MB?3-#NM$\/\ AW4=0N?LFEZWJ%[%;:C+;7BVB2_9I&'?_&+]OK]GSX%ZSJ&F
M>.[CXDOI.@V7AG4?%GC[PQ\(/B-XM^&'@VP\81VMQX=O?%?Q%T#P]>^$]'M]
M2M;VTN89)=38+%<P^9B1O+H ^U**_+O3?^"B\.N?MK?$;]D^U^'/C>+PSX>^
M&VA^(?#?Q3TGX>^/->#Z_K;LSZ_KMG!HIT;3?A-%826]WHWQ&N-0C\.:Y>;=
M.@OC),@I_P #?V[?A[X;_9G^#OCGXJ_&[Q)^T1XR^+'B?QSX>\#WWP^_9^\1
M:'\0OB9?>&==U6/4K/PS\#/!MGK>O?9_"&GVJ6VJZI!;FVEAABOYY5>]B5@#
M]0:*^"M1_P""E'[)FF^"/A=\09/''B"\T#XP>*O%_@+P;;Z7\/\ QGJ?B,^/
M? ]FUUK_ ('UGPI9:-+XCT;Q9%<>3I-GHMYIJW5]JUY96=NK_:X9#\__ +0G
M_!6?X:> _P!G=?C?\$?"OBCXF:C:?&O2_@QXH\(^)?!/CSPE?^ M?34--'B/
M3_']C-H9U7PAKJZ5J"OX4T_6K:V'B?5R-'T]IKZ"[@A /UUHKX9UK_@H7^S]
MX?U[PGX3U:S^,MMXO\3^$M-\=ZCX03X%?%*Y\5_#KP;J^O2>&=-\2_%C0+7P
MU-J7PXTN]U>)X89_$]K98C,4\BK#-"TGN'QF_:*^&/P"D^%Z_$W5-3T6W^+_
M ,2= ^$W@W4;;1=0U/3'\:^*%F;0;#6;^R@DM]"MM0-O-'%J.I-%9B161I P
M( ![M17Q!K/_  4-_9;T'3/VG=6O_'&H"V_9!US1?#GQNCM_#6KW5WI&K^(=
M3;0])M= M(;=KCQ2;G7(Y=(WZ*MTL>HQ26DA$B\_&'QO_P""BVO?L]VW[:?Q
M T_QEJGQSF^%>J?!.S\'? NZ^!^O^!=/^#+?$303K!7Q]\3]+M[^[U;2]8L8
M[J>?7-7MK2U\/^(?[*\+2LE[J]M$X!^UU%?BY\2_^"COB#PY^T/^P[=I:?$G
MPG\#_C;\-?C1KGQ ^&NH? [Q1<?%+Q#XJ\,Z590^#[;P[X2N?"\WQ*,,FOW
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M)'B<?#?X<>-?B3:^ _AYJ[*NE^-_B#>>#]%U2V\&^&]01O/M-1UN6U26W4W
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M4U\4_M;ZUY7B?59(V^$VL7$4MG#9R'PQ$;GQ?M0F?1I([>Q1C\NL,.G[P44
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M)&F^,M9UK_A+?B9JOPQU&]N?@]\/!>V'DR:S;:7H^G)+97*VUA=S7HFO8_[
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M@KQ7/X[U'37U*77-?N)XM+FO7GETR_=6CK^AA((HRS1QHA=MSE$53(W'S.0
M78XY9LMR>>:EH _)3PE^R+^T9\,OVLM*^-'AJW^&'BKP1X[_ &1OAC^SA\3D
MUGQAKVA>(_!.J>!;*%;_ ,0>%K*#PEK-IXTM]0N+*WCM;?4-0\,NJW$\\\H,
M*1S_ "%:?\$IOCQIWP9_8Q@U/2_A)\1/''[-&L?'VT\8_"C5_B=\2/ '@_QQ
MX6^,_B)]6MKC1OBMX#TBV\6^']=T%;6PN40:'+I]Q<22V]Y#?V4<UK>?T444
M ?BUI'_!/?XBZ3J/[#VJ^$_AW\%/A'8?!']J+Q]\=?BMX+\%?$'XC^+=/BTS
MQ5HMEI-I/I7BCQ]8ZAKWC;QE/'IEI_;EU=)X7TJ:4>;96=N!(LG#_$[_ ()K
M_'[QM\-?V[/#NFZO\.;3Q%\=/VQ?"'[2'PEBO=<U<Z7J&@^$]4TW4O[%\97<
M'AYI_#FI:@EO<PJUC:Z]#!(L#M(RNQC_ '=HH _%/]J;]D3]KS]H7QO\//BA
MX/\  _P1^!?QPM?#_@BRO?V@/A_\>_BKIWC3X=?V3XHN]2\4>$+[0].\ Z=H
M7QP\(7.F-#_PCZ:['X0ET^\O-2BN+:YMC&&^U?V\OV:O$O[4?[+GBGX6^$M1
MTJT^*&GWOA#QO\-?$&M7$^FZ;8_$;P'K=CK>C:A>75E:WMQI]O>&WO+&XFMK
M2Y:"WOY0(9%)4_:]% '\W&G?\$A/VBI/%?P,U77?%_P]N-*^(FLZ)XP_;\A@
MUO4R_CGQ3X9^-VL_&#23X.MSX;CAUFT,.J6OAJ0:@VC*+;2XW,313M&OTO\
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M$;+I"67]JF^V+]HFLE*A?W/HH _"KXW?\$S/C9\7;[]ON>V\1> M"/Q^U/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_;K^(GC2;X"^)?B)\#M \"?"[]HNW\?V_@;Q)H?Q.E\8>)[#6/A_P"']?\
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M2W?BO1(+JXT;0_#9\1VVBZQI=U+J%_J>G:A'#;U[#\'?V4_"?P0U'2/^$/\
MB-\:[OP7X7L]0T[P1\*/$?Q#GU?X:>"=,OHY+>'2]#T8:;;:I>:;HME*^G^'
M+'Q/KGB&V\/V7EQ:5';-! \74>./V>O"7CCXL^!_C--XA\<>'/%_@KP_J?@Z
M:'POKMK8:#XU\#ZQK&FZ_J/@OQUI-[I6I1ZSX?N-7TFRO&CLY=+U#*2PC4/L
M]Q<0R@'R]\/?VU/B)XDF_9^\;>,/@?I/A+X%?M2>+;?PA\)?%]A\1Y->\?:?
M=>(M#UWQ+\.=1^('@9O".FZ5I-AXZT7P[=7,2Z'XMU^XT)KNPAU*,DSF'PW_
M (* ?%+XT?#3]IOX!^*?AKXU\8V/A;X4?"+XF_'7XD?#31M:U&V\.?$KP/X%
M\:?#_3_'^G^(-!MW^PZS?:;\/]=\1ZMX?FO+>YET_4]/AEL$2Y=%E^P?AU^P
MW\(_AMXC\$:OIWB/XJ^(?#?PKU35]:^$/PP\8>.)-<^&GPIU75X=0LVOO!V@
M?V=:WS3Z5INK:II?AP^)=8\1)X<L-0N(M%2S;RY(_8_%/P%\ ^,_BKX=^+_B
M"+5+WQ'X;^'7C?X6VVF&\A'AJ_\ "?Q!N=(N?$<&JZ6;1IKJZE.C6T-M,E[#
M'#;RW2/!,TJN@!^</Q9^-GCGXD_M?_ '6_A?\1O$VE_ KX??'?X7_!?6K'PO
MKU_8^%_BUXW^*GPG^(OQ4\50>(K>QN([#Q%H_@CPCI?PXCT^UODN8;77/$>J
ME0)X0T/L&E?MS>.[VR\%_%JY^">D6G[,'C[XV0?!3P_X]'Q&EG^)<<VH>/;_
M .&&B_$#5?AN/!\>E6_A#5?&EB\ M+?QI<^([31[FUU:72GWR6L7M'PW_8@^
M!WPH^'/P;^%W@R#Q39>&O@?\69/C3X3DN==2\U?4O&LFG^+M*\WQ1J,U@6U?
M3HM-\97]A#9QQV3Q6FG:+ EP([!EGS="_83^#OA_Q1I.K6VO_%.[\$>'/B3>
M?%_PO\$=0\<2W/P9\-?$F[UB^\2?\)-I/A4:='J8-GXGU/4/$NF:'?\ B"^\
M,Z;KUTVHV6BPS16YA /*?#O[;?Q/U#Q/X>OM<^!GAW2/@]XF_:E\>_LGZ;XT
MM?BA-J?C%O&GAGQEXV\%:#XKG\$+X,MK.#PCK>L>#C97X/B@ZYI5Q=O<Q:7>
MZ?%'=7'R?XD^,G[4?C7]B[]HSQ)\2K#POJ%_X5_:O\,>&?!-SX1\?7L6O7=[
MX<_;-^'FB#X?EY?!?A33=,\+:=9QQ^']'\37.I7M_J^ES/<:[86I:97_ $\B
M_9/^%\/A_P .>&EN?%AT[PM^T5K'[3^F,VLVQNF^)6M^-?$_CV\ANI_[- F\
M,KKGBS4UM])6.*XCL4L[=M1=H'FEYI_V*_A>^F?%;PZ?%'Q/'@WXN?$G0OBU
MJ_@C_A*;%O"_AKQOHWQ'T/XJW6I>#+1]!:\T>'Q'XO\ #]C<Z_9W5_J=O+:2
M7=KI::4MP74 U_@/\=/''Q!\>_&3X3?%/X?:%\/OB+\(G\#ZC>0>$O&=WXZ\
M+:[X9^(NCWNJ^'M2L-;OO#/A*_MM2M)M*U/3=9TVYT:-(;BVCN+&ZO+6X65?
MSZ_X7CXSNOBS\3_C5\5M#_:-D^$/PY_:[N_@+HGB?X<?&NP\)?"WP-IN@^.O
M#WPL\/'7?@UH?B&QUSX@V7B#QKJ,,OCK6_$^F:FT*Z^EII-F-'TDR5^KGA[X
M1>%/#/Q2^)/Q>TZ35F\6?%/2? VC>)DNKV*;2([/X?6NK6F@_P!E6*VL<EI*
M\>M7AU"26YN?M+^28U@$95O"]5_8?^$&L?$#6/&EWK7Q+3P_XD^)6D_&3Q-\
M';?QD\/P<\1_%31I-+NK+QQJ_A,:>;V?4FU70]&UV\T^/7(?#U_KVFVNK7NB
MSWBO(X!]BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Q/B?P:_B75?#NIKXN\:^'1X?O!=MIWAC68=-TK70)[>
M?[)XBM9-/O&U"T(M_)\J.:U8P3W,8D!D5E^?OA=X*^,.C?M)_'/XC^*_!?A'
M2O _Q0T;X:Z3H]_I7Q!NM<UZR;X8VOB^Q@GU#09?!6D6R)XAC\3Q7");:W.V
ME_99HIC=%XW/UO10 ULY7 /)YQZ?U_F!DCI7Y5_\$CO&OQ"_:1_X)X?LZ?&K
MXT?$CQUXX^)OCBS^)=SXH\4W6OS:5/JTND?&7XB>'M,9]/T&/2](M5L]%TG3
M=.ABL=/MHA!9Q$HTA>1_U5/4?7^AK\B/^"#?_*)S]D?_ +!?Q;_]7[\5: /U
M!_X02P_Z#OC/_P *_7?_ ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/
M^@[XS_\ "OUW_P"3*/\ A!+#_H.^,_\ PK]=_P#DRNWHH XC_A!+#_H.^,__
M  K]=_\ DRC_ (02P_Z#OC/_ ,*_7?\ Y,KMZ* .(_X02P_Z#OC/_P *_7?_
M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
MA!+#_H.^,_\ PK]=_P#DRNWHH XC_A!+#_H.^,__  K]=_\ DRC_ (02P_Z#
MOC/_ ,*_7?\ Y,KMZ* .(_X02P_Z#OC/_P *_7?_ ),H_P"$$L/^@[XS_P#"
MOUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\ A!+#_H.^,_\ PK]=_P#D
MRNWHH XC_A!+#_H.^,__  K]=_\ DRC_ (02P_Z#OC/_ ,*_7?\ Y,KMZ* .
M(_X02P_Z#OC/_P *_7?_ ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/
M^@[XS_\ "OUW_P"3*/\ A!+#_H.^,_\ PK]=_P#DRNWHH XC_A!+#_H.^,__
M  K]=_\ DRC_ (02P_Z#OC/_ ,*_7?\ Y,KMZ* .(_X02P_Z#OC/_P *_7?_
M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@%+X6_&WQ!XO\;>._AEX_P#A];_#[X@>!_"?@?QY)INE>,H/'.AZIX3\?_\
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M$1?_ !='VZR_Y_+7_P "(O\ XNN<_P"$!\$?]"CX<_\ !/8?_&*/^$!\$?\
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MMUE_S^6O_@1%_P#%USG_  @/@C_H4?#G_@GL/_C%'_" ^"/^A1\.?^">P_\
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M=<W_ ,(%X'_Z%+PW_P"">P_^,4O_  @7@?I_PB7AS/I_8]A_\8H Z/[=9?\
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ME;1>!?C#\2+SQ5X1@U1[K3-+:T\01Z7/&NLZ=!%=VME>%H;?4;U!YS']=?\
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M>O\ 45]+@N&N'LM26 R/*,)R[2H9?A:<^FO.J7M+Z+[=^MSU,/EF783_ ';
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MD?O+?&XC*74?^"W?[1*'[+I_A']FWP_>,0'E@T#PUJL5G<*=A8W;^,O%L<L
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M4^_X-R=$"BQ_:1_8[(3I]NTG5M6/&#R=5\-7I;G^]G/U))]&TO\ X++_ /!
MS0P/[%_:U_9 TC:<K_9GAD6(!]1]F\%1<X)YS2> \4*R2GG_  I@TWK]5R7'
MXE]$]<7BVEY7;5]UT%[#BN=N;,<FH?\ 7G XBHUMJG5Q&MK76B/4[C_@KM\/
M+H[?#/P1^)VN,3M7?<:#;JS'H!_9LNM/@Y&?W>\'HIK+/_!3OXJ:RYC\)?L?
M>.;QF8"-KG4/$-V7!Z'R;'P-"O/^S='/054M_P#@O!_P1/LL?9/V[_V<+7'W
M?LR:Q"%],"'PNF".Q_2M-?\ @OY_P1J7 7_@H/\  55Y&!J'B4 #Z?\ ".84
M_EZ#BG_JWQY6M[?Q!5#NL#PSET+;:1G5KSEMU<7LA_V;G\]*O$?*NU#+,-#:
MW\\YZ=->9V1 /VUOV]=:.SP[^QA?VL<JYBFU'P_X[=0'/RMY]W_9=J01CJ0.
MYPIX0?&3_@J]X@;.E? ?PEX?AEX5KW3]"A:$'H3_ &OX[CFXP3AK4XR,J1C-
MD_\ !?O_ ((TG'_&P?X"<'.?MWB,G/\ X3G^>]'_  _[_P""-0Q_QL(^ O\
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M5_TD'^ O_@P\2?\ S.T?\/\ [_@C5_TD'^ O_@P\2?\ S.T ?L)17X]_\/\
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M-C'XJEM4MM:^)OB7R]?^(6O8W&0W7B"[C#Z=:R,S$:5H<6FZ9&NU1:N=SO\
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MVU@L+BTU'0[B]\(/_!?S_@C43G_AX1\!?_!AXD],?]"[Z=:/^'_?_!&G)/\
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M WZEX9<=4Y)*#QN:\-4</5X"XIQ"24FL1E63SERJ,*])7O\  OPK_P""7O\
MP0X^.'AN#Q?\(/V*_P!@SXD^&KA$=-7\'?"[X<:[:H9!N6.X^Q64LEE-C.;>
MZCAF'*L@92*]/'_!%7_@D?W_ ."<O['W(Z#X(>!R?UTOOD8QGZ]*_-OXI_\
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M$5/^"1X_YQR_L?\ _ACO _X_\PKKCI49_P""*O\ P20!Q_P[F_8^Y X/P/\
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M>$IY]P'Q?@91C&K@N(^&,<Y8#&0J03IQQ=*&&S+#*3^JXR@TF?Q2_L?^)/\
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M.IX?>,.48?C_ (:6'CI[+ 2S=RSK(G"',J%3(<VRV6'E)U*7+/WC^:7X2?\
M!P+<> O$<'PQ_P""@7[,_CWX ^-H'CM+[Q'X>T/6I=*9DQ%/J%]X(\0PVWB2
MRM1(P9Y-"OO%,.TL\1!"05^ZGP'_ &K?V=?VF]%77O@3\8?!'Q(LVC1Y[/0M
M7@77+ $\KJ?AN]^R>(-+=2=KIJ.FVS*X*$9R*ZKXN_ ?X.?'KP]<>%/C/\,_
M!7Q*\/W$;Q'3_%WA_3]8-N)!@RZ==74+7FF72]8[O3KBVN83S'*C$M7X6_'C
M_@WK^$DVM2?$3]C+XR?$#]F7X@V4CWNCZ<-:UG6_"MO>J2Z)I>L65_I_CCPV
MC-\@-OK>KV\4;8ALT4&-O-]GXB</V]G/+N.<NIV:I55#(>((4UR_\O8*65XR
M44FY2E##U*L[O=V7VCQ7T,?&*WUO!<8_17XSQ"2^M96\7XI>#^(Q<KMRK9;7
ME0XZX:I5ZC2C#"U\\P6$IM)TVJ?M#^C $>HSZ<>^.Y]*,@]"*_E-_P"&D/\
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MIWEA,E52+?+*I[?%TW[\5![?T3]2^BW]')N69U\!]*WQ>PON_P!F9?6QN6>
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MZ=17T?Z]]?Z]#\8ZWZ_/YZ?+KKYV"BBB@84444 %%%% !1110 4444 %%%%
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ME?#.UU'P=X<T#PMX/FM+KQ<FE:YXUOM5MK*XU"WL*][^%WP=_;>_: _:K_9
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M '&.&PO&? 688>2M4P^)X5XCHYAE=*G67NU9X&EA,0TE:LGJOY7=(_X*U_\
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M;P7'XB\7QA@B7\1+5]K_ +'G_!"3]G_X-:K;_%']IG6+G]J?XWW5W'K5_?\
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MJTY_VB_V)OV1_&^C^+O$7PJ^)5I\'/"WPZ\"? 3Q7HGAGQ!X9U*[L;S4]/\
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M$CXI_P#E/1_PL'P[_P \_$/_ (2/BG_Y3UV]% '$?\+!\._\\_$/_A(^*?\
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M'P[_ ,\_$/\ X2/BG_Y3UV]% '$?\+!\._\ //Q#_P"$CXI_^4]'_"P?#O\
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M_$/_ (2/BG_Y3T?\+!\._P#//Q#_ .$CXI_^4]=O10!Q'_"P?#O_ #S\0_\
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M;4=8U+7)K'1-':ZOCHOAO1Y=3?1O#&C"\N1I/A^PTW3Q-(+?=7N]% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 %%%% !2'M]?\X_STS2TA[?48_K^F: /D?\
M8UX\"_%J/DB+]JO]JB,$]2!\<?&;9..,Y8]*^N:^1OV.?^10^-*CHG[6_P"U
M4JC^Z/\ A=GBUL8[<L3CWKZYH **** "BBB@!#U'U_H:_(C_ ((-_P#*)S]D
M?_L%_%O_ -7[\5:_7<]1]?Z&OR(_X(-_\HG/V1_^P7\6_P#U?OQ5H _7BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T
M=Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"
M_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG
M9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)P
MO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )
MV7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17
M#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0
MI^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\
MX_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I
M^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X
M_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\
M"<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./
M_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_
MPG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_
M  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W
M%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_
M -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E
M_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_
M]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9
M?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</
M_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"G
MXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C
M]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GX
MX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C]
M '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )
MPO\ T*?CC_PG9?\ X_1_PG"_]"EXX_\ "<E_^/T =Q16?IFH?VG9QW@L[^P\
MPR#[+J5L;2]C\N1X\S6Y9RF_9YD?S'?$R/QNP-"@ HHHH **** "BBB@ HHH
MH **** "BBB@ K"\3^'-"\8^'->\(^*=(L]?\,>*=&U7PYXCT+4H%N=.UG0M
M;L+C3-7TK4+9\I<6.HZ?=7%I=PN-LL$SH>H!W:* /PH_X(K_ /!%KP#_ ,$D
MT_:NO],U6P\7^*/CG\;-?NO!?B-5EGU/PU^SCX>O[B3X1^ =2NKBVMY#X@ME
MU'5-4\87%L6LM0U-]-*;UT^';^Z]%% !1110 F >HKR#P/\  7X5?#?Q;XD\
M=>#?#,^D^+/%X4>*-9D\2^*]6FUTQB%+>34H=:US4;2YGLH+>&TT^X>W,^G6
M"#3[&2WLBT!]@HH 0]1]?Z&OR(_X(-_\HG/V1_\ L%_%O_U?OQ5K]=SU'U_H
M:_(C_@@W_P HG/V1_P#L%_%O_P!7[\5: /UXHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\76>J7_AG3M1\,>.O"_C.'^V[31F75)+*['AUK*4V!^T1_:5E0'80?F?Q/\
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M<_X)\_$WX.?LU?L$>$8?%FC>.O$W[ MM\<_&&N:;X7T.Y>_^+%[XN^!/QP\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]#7Y$?\ !!O_ )1.?LC_ /8+^+?_ *OWXJT ?KQ1110 4444 %%%% !1110
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MJD2PZ;XDL[6Z2\MHG6^@N5C$D BFD_0TX/7''3/8]?S[T CH,<8X';/3\^U
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MH XG^V/'/_0E:;_X5\?_ ,HJ/[8\<_\ 0E:;_P"%?'_\HJ[:B@#B?[8\<_\
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MS_T)6F_^%?'_ /**C^V/'/\ T)6F_P#A7Q__ "BKMJ* .)_MCQS_ -"5IO\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375204799536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001069530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CASSAVA SCIENCES INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-29959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1911336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6801 N. Capital of Texas Highway, Building 1; Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-2444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,174,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205798688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,350<span></span>
</td>
<td class="nump">$ 201,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,834<span></span>
</td>
<td class="nump">10,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">150,184<span></span>
</td>
<td class="nump">211,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,077<span></span>
</td>
<td class="nump">22,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">172,529<span></span>
</td>
<td class="nump">234,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">9,492<span></span>
</td>
<td class="nump">4,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_AccruedDevelopmentExpenseCurrent', window );">Accrued development expense</a></td>
<td class="nump">7,344<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,414<span></span>
</td>
<td class="nump">7,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,414<span></span>
</td>
<td class="nump">7,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 9, 10 and 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 120,000,000 shares authorized; 42,129,798 and 41,735,557 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">514,923<span></span>
</td>
<td class="nump">511,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">(359,850)<span></span>
</td>
<td class="num">(283,552)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">155,115<span></span>
</td>
<td class="nump">227,539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 172,529<span></span>
</td>
<td class="nump">$ 234,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_AccruedDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued development expense, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_AccruedDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205719456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">42,129,798<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,129,798<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375204721984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of grant reimbursement</a></td>
<td class="nump">$ 23,603<span></span>
</td>
<td class="nump">$ 18,526<span></span>
</td>
<td class="nump">$ 70,692<span></span>
</td>
<td class="nump">$ 50,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">12,476<span></span>
</td>
<td class="nump">8,703<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">27,879<span></span>
</td>
<td class="nump">21,345<span></span>
</td>
<td class="nump">83,168<span></span>
</td>
<td class="nump">59,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(27,879)<span></span>
</td>
<td class="num">(21,345)<span></span>
</td>
<td class="num">(83,168)<span></span>
</td>
<td class="num">(59,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="nump">6,254<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,651)<span></span>
</td>
<td class="num">$ (20,257)<span></span>
</td>
<td class="num">$ (76,298)<span></span>
</td>
<td class="num">$ (57,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.82)<span></span>
</td>
<td class="num">$ (1.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">42,002<span></span>
</td>
<td class="nump">40,050<span></span>
</td>
<td class="nump">41,845<span></span>
</td>
<td class="nump">40,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375197868752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Share-Based Payment Arrangement, Employee [Member]</div></th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Share-Based Payment Arrangement, Nonemployee [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,016,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 461,181<span></span>
</td>
<td class="num">$ (207,306)<span></span>
</td>
<td class="nump">$ 253,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,527)<span></span>
</td>
<td class="num">(17,527)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,031,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">461,887<span></span>
</td>
<td class="num">(224,833)<span></span>
</td>
<td class="nump">237,094<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,016,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">461,181<span></span>
</td>
<td class="num">(207,306)<span></span>
</td>
<td class="nump">253,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,112)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,059,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">463,097<span></span>
</td>
<td class="num">(264,418)<span></span>
</td>
<td class="nump">198,719<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,031,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">461,887<span></span>
</td>
<td class="num">(224,833)<span></span>
</td>
<td class="nump">237,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,328)<span></span>
</td>
<td class="num">(19,328)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,097,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">462,491<span></span>
</td>
<td class="num">(244,161)<span></span>
</td>
<td class="nump">218,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,257)<span></span>
</td>
<td class="num">(20,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Expiration of restricted stock Performance Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Expiration of restricted stock Performance Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,059,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">463,097<span></span>
</td>
<td class="num">(264,418)<span></span>
</td>
<td class="nump">198,719<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,049<span></span>
</td>
<td class="num">(283,552)<span></span>
</td>
<td class="nump">227,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,271)<span></span>
</td>
<td class="num">(24,271)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,749,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,786<span></span>
</td>
<td class="num">(307,823)<span></span>
</td>
<td class="nump">204,005<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,049<span></span>
</td>
<td class="num">(283,552)<span></span>
</td>
<td class="nump">$ 227,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76,298)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,129,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">514,923<span></span>
</td>
<td class="num">(359,850)<span></span>
</td>
<td class="nump">155,115<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,749,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,786<span></span>
</td>
<td class="num">(307,823)<span></span>
</td>
<td class="nump">204,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,376)<span></span>
</td>
<td class="num">(26,376)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,919,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">513,510<span></span>
</td>
<td class="num">(334,199)<span></span>
</td>
<td class="nump">$ 179,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,651)<span></span>
</td>
<td class="num">(25,651)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,129,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 514,923<span></span>
</td>
<td class="num">$ (359,850)<span></span>
</td>
<td class="nump">$ 155,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205738224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,651,000)<span></span>
</td>
<td class="num">$ (20,257,000)<span></span>
</td>
<td class="num">$ (76,298,000)<span></span>
</td>
<td class="num">$ (57,112,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,457,000<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">273,000<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
<td class="nump">817,000<span></span>
</td>
<td class="nump">533,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">119,000<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="nump">357,000<span></span>
</td>
<td class="nump">379,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377,000<span></span>
</td>
<td class="nump">2,790,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,815,000<span></span>
</td>
<td class="num">(3,592,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInDevelopmentExpense', window );">Accrued development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,064,000<span></span>
</td>
<td class="nump">1,293,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="num">(1,717,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(298,000)<span></span>
</td>
<td class="num">(212,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,709,000)<span></span>
</td>
<td class="num">(56,194,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(373,000)<span></span>
</td>
<td class="num">(3,047,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(373,000)<span></span>
</td>
<td class="num">(3,047,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,417,000<span></span>
</td>
<td class="nump">466,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,417,000<span></span>
</td>
<td class="nump">466,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,665,000)<span></span>
</td>
<td class="num">(58,775,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,015,000<span></span>
</td>
<td class="nump">233,437,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 142,350,000<span></span>
</td>
<td class="nump">$ 174,662,000<span></span>
</td>
<td class="nump">$ 142,350,000<span></span>
</td>
<td class="nump">$ 174,662,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease right of use assets and liabilities, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207610176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - General and Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">1.</em> General and Liquidity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discover and develop proprietary pharmaceutical product candidates that <em style="font: inherit;"> may </em>offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> All intercompany transactions and balances have been eliminated in consolidation. Accordingly, the condensed consolidated financial statements do <em style="font: inherit;">not</em> include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em> are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>be expected for any other interim period or for the year <em style="font: inherit;">2023.</em> For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form&#160;<em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $359.9&#160;million at <em style="font: inherit;"> September 30, 2023</em>. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company <em style="font: inherit;"> may </em>seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are <em style="font: inherit;">no</em> assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207684192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">2.</em></b>&#160;&#160;<b>Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> September 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business Segments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to one business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>,&#160;there were no reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022</em>, the Company received reimbursements totaling $0.4 million and $0.9&#160;million, respectively, pursuant to NIH research grants. The Company records the proceeds from these grants as reductions to its research and development expenses.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b>&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c104255958">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(25,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(20,257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(76,298</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(57,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shares used in computing net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,050</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,009</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.61</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,946</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,938</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,064</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti<b>-</b>dilutive. The Company also excluded 57,143 restricted stock awards from the calculation of net loss per share, diluted, until their expiration in <em style="font: inherit;"> June 2022 </em>because the effect of including restricted stock awards would have been anti<b>-</b>dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b>&#160; &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research Contract Costs and Accruals </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) <em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">10</em> for further discussion of the Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Leases</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities. As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.6&#160;years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible assets</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately 0.5&#160;years at <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s condensed consolidated financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375209284848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PrepaidExpensesAndOtherCurrentAssetsTextBock', window );">Prepaid Expenses and Other Current Assets [Text Bock]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid expenses and other current assets at <em style="font: inherit;"> September 30, 2023</em> and&#160;<em style="font: inherit;"> December 31, 2022</em> consisted of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,136</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">874</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract research organization and other deposits</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,224</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,177</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest receivable</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,285</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">189</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">160</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total prepaid expenses and other current assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,834</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,211</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PrepaidExpensesAndOtherCurrentAssetsTextBock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PrepaidExpensesAndOtherCurrentAssetsTextBock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207814416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstateOwnedTextBlock', window );">Real Estate Owned [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">4.</em> Real Property</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company owns a <em style="font: inherit;">two</em>-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#160;outsourced to professional real-estate managers. The office complex has&#160;approximately 90,000 square feet of rentable space. At <em style="font: inherit;"> September 30, 2023</em>, the property was over 60% leased. The Company also occupies approximately 25% of the property.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company records the net income from building operations and leases as other income, net, as leasing is <em style="font: inherit;">not</em> core to the Company&#8217;s operations. Building depreciation and amortization for space <em style="font: inherit;">not</em> occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company are&#160;allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">583</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">620</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,699</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(410</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,083</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,032</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">616</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateOwnedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for real estate owned (as defined). Generally, the largest component of real estate owned by lenders is assets taken in settlement of troubled loans through surrender or foreclosure. Real estate investments, real estate loans that qualify as investments in real estate, and premises that are no longer used in operations may also be included in real estate owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateOwnedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207803760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">5.</em> Property and equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of property and equipment, net, as of <em style="font: inherit;"> September 30, 2023</em>&#160;and&#160;<em style="font: inherit;"> December 31, 2022</em> were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,018</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,016</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in progress</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,094</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,064</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,077</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,864</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation expense for property and equipment was&#160;$273,000&#160;and&#160;$181,000&#160;for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>, respectively. Depreciation expense for property and equipment was $817,000 and $533,000 for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207805360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">6.</em> Intangible assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of intangible assets, net, as of&#160;<em style="font: inherit;"> September 30, 2023</em> and&#160;<em style="font: inherit;"> December 31, 2022</em> were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,343</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">622</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for intangible assets was&#160;$119,000 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>. Amortization expense for intangible assets was&#160;$357,000 and $379,000 for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for finite-lived intangible assets as of <em style="font: inherit;"> September 30, 2023</em> is expected to be as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">97</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207682096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity and Share-Based Payments [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">7.</em> Stockholders</b>&#8217;<b> Equity and Stock-Based Compensation Expense</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><em style="font: inherit;">2022</em> Registered Direct Offering</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November&#160;</em><em style="font: inherit;">22,</em> <em style="font: inherit;">2022,</em> the Company completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>At-the-Market Common Stock Offering </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> May 1, 2023, </em>the Company entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on <em style="font: inherit;"> May 1, 2023 </em>and became effective immediately upon filing. The Company is obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock in the offering. The Company is <em style="font: inherit;">not</em> obligated to sell any shares in the offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were no common stock sales under the ATM during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> March 2020, </em>the Company entered into an at-the-market offering program (<em style="font: inherit;">&#8220;2020</em> Program&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on <em style="font: inherit;"> May 5, 2020. </em>The Company gave notice of termination for the <em style="font: inherit;">2020</em> Program on <em style="font: inherit;"> April 26, 2023, </em>which was effective <em style="font: inherit;"> May 1, 2023. </em>There were no common stock sales under the <em style="font: inherit;">2020</em> Program through its termination.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock Option and Performance Award Activity in <em style="font: inherit;">2023</em></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>, stock options and unvested Performance Awards outstanding under the Company&#8217;s stock option plans changed as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Stock Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,529,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">132,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(495,299</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of September 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,159,007</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The weighted average exercise price per share of options outstanding at <em style="font: inherit;"> September 30, 2023</em> was $13.71. As outstanding options vest over the current remaining vesting period of 2.3&#160;years, the Company expects to recognize stock-based compensation expense of $8.0&#160;million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $0.1 million over the implicit service period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em>, there were 214,124 stock options exercised. Of the stock options exercised, 3,853&#160;stock options were net settled in satisfaction of the exercise price, with no cash proceeds received. Cash proceeds to the Company for options <em style="font: inherit;">not</em> net settled totaled $464,000 during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>, there were 495,299&#160;stock options exercised. Of the stock options exercised, 101,058 stock options were net settled in satisfaction of the exercise price, with no cash proceeds received. Cash proceeds to the Company for options <em style="font: inherit;">not</em> net settled totaled $1,417,000 during the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Subsequent to <em style="font: inherit;"> September 30, 2023, </em>there were 800,000 stock options granted to officers and employees at an exercise price of $17.54 per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock-based Compensation Expense in <em style="font: inherit;">2023</em></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em>, the Company&#8217;s stock-based compensation expense was as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">399</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,186</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,234</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">469</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,457</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2018</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or a designated committee of the Board is responsible for administration of the Company&#8217;s <em style="font: inherit;">2018</em> Omnibus Incentive Plan, as amended (the <em style="font: inherit;">&#8220;2018</em> Plan&#8221;) and determines the terms and conditions of each option granted, consistent with the terms of the <em style="font: inherit;">2018</em> Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the <em style="font: inherit;">2018</em> Plan, including grants of stock options and Performance Awards. Share-based awards generally expire 10 years from the date of grant. The <em style="font: inherit;">2018</em> Plan, as amended on <em style="font: inherit;"> May 5, 2022, </em>provides for issuance of up to 5,000,000 shares of common stock, par value $0.001 per share, subject to adjustment as provided in the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#160;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207627968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">8.</em> Income Taxes</b><b><i> </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company did <span style="-sec-ix-hidden:c104256210"><span style="-sec-ix-hidden:c104256211">not</span></span> provide for income taxes during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>, because it has projected a net loss for the full year <em style="font: inherit;">2023</em> for which any benefit will be offset by an increase in the valuation allowance. There was also no provision for income taxes for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375197842720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">9.</em> Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Right-of-use Asset and Liability</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company had an operating lease for approximately 6,000 square feet of office space in Austin, Texas with an expiration of <em style="font: inherit;"> April 30, 2024. </em>The Company and the landlord consented to early terminate this lease on <em style="font: inherit;"> February 22, 2023 </em>with <em style="font: inherit;">no</em> continuing obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There was no rent expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em>. Rent expense for the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> September 30, 2022</em> totaled $41,000.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Rent expense for the&#160;<em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> totaled $24,000 and $123,000, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There was no cash paid for operating lease liabilities during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em>. Cash paid for operating lease liabilities during the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> September 30, 2022</em> totaled $41,000.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cash paid for operating lease liabilities during the&#160;<em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> totaled $24,000 and $124,000, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375204694624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - 2020 Cash Incentive Bonus Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanTextBlock', window );">Cash Incentive Bonus Plan [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note</b>&#160;<b><em style="font: inherit;">10.</em></b>&#160;<b> <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2020, </em>the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;<em style="font: inherit;">not</em> receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;<em style="font: inherit;">not</em>&#160;be paid&#160;any cash bonuses unless (<em style="font: inherit;">1</em>) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a "Merger Transaction") or (<em style="font: inherit;">2</em>) the Compensation Committee of the Board&#160;(the "Compensation Committee") determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has <em style="font: inherit;">not</em> occurred&#160;as of <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company&#8217;s independent directors were participants in the Plan. However, effective <em style="font: inherit;"> March 16, 2023, </em>the Board&#160;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the Plan were completely forfeited to the Company and will <em style="font: inherit;">not</em> be allocated to any other participant under the Plan. The Company&#8217;s independent directors have <em style="font: inherit;">not</em> received, and as a result of such amendment will never receive, any payments under the Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (<em style="font: inherit;">1</em>) the closing price&#160;of <em style="font: inherit;">one</em> share&#160;of the Company&#8217;s common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (<em style="font: inherit;">2</em>) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;This constitutes a market condition under applicable accounting guidance.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;<em style="font: inherit;">$5</em>&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$200&#160;million and&#160;$5&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for <em style="font: inherit;">no</em> less than 20 consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately 67% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;<em style="font: inherit;">not</em> awarded by the Compensation Committee&#160;are&#160;<em style="font: inherit;">no</em> longer available for distribution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If the Company were to exceed a $5&#160;billion market capitalization&#160;for <em style="font: inherit;">no</em> less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(<em style="font: inherit;">1</em>)&#160;the Company completes a Merger Transaction, or&#160;(<em style="font: inherit;">2</em>)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which <em style="font: inherit;"> may </em>ever occur. Accordingly, there can be <em style="font: inherit;">no</em> assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> October 2020, </em>the Company&#160;achieved&#160;the <em style="font: inherit;">first</em>&#160;Valuation&#160;Milestone.&#160;Subsequently, the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$6.5&#160;million&#160;in total&#160;for&#160;all Plan participants (after the <em style="font: inherit;"> March 2023 </em>Plan amendment), subject to future satisfaction of a Performance Condition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million (after the <em style="font: inherit;"> March 2023 </em>Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense was recorded&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.&#160;There is <em style="font: inherit;">no</em> continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> Valuation Milestones were achieved during <em style="font: inherit;">2022</em> or the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No actual cash payments were authorized or made to participants under the Plan through the date of filing of this Form <em style="font: inherit;">10</em>-Q.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the cash incentive bonus plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375208437040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em> Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">From time to time, the Company <em style="font: inherit;"> may </em>become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA, and <em style="font: inherit;"> may </em>receive inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company. <em style="font: inherit;">No</em> information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, <em style="font: inherit;">no</em> accrual for these matters has been recorded within the condensed consolidated financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Government Investigations</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 15, 2021, </em>the Company disclosed that certain government agencies had asked the Company to provide corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and intends to continue to cooperate with these inquiries. <em style="font: inherit;">No</em> government agency has informed the Company that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors. <em style="font: inherit;">No</em> government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em>four putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the four class action lawsuits into one case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs&#8217; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#8217; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023. </em>The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since <em style="font: inherit;"> November 4, 2021, </em>four additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, one in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the three federal court actions were consolidated into a single action.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan in <em style="font: inherit;"> August 2020. </em>The complaints seek unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023. </em>Defendants&#8217; motion to dismiss remains pending. Although the plaintiffs in this derivative case do <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-20/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-30/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375208066080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arr Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a href="#" id="other" title="other"></a>Item <em style="font: inherit;">5.</em> </b><b><i>Other Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the quarter ended <em style="font: inherit;"> September 30, 2023</em>, none of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) of the Exchange Act) informed us of the adoption or termination of a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement,&#8221; as those terms are defined in Regulation S-K, Item <em style="font: inherit;">408.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375208242832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> September 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business Segments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to one business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Assistance [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>,&#160;there were no reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022</em>, the Company received reimbursements totaling $0.4 million and $0.9&#160;million, respectively, pursuant to NIH research grants. The Company records the proceeds from these grants as reductions to its research and development expenses.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b>&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c104255958">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(25,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(20,257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(76,298</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(57,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shares used in computing net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,050</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,009</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.61</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,946</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,938</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,064</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti<b>-</b>dilutive. The Company also excluded 57,143 restricted stock awards from the calculation of net loss per share, diluted, until their expiration in <em style="font: inherit;"> June 2022 </em>because the effect of including restricted stock awards would have been anti<b>-</b>dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b>&#160; &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research Contract Costs and Accruals </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Compensation Related Costs, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) <em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">10</em> for further discussion of the Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Leases</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities. As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.6&#160;years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible assets</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately 0.5&#160;years at <em style="font: inherit;"> September 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s condensed consolidated financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375210056752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(25,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(20,257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(76,298</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(57,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shares used in computing net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,050</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,009</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.61</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,946</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,938</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,064</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207912304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,136</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">874</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract research organization and other deposits</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,224</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,177</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest receivable</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,285</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">189</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">160</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total prepaid expenses and other current assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,834</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,211</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375208437040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">583</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">620</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,699</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(410</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,083</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,032</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">616</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207674560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,018</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,016</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in progress</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,094</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,064</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,077</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,864</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375209284976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,343</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">622</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">97</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207688832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Stock Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,529,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">132,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(495,299</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of September 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,159,007</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine months ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">September 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">399</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,186</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,234</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">469</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,457</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375207808144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - General and Liquidity (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (359,850)<span></span>
</td>
<td class="num">$ (283,552)<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205063808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government Assistance, Amount | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term (Year)</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Leases, Acquired-in-Place [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life (Year)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375204807312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,651)<span></span>
</td>
<td class="num">$ (26,376)<span></span>
</td>
<td class="num">$ (24,271)<span></span>
</td>
<td class="num">$ (20,257)<span></span>
</td>
<td class="num">$ (19,328)<span></span>
</td>
<td class="num">$ (17,527)<span></span>
</td>
<td class="num">$ (76,298)<span></span>
</td>
<td class="num">$ (57,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">42,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,845<span></span>
</td>
<td class="nump">40,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.82)<span></span>
</td>
<td class="num">$ (1.43)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common stock options excluded from net loss per share, diluted (in shares)</a></td>
<td class="nump">1,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205096704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsAssets', window );">Contract research organization and other deposits</a></td>
<td class="nump">5,224<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 7,834<span></span>
</td>
<td class="nump">$ 10,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483081/340-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483054/340-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375406512320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Real Property (Details Textual) - Office Building [Member] - TEXAS<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area (Square Foot)</a></td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfCurrentlyLeased', window );">Percentage of Currently Leased</a></td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfOccupancy', window );">Percentage of Occupancy</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfCurrentlyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of currently leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfCurrentlyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfOccupancy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfOccupancy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375202825440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property - Components of Other Income, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Lease revenue</a></td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">$ 1,699<span></span>
</td>
<td class="nump">$ 1,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Property operating expenses</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(410)<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
<td class="num">(1,032)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375202876016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="nump">$ 817,000<span></span>
</td>
<td class="nump">$ 533,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205769824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Property and Equipment - Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 24,094<span></span>
</td>
<td class="nump">$ 24,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(2,017)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,077<span></span>
</td>
<td class="nump">22,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,734<span></span>
</td>
<td class="nump">3,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">15,980<span></span>
</td>
<td class="nump">15,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,018<span></span>
</td>
<td class="nump">3,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205093760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 357,000<span></span>
</td>
<td class="nump">$ 379,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205053024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 1,346<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,078)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Leases, Acquired-in-Place [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember', window );">Leasing Commissions and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375204796816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375201663104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2023</div></th>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 26, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.71<span></span>
</td>
<td class="nump">$ 13.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,124<span></span>
</td>
<td class="nump">495,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="nump">$ 1,417,000<span></span>
</td>
<td class="nump">$ 466,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember', window );">The 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 17.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember', window );">Stock Options Net Settled in Satisfaction of the Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,853<span></span>
</td>
<td class="nump">101,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember', window );">The 2022 Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember', window );">At-the-market Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EquityOfferingPercentageOfCommission', window );">Equity Offering, Percentage of Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EquityOfferingMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount to be issued in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EquityOfferingMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EquityOfferingPercentageOfCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission in equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EquityOfferingPercentageOfCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375200870128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,529,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(214,124)<span></span>
</td>
<td class="num">(495,299)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="nump">2,159,007<span></span>
</td>
<td class="nump">2,159,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, performance awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Performance awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Performance awards exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Performance awards forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, performance awards (in shares)</a></td>
<td class="nump">7,142<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375205081680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">$ 2,457<span></span>
</td>
<td class="nump">$ 1,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375204673520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375208111360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 123,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=sava_OfficeSpaceMember', window );">Office Space [Member] | Austin, Texas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sava_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sava_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375202695120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual) - Cash Incentive Bonus Plan [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashBonusIncentiveIncrementalAmounts', window );">Cash Bonus Incentive, Incremental Amounts</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained', window );">Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment', window );">Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash Incentive Bonus Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-Based Payment Arrangement, Expense, after Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PaymentsForCashIncentiveBonus', window );">Payments for Cash Incentive Bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationMilestoneAmount', window );">Performance Plan, Valuation Milestone Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAwardExceedsMaximum', window );">Cash Incentive Bonus Award, Exceeds Maximum</a></td>
<td class="nump">111,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationMilestoneAmount', window );">Performance Plan, Valuation Milestone Amount</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAwardExceedsMaximum', window );">Cash Incentive Bonus Award, Exceeds Maximum</a></td>
<td class="nump">$ 289,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashBonusIncentiveIncrementalAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of incremental amounts for cash bonus incentive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashBonusIncentiveIncrementalAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash incentive bonus award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAwardExceedsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash incentive bonus award if the maximum milestone is exceeded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAwardExceedsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsForCashIncentiveBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments for cash incentive bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsForCashIncentiveBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>the percentage of valuation milestone cash bonus award subject to approval and adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum number of days valuation milestone must be achieved and maintained in performance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanValuationMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation milestone for performance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanValuationMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140375200813120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 05, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Oct. 26, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember', window );">Violations of Federal Securities Laws [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember', window );">Shareholder Derivative Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember', window );">Shareholder Derivative Actions, Texas Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember', window );">Shareholder Derivative Actions, Texas State Court Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember', window );">Shareholder Derivative Actions, Delaware Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>sava20230930_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sava="http://www.cassavasciences.com/20230930"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sava-20230930.xsd" xlink:type="simple"/>
    <context id="d_2023-01-01_2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i_2023-11-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="i_2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="d_2020-04-01_2023-04-26_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i_2023-09-30_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sava:StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sava:StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2023-10-01_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i_2023-09-30_LeaseContractualTermAxis-OfficeSpaceMember_StatementGeographicalAxis-AustinTexasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinTexasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-16</startDate>
            <endDate>2023-03-16</endDate>
        </period>
    </context>
    <context id="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-09-30_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2023-11-07_PlanNameAxis-CashIncentiveBonusPlanMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-28</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasStateCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsDelawareCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-05</startDate>
            <endDate>2022-07-05</endDate>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2023-01-01_2023-09-30"
      id="thunderdome-EntityCentralIndexKey">0001069530</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2023-01-01_2023-09-30"
      id="thunderdome-EntityRegistrantName">CASSAVA SCIENCES INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2023-01-01_2023-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2023-01-01_2023-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2023-01-01_2023-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2023-01-01_2023-09-30">2023</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-09-30"
      id="c104255596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2022-12-31"
      id="c104255597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c104255601"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c104255602"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c104255603"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c104255604"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255605"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255607"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255606"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255608"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c104255611"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c104255612"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c104255613"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c104255614"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c104255615"
      unitRef="Share">42129798</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c104255617"
      unitRef="Share">42129798</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c104255616"
      unitRef="Share">41735557</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c104255618"
      unitRef="Share">41735557</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255953"
      unitRef="USD">0</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c104255958">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c104256090"
      unitRef="USD">119000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-09-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-3"
      id="c104256128"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104256210"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104256211"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104256216"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2023-07-01_2023-09-30" id="c104256307">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2023-07-01_2023-09-30" id="c104256308">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2023-07-01_2023-09-30" id="c104256309">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType contextRef="d_2023-01-01_2023-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2023-01-01_2023-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2023-01-01_2023-09-30">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2023-01-01_2023-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2023-01-01_2023-09-30">000-29959</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2023-01-01_2023-09-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2023-01-01_2023-09-30">91-1911336</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2023-01-01_2023-09-30">6801 N. Capital of Texas Highway, Building 1; Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2023-01-01_2023-09-30">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2023-01-01_2023-09-30">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2023-01-01_2023-09-30">78731</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2023-01-01_2023-09-30">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2023-01-01_2023-09-30">501-2444</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2023-01-01_2023-09-30">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2023-01-01_2023-09-30">SAVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2023-01-01_2023-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2023-01-01_2023-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2023-01-01_2023-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2023-01-01_2023-09-30">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2023-01-01_2023-09-30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2023-01-01_2023-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2023-01-01_2023-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2023-11-02" decimals="INF" unitRef="Share">42174062</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-09-30"
      decimals="-4"
      id="c104255560"
      unitRef="USD">142350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255561"
      unitRef="USD">201015000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255562"
      unitRef="USD">7834000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255563"
      unitRef="USD">10211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255564"
      unitRef="USD">150184000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255565"
      unitRef="USD">211226000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255566"
      unitRef="USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255567"
      unitRef="USD">122000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255568"
      unitRef="USD">22077000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255569"
      unitRef="USD">22864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255570"
      unitRef="USD">268000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255571"
      unitRef="USD">622000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255572"
      unitRef="USD">172529000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255573"
      unitRef="USD">234834000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255577"
      unitRef="USD">9492000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255578"
      unitRef="USD">4017000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <sava:AccruedDevelopmentExpenseCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255579"
      unitRef="USD">7344000</sava:AccruedDevelopmentExpenseCurrent>
    <sava:AccruedDevelopmentExpenseCurrent
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c104255580"
      unitRef="USD">2280000</sava:AccruedDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255581"
      unitRef="USD">187000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c104255582"
      unitRef="USD">170000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255583"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255584"
      unitRef="USD">104000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255585"
      unitRef="USD">391000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255586"
      unitRef="USD">492000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255587"
      unitRef="USD">17414000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255588"
      unitRef="USD">7063000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255589"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255590"
      unitRef="USD">35000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255591"
      unitRef="USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255592"
      unitRef="USD">197000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255593"
      unitRef="USD">17414000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255594"
      unitRef="USD">7295000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255599"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255600"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255609"
      unitRef="USD">42000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255610"
      unitRef="USD">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255619"
      unitRef="USD">514923000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255620"
      unitRef="USD">511049000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-09-30"
      decimals="-4"
      id="c104255621"
      unitRef="USD">-359850000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255622"
      unitRef="USD">-283552000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255623"
      unitRef="USD">155115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255624"
      unitRef="USD">227539000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255625"
      unitRef="USD">172529000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255626"
      unitRef="USD">234834000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255640"
      unitRef="USD">23603000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255641"
      unitRef="USD">18526000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255642"
      unitRef="USD">70692000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-4"
      id="c104255643"
      unitRef="USD">50380000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255644"
      unitRef="USD">4276000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255645"
      unitRef="USD">2819000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255646"
      unitRef="USD">12476000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255647"
      unitRef="USD">8703000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255648"
      unitRef="USD">27879000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255649"
      unitRef="USD">21345000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255650"
      unitRef="USD">83168000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255651"
      unitRef="USD">59083000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255652"
      unitRef="USD">-27879000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255653"
      unitRef="USD">-21345000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255654"
      unitRef="USD">-83168000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255655"
      unitRef="USD">-59083000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255656"
      unitRef="USD">2005000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255657"
      unitRef="USD">878000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255658"
      unitRef="USD">6254000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255659"
      unitRef="USD">1223000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255660"
      unitRef="USD">223000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-4"
      id="c104255661"
      unitRef="USD">210000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255662"
      unitRef="USD">616000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255663"
      unitRef="USD">748000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255664"
      unitRef="USD">-25651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255665"
      unitRef="USD">-20257000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255666"
      unitRef="USD">-76298000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255667"
      unitRef="USD">-57112000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-07-01_2023-09-30"
      decimals="INF"
      id="c104255668"
      unitRef="USDPerShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c104255669"
      unitRef="USDPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104255670"
      unitRef="USDPerShare">-1.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c104255671"
      unitRef="USDPerShare">-1.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255672"
      unitRef="Share">42002000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-4"
      id="c104255673"
      unitRef="Share">40050000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255674"
      unitRef="Share">41845000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255675"
      unitRef="Share">40009000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255691"
      unitRef="Share">40016792</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c104255692"
      unitRef="USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255693"
      unitRef="USD">461181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255694"
      unitRef="USD">-207306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c104255695"
      unitRef="USD">253915000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255698"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255699"
      unitRef="USD">471000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255700"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c104255701"
      unitRef="USD">471000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255703"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255704"
      unitRef="USD">24000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255705"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c104255706"
      unitRef="USD">24000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255707"
      unitRef="Share">14488</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255708"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255709"
      unitRef="USD">211000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255710"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c104255711"
      unitRef="USD">211000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255713"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255714"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255715"
      unitRef="USD">-17527000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c104255716"
      unitRef="USD">-17527000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255717"
      unitRef="Share">40031280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c104255718"
      unitRef="USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255719"
      unitRef="USD">461887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255720"
      unitRef="USD">-224833000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c104255721"
      unitRef="USD">237094000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255724"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255725"
      unitRef="USD">462000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255726"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c104255727"
      unitRef="USD">462000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255729"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255730"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255731"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c104255732"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255733"
      unitRef="Share">66637</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255734"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255735"
      unitRef="USD">119000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255736"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c104255737"
      unitRef="USD">119000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255739"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255740"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255741"
      unitRef="USD">-19328000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c104255742"
      unitRef="USD">-19328000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255743"
      unitRef="Share">40097917</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c104255744"
      unitRef="USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255745"
      unitRef="USD">462491000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255746"
      unitRef="USD">-244161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30"
      decimals="-4"
      id="c104255747"
      unitRef="USD">218370000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255750"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255751"
      unitRef="USD">447000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255752"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c104255753"
      unitRef="USD">447000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255755"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255756"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255757"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-07-01_2022-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c104255758"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255759"
      unitRef="Share">57143</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255760"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255761"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255762"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255763"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255764"
      unitRef="Share">18740</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255765"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255766"
      unitRef="USD">136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255767"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255768"
      unitRef="USD">136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255770"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255771"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255772"
      unitRef="USD">-20257000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255773"
      unitRef="USD">-20257000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255774"
      unitRef="Share">40059514</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c104255775"
      unitRef="USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255776"
      unitRef="USD">463097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255777"
      unitRef="USD">-264418000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30"
      decimals="-3"
      id="c104255778"
      unitRef="USD">198719000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255779"
      unitRef="Share">41735557</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255780"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255781"
      unitRef="USD">511049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255782"
      unitRef="USD">-283552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255783"
      unitRef="USD">227539000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255786"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c104255787"
      unitRef="USD">650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255788"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-4"
      id="c104255789"
      unitRef="USD">650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255791"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255792"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255793"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c104255794"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255795"
      unitRef="Share">13878</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255796"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255797"
      unitRef="USD">64000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255798"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c104255799"
      unitRef="USD">64000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255801"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255802"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255803"
      unitRef="USD">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c104255804"
      unitRef="USD">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255805"
      unitRef="Share">41749435</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255806"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255807"
      unitRef="USD">511786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255808"
      unitRef="USD">-307823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31"
      decimals="-3"
      id="c104255809"
      unitRef="USD">204005000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255812"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255813"
      unitRef="USD">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255814"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c104255815"
      unitRef="USD">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255817"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255818"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255819"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c104255820"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255821"
      unitRef="Share">170092</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255822"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255823"
      unitRef="USD">889000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255824"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c104255825"
      unitRef="USD">889000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255827"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255828"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255829"
      unitRef="USD">-26376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c104255830"
      unitRef="USD">-26376000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255831"
      unitRef="Share">41919527</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255832"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c104255833"
      unitRef="USD">513510000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255834"
      unitRef="USD">-334199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c104255835"
      unitRef="USD">179353000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255838"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255839"
      unitRef="USD">926000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255840"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c104255841"
      unitRef="USD">926000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255843"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255844"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255845"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-07-01_2023-09-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c104255846"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255847"
      unitRef="Share">210271</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255848"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255849"
      unitRef="USD">464000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255850"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255851"
      unitRef="USD">464000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255853"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255854"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c104255855"
      unitRef="USD">-25651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255856"
      unitRef="USD">-25651000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c104255857"
      unitRef="Share">42129798</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c104255858"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c104255859"
      unitRef="USD">514923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-4"
      id="c104255860"
      unitRef="USD">-359850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104255861"
      unitRef="USD">155115000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255867"
      unitRef="USD">-76298000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255868"
      unitRef="USD">-57112000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255870"
      unitRef="USD">2457000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-4"
      id="c104255871"
      unitRef="USD">1450000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255872"
      unitRef="USD">817000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255873"
      unitRef="USD">533000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255874"
      unitRef="USD">357000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255875"
      unitRef="USD">379000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255877"
      unitRef="USD">-2377000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-4"
      id="c104255878"
      unitRef="USD">-2790000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255879"
      unitRef="USD">17000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255880"
      unitRef="USD">6000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255881"
      unitRef="USD">5815000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255882"
      unitRef="USD">-3592000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255883"
      unitRef="USD">5064000</sava:IncreaseDecreaseInDevelopmentExpense>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255884"
      unitRef="USD">1293000</sava:IncreaseDecreaseInDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255885"
      unitRef="USD">17000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255886"
      unitRef="USD">-1717000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255887"
      unitRef="USD">-298000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255888"
      unitRef="USD">-212000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255889"
      unitRef="USD">-59709000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255890"
      unitRef="USD">-56194000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255892"
      unitRef="USD">373000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255893"
      unitRef="USD">3047000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255894"
      unitRef="USD">-373000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255895"
      unitRef="USD">-3047000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255897"
      unitRef="USD">1417000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255898"
      unitRef="USD">466000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255899"
      unitRef="USD">1417000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255900"
      unitRef="USD">466000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255901"
      unitRef="USD">-58665000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255902"
      unitRef="USD">-58775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104255903"
      unitRef="USD">201015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c104255904"
      unitRef="USD">233437000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-09-30"
      decimals="-4"
      id="c104255905"
      unitRef="USD">142350000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-09-30"
      decimals="-3"
      id="c104255906"
      unitRef="USD">174662000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493870">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1.&lt;/em&gt; General and Liquidity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#x201c;Company&#x201d;) discover and develop proprietary pharmaceutical product candidates that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and Article &lt;em style="font: inherit;"&gt;10&lt;/em&gt; of Regulation S-&lt;em style="font: inherit;"&gt;X.&lt;/em&gt; All intercompany transactions and balances have been eliminated in consolidation. Accordingly, the condensed consolidated financial statements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt; are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be expected for any other interim period or for the year &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#x2019;s Annual Report on Form&#160;&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $359.9&#160;million at &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#x2019;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-09-30"
      decimals="-5"
      id="c104255917"
      unitRef="USD">-359900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493871">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&lt;b&gt;Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates and assumptions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; includes quoted prices in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; includes unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs at &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Business Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Proceeds from Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;,&#160;there were no reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2022&lt;/em&gt;, the Company received reimbursements totaling $0.4 million and $0.9&#160;million, respectively, pursuant to NIH research grants. The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;span style="-sec-ix-hidden:c104255958"&gt;four&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(25,651&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(20,257&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(76,298&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(57,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,002&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,050&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,845&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,009&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.61&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.51&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.43&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,780&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,946&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,938&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,064&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti&lt;b&gt;-&lt;/b&gt;dilutive. The Company also excluded 57,143 restricted stock awards from the calculation of net loss per share, diluted, until their expiration in &lt;em style="font: inherit;"&gt; June 2022 &lt;/em&gt;because the effect of including restricted stock awards would have been anti&lt;b&gt;-&lt;/b&gt;dilutive.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&#160; &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research Contract Costs and Accruals &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has entered into various research and development contracts with research institutions and other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been materially different from actual costs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Incentive Bonus Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company established the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) &lt;em style="font: inherit;"&gt;718&lt;/em&gt; &#x201c;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&#x201d;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; for further discussion of the Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize right-of-use assets or lease liabilities. As the Company`s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.6&#160;years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately 0.5&#160;years at &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s condensed consolidated financial statements only if that position is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2023-01-01_2023-09-30" id="c104257155">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates and assumptions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257156">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257157">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; includes quoted prices in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; includes unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs at &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257158">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Business Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104255949"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257159">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Proceeds from Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;,&#160;there were no reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2022&lt;/em&gt;, the Company received reimbursements totaling $0.4 million and $0.9&#160;million, respectively, pursuant to NIH research grants. The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255952"
      unitRef="USD">0</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-5"
      id="c104255956"
      unitRef="USD">400000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-5"
      id="c104255957"
      unitRef="USD">900000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2023-01-01_2023-09-30" id="c104257160">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;span style="-sec-ix-hidden:c104255958"&gt;four&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257161">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(25,651&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(20,257&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(76,298&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(57,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,002&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,050&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,845&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,009&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.61&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.51&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.43&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,780&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,946&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,938&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,064&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti&lt;b&gt;-&lt;/b&gt;dilutive. The Company also excluded 57,143 restricted stock awards from the calculation of net loss per share, diluted, until their expiration in &lt;em style="font: inherit;"&gt; June 2022 &lt;/em&gt;because the effect of including restricted stock awards would have been anti&lt;b&gt;-&lt;/b&gt;dilutive.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493872">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(25,651&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(20,257&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(76,298&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(57,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,002&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,050&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,845&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,009&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.61&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.51&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.43&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,780&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,946&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,938&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,064&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255993"
      unitRef="USD">-25651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104255994"
      unitRef="USD">-20257000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104255995"
      unitRef="USD">-76298000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104255996"
      unitRef="USD">-57112000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104255998"
      unitRef="Share">42002000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-4"
      id="c104255999"
      unitRef="Share">40050000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104256000"
      unitRef="Share">41845000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104256001"
      unitRef="Share">40009000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-07-01_2023-09-30"
      decimals="INF"
      id="c104256002"
      unitRef="USDPerShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c104256003"
      unitRef="USDPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256004"
      unitRef="USDPerShare">-1.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c104256005"
      unitRef="USDPerShare">-1.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-07-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-4"
      id="c104256006"
      unitRef="Share">1780000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-07-01_2022-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c104256007"
      unitRef="Share">1946000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c104256008"
      unitRef="Share">1938000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c104256009"
      unitRef="Share">2064000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c104255961"
      unitRef="Share">57143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2023-01-01_2023-09-30" id="c104257162">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&#160; &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2023-01-01_2023-09-30" id="c104257163">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research Contract Costs and Accruals &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has entered into various research and development contracts with research institutions and other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been materially different from actual costs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257164">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Incentive Bonus Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company established the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) &lt;em style="font: inherit;"&gt;718&lt;/em&gt; &#x201c;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&#x201d;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; for further discussion of the Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257165">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize right-of-use assets or lease liabilities. As the Company`s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257166">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.6&#160;years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      id="c104255972">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      id="c104255973">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2023-09-30" id="c104255974">P0Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2023-01-01_2023-09-30" id="c104257167">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately 0.5&#160;years at &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      id="c104255976">P0Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2023-01-01_2023-09-30" id="c104257168">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s condensed consolidated financial statements only if that position is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <sava:PrepaidExpensesAndOtherCurrentAssetsTextBock contextRef="d_2023-01-01_2023-09-30" id="c2493873">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3.&lt;/em&gt; Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Prepaid expenses and other current assets at &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; consisted of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,136&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;874&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Contract research organization and other deposits&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,224&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,177&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest receivable&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,285&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;189&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;160&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,834&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,211&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </sava:PrepaidExpensesAndOtherCurrentAssetsTextBock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493874">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,136&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;874&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Contract research organization and other deposits&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,224&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,177&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest receivable&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,285&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;189&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;160&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,834&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,211&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256015"
      unitRef="USD">1136000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104256016"
      unitRef="USD">874000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositContractsAssets
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256017"
      unitRef="USD">5224000</us-gaap:DepositContractsAssets>
    <us-gaap:DepositContractsAssets
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104256018"
      unitRef="USD">9177000</us-gaap:DepositContractsAssets>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256019"
      unitRef="USD">1285000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104256020"
      unitRef="USD">0</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256021"
      unitRef="USD">189000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c104256022"
      unitRef="USD">160000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256023"
      unitRef="USD">7834000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104256024"
      unitRef="USD">10211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RealEstateOwnedTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493875">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4.&lt;/em&gt; Real Property&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company owns a &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#x2019;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#160;outsourced to professional real-estate managers. The office complex has&#160;approximately 90,000 square feet of rentable space. At &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;, the property was over 60% leased. The Company also occupies approximately 25% of the property.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company records the net income from building operations and leases as other income, net, as leasing is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; core to the Company&#x2019;s operations. Building depreciation and amortization for space &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company are&#160;allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;583&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;620&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,699&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,780&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(360&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(410&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,083&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,032&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other income, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;210&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;616&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;748&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:RealEstateOwnedTextBlock>
    <us-gaap:NetRentableArea
      contextRef="i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="INF"
      id="c104256027"
      unitRef="SquareFoot">90000</us-gaap:NetRentableArea>
    <sava:PercentageOfCurrentlyLeased
      contextRef="i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="1"
      id="c104256028"
      unitRef="Pure">0.60</sava:PercentageOfCurrentlyLeased>
    <sava:PercentageOfOccupancy
      contextRef="i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="2"
      id="c104256029"
      unitRef="Pure">0.25</sava:PercentageOfOccupancy>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493876">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;583&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;620&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,699&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,780&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(360&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(410&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,083&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,032&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other income, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;210&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;616&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;748&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104256045"
      unitRef="USD">583000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-4"
      id="c104256046"
      unitRef="USD">620000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104256047"
      unitRef="USD">1699000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-4"
      id="c104256048"
      unitRef="USD">1780000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-4"
      id="c104256049"
      unitRef="USD">360000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-4"
      id="c104256050"
      unitRef="USD">410000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104256051"
      unitRef="USD">1083000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104256052"
      unitRef="USD">1032000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104256053"
      unitRef="USD">223000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-4"
      id="c104256054"
      unitRef="USD">210000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104256055"
      unitRef="USD">616000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-3"
      id="c104256056"
      unitRef="USD">748000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493877">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5.&lt;/em&gt; Property and equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The components of property and equipment, net, as of &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Land&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Buildings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Site improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;470&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tenant improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,018&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,016&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;868&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;851&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Construction in progress&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gross property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,094&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,064&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,017&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,200&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,077&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,864&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Depreciation expense for property and equipment was&#160;$273,000&#160;and&#160;$181,000&#160;for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;, respectively. Depreciation expense for property and equipment was $817,000 and $533,000 for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493878">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Land&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Buildings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Site improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;470&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tenant improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,018&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,016&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;868&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;851&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Construction in progress&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gross property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,094&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,064&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,017&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,200&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,077&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,864&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-LandMember"
      decimals="-3"
      id="c104256070"
      unitRef="USD">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"
      decimals="-3"
      id="c104256071"
      unitRef="USD">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      decimals="-4"
      id="c104256072"
      unitRef="USD">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      decimals="-4"
      id="c104256073"
      unitRef="USD">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      decimals="-3"
      id="c104256074"
      unitRef="USD">494000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      decimals="-4"
      id="c104256075"
      unitRef="USD">470000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c104256076"
      unitRef="USD">3018000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c104256077"
      unitRef="USD">3016000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c104256078"
      unitRef="USD">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c104256079"
      unitRef="USD">851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"
      decimals="-3"
      id="c104256080"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"
      decimals="-3"
      id="c104256081"
      unitRef="USD">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256082"
      unitRef="USD">24094000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104256083"
      unitRef="USD">24064000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256084"
      unitRef="USD">2017000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c104256085"
      unitRef="USD">1200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256086"
      unitRef="USD">22077000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c104256087"
      unitRef="USD">22864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2023-07-01_2023-09-30"
      decimals="INF"
      id="c104256058"
      unitRef="USD">273000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c104256059"
      unitRef="USD">181000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256062"
      unitRef="USD">817000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c104256063"
      unitRef="USD">533000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493879">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6.&lt;/em&gt; Intangible assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The components of intangible assets, net, as of&#160;&lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease-in-place agreements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasing commissions and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;293&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gross intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,346&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,343&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,078&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(721&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Intangible assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;268&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;622&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Amortization expense for intangible assets was&#160;$119,000 for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;. Amortization expense for intangible assets was&#160;$357,000 and $379,000 for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Amortization expense for finite-lived intangible assets as of &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt; is expected to be as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;For the year ending December 31,&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;97&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;167&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;268&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493880">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease-in-place agreements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasing commissions and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;293&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gross intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,346&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,343&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,078&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(721&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Intangible assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;268&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;622&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="c104256101"
      unitRef="USD">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2022-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="c104256102"
      unitRef="USD">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="c104256103"
      unitRef="USD">293000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2022-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"
      decimals="-4"
      id="c104256104"
      unitRef="USD">290000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256105"
      unitRef="USD">1346000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2022-09-30"
      decimals="-3"
      id="c104256106"
      unitRef="USD">1343000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256107"
      unitRef="USD">1078000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2022-09-30"
      decimals="-3"
      id="c104256108"
      unitRef="USD">721000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256109"
      unitRef="USD">268000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2022-09-30"
      decimals="-3"
      id="c104256110"
      unitRef="USD">622000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-07-01_2023-09-30"
      decimals="INF"
      id="c104256089"
      unitRef="USD">119000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256093"
      unitRef="USD">357000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c104256094"
      unitRef="USD">379000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493881">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;For the year ending December 31,&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;97&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;167&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;268&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256112"
      unitRef="USD">97000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256113"
      unitRef="USD">167000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256114"
      unitRef="USD">4000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c104256115"
      unitRef="USD">268000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493882">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7.&lt;/em&gt; Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity and Stock-Based Compensation Expense&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Registered Direct Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;22,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;At-the-Market Common Stock Offering &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; May 1, 2023, &lt;/em&gt;the Company entered into an&#160;at-the-market offering program (&#x201c;ATM&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on &lt;em style="font: inherit;"&gt; May 1, 2023 &lt;/em&gt;and became effective immediately upon filing. The Company is obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock in the offering. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to sell any shares in the offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;There were no common stock sales under the ATM during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; March 2020, &lt;/em&gt;the Company entered into an at-the-market offering program (&lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Program&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on &lt;em style="font: inherit;"&gt; May 5, 2020. &lt;/em&gt;The Company gave notice of termination for the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Program on &lt;em style="font: inherit;"&gt; April 26, 2023, &lt;/em&gt;which was effective &lt;em style="font: inherit;"&gt; May 1, 2023. &lt;/em&gt;There were no common stock sales under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Program through its termination.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Stock Option and Performance Award Activity in &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;, stock options and unvested Performance Awards outstanding under the Company&#x2019;s stock option plans changed as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Stock Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Performance Awards&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,529,448&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;132,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(495,299&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Options forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of September 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,159,007&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The weighted average exercise price per share of options outstanding at &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt; was $13.71. As outstanding options vest over the current remaining vesting period of 2.3&#160;years, the Company expects to recognize stock-based compensation expense of $8.0&#160;million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $0.1 million over the implicit service period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;, there were 214,124 stock options exercised. Of the stock options exercised, 3,853&#160;stock options were net settled in satisfaction of the exercise price, with no cash proceeds received. Cash proceeds to the Company for options &lt;em style="font: inherit;"&gt;not&lt;/em&gt; net settled totaled $464,000 during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;, there were 495,299&#160;stock options exercised. Of the stock options exercised, 101,058 stock options were net settled in satisfaction of the exercise price, with no cash proceeds received. Cash proceeds to the Company for options &lt;em style="font: inherit;"&gt;not&lt;/em&gt; net settled totaled $1,417,000 during the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Subsequent to &lt;em style="font: inherit;"&gt; September 30, 2023, &lt;/em&gt;there were 800,000 stock options granted to officers and employees at an exercise price of $17.54 per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Stock-based Compensation Expense in &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;, the Company&#x2019;s stock-based compensation expense was as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;405&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;399&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,186&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,234&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;544&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;70&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,271&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;216&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;949&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;469&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,457&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) or a designated committee of the Board is responsible for administration of the Company&#x2019;s &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Omnibus Incentive Plan, as amended (the &lt;em style="font: inherit;"&gt;&#x201c;2018&lt;/em&gt; Plan&#x201d;) and determines the terms and conditions of each option granted, consistent with the terms of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, including grants of stock options and Performance Awards. Share-based awards generally expire 10 years from the date of grant. The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, as amended on &lt;em style="font: inherit;"&gt; May 5, 2022, &lt;/em&gt;provides for issuance of up to 5,000,000 shares of common stock, par value $0.001 per share, subject to adjustment as provided in the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#160;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="INF"
      id="c104256120"
      unitRef="Share">1666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="INF"
      id="c104256121"
      unitRef="USDPerShare">30</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="-5"
      id="c104256122"
      unitRef="USD">47300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <sava:EquityOfferingMaximumAmount
      contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-8"
      id="c104256124"
      unitRef="USD">200000000</sava:EquityOfferingMaximumAmount>
    <sava:EquityOfferingPercentageOfCommission
      contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="2"
      id="c104256125"
      unitRef="Pure">0.03</sava:EquityOfferingPercentageOfCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-07-01_2023-09-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-3"
      id="c104256127"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sava:EquityOfferingMaximumAmount
      contextRef="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-8"
      id="c104256132"
      unitRef="USD">100000000</sava:EquityOfferingMaximumAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-04-01_2023-04-26_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-3"
      id="c104256134"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493883">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Stock Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Performance Awards&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,529,448&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;132,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(495,299&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Options forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of September 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,159,007&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c104256175"
      unitRef="Share">2529448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c104256176"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256177"
      unitRef="Share">132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c104256178"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256179"
      unitRef="Share">495299</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c104256180"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256181"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c104256182"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c104256183"
      unitRef="Share">2159007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2023-09-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c104256184"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c104256138"
      unitRef="USDPerShare">13.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-01-01_2023-09-30" id="c104256139">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2023-09-30"
      decimals="-6"
      id="c104256140"
      unitRef="USD">8000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i_2023-09-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="-5"
      id="c104256141"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30"
      decimals="INF"
      id="c104256143"
      unitRef="Share">214124</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"
      decimals="INF"
      id="c104256144"
      unitRef="Share">3853</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"
      decimals="-3"
      id="c104256145"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-07-01_2023-09-30"
      decimals="INF"
      id="c104256147"
      unitRef="USD">464000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256150"
      unitRef="Share">495299</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"
      decimals="INF"
      id="c104256151"
      unitRef="Share">101058</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-09-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"
      decimals="-3"
      id="c104256152"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256154"
      unitRef="USD">1417000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-10-01_2023-10-01_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c104256156"
      unitRef="Share">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-10-01_2023-10-01_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c104256157"
      unitRef="USDPerShare">17.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493884">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;405&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;399&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,186&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,234&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;544&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;70&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,271&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;216&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;949&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;469&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,457&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-07-01_2023-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c104256197"
      unitRef="USD">405000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2022-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c104256198"
      unitRef="USD">399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c104256199"
      unitRef="USD">1186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c104256200"
      unitRef="USD">1234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-07-01_2023-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c104256201"
      unitRef="USD">544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2022-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-4"
      id="c104256202"
      unitRef="USD">70000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c104256203"
      unitRef="USD">1271000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c104256204"
      unitRef="USD">216000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104256205"
      unitRef="USD">949000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104256206"
      unitRef="USD">469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-09-30"
      decimals="-3"
      id="c104256207"
      unitRef="USD">2457000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="-4"
      id="c104256208"
      unitRef="USD">1450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      id="c104256168">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c104256170"
      unitRef="Share">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c104256171"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493885">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8.&lt;/em&gt; Income Taxes&lt;/b&gt;&lt;b&gt;&lt;i&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company did &lt;span style="-sec-ix-hidden:c104256210"&gt;&lt;span style="-sec-ix-hidden:c104256211"&gt;not&lt;/span&gt;&lt;/span&gt; provide for income taxes during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;, because it has projected a net loss for the full year &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; for which any benefit will be offset by an increase in the valuation allowance. There was also no provision for income taxes for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2022-09-30"
      decimals="-3"
      id="c104256215"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493886">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;9.&lt;/em&gt; Commitments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Right-of-use Asset and Liability&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company had an operating lease for approximately 6,000 square feet of office space in Austin, Texas with an expiration of &lt;em style="font: inherit;"&gt; April 30, 2024. &lt;/em&gt;The Company and the landlord consented to early terminate this lease on &lt;em style="font: inherit;"&gt; February 22, 2023 &lt;/em&gt;with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; continuing obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;There was no rent expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;. Rent expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; September 30, 2022&lt;/em&gt; totaled $41,000.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Rent expense for the&#160;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; totaled $24,000 and $123,000, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;There was no cash paid for operating lease liabilities during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;. Cash paid for operating lease liabilities during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; September 30, 2022&lt;/em&gt; totaled $41,000.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Cash paid for operating lease liabilities during the&#160;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; totaled $24,000 and $124,000, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Other Commitments&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#x2019;s obligations under these contracts are largely based on services performed.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2023-09-30_LeaseContractualTermAxis-OfficeSpaceMember_StatementGeographicalAxis-AustinTexasMember"
      decimals="INF"
      id="c104256220"
      unitRef="SquareFoot">6000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104256222"
      unitRef="USD">0</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c104256225"
      unitRef="USD">41000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256228"
      unitRef="USD">24000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c104256229"
      unitRef="USD">123000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2023-07-01_2023-09-30"
      decimals="-3"
      id="c104256230"
      unitRef="USD">0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c104256233"
      unitRef="USD">41000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2023-01-01_2023-09-30"
      decimals="INF"
      id="c104256236"
      unitRef="USD">24000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c104256237"
      unitRef="USD">124000</us-gaap:OperatingLeasePayments>
    <sava:CashIncentiveBonusPlanTextBlock contextRef="d_2023-01-01_2023-09-30" id="c2493887">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#x201c;at-risk&#x201d; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The Plan is considered &#x201c;at-risk&#x201d; because Plan participants&#160;will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; receive a cash bonus&#160;unless&#160;the Company&#x2019;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;be paid&#160;any cash bonuses unless (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a "Merger Transaction") or (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the Compensation Committee of the Board&#160;(the "Compensation Committee") determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occurred&#160;as of &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, the Company&#x2019;s independent directors were participants in the Plan. However, effective &lt;em style="font: inherit;"&gt; March 16, 2023, &lt;/em&gt;the Board&#160;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#x2019; share of potential benefits under the Plan were completely forfeited to the Company and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be allocated to any other participant under the Plan. The Company&#x2019;s independent directors have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; received, and as a result of such amendment will never receive, any payments under the Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the closing price&#160;of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share&#160;of the Company&#x2019;s common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;This constitutes a market condition under applicable accounting guidance.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#x2019;s market capitalization increases significantly, up to a maximum&#160;&lt;em style="font: inherit;"&gt;$5&lt;/em&gt;&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$200&#160;million and&#160;$5&#160;billion&#160;(each increment,&#160;a &#x201c;Valuation Milestone&#x201d;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 20 consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately 67% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; awarded by the Compensation Committee&#160;are&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer available for distribution.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If the Company were to exceed a $5&#160;billion market capitalization&#160;for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;the Company completes a Merger Transaction, or&#160;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#x201c;Performance Condition&#x201d;),&#160;neither&#160;of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;ever occur. Accordingly, there can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#x2019;s market capitalization increases&#160;significantly.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; October 2020, &lt;/em&gt;the Company&#160;achieved&#160;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;Valuation&#160;Milestone.&#160;Subsequently, the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$6.5&#160;million&#160;in total&#160;for&#160;all Plan participants (after the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;Plan amendment), subject to future satisfaction of a Performance Condition.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million (after the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense was recorded&#160;since &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;grant date has occurred and &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;Performance Conditions are considered probable of being met.&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; Valuation Milestones were achieved during &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; or the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;No actual cash payments were authorized or made to participants under the Plan through the date of filing of this Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </sava:CashIncentiveBonusPlanTextBlock>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c104256252"
      unitRef="Pure">14</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-8"
      id="c104256253"
      unitRef="USD">200000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-9"
      id="c104256254"
      unitRef="USD">5000000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      id="c104256256">P20D</sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="2"
      id="c104256257"
      unitRef="Pure">0.67</sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-9"
      id="c104256260"
      unitRef="USD">5000000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      id="c104256262">P20D</sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:CashIncentiveBonusAwardExceedsMaximum
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-5"
      id="c104256263"
      unitRef="USD">111400000</sava:CashIncentiveBonusAwardExceedsMaximum>
    <sava:CashIncentiveBonusAwardExceedsMaximum
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-5"
      id="c104256264"
      unitRef="USD">289700000</sava:CashIncentiveBonusAwardExceedsMaximum>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c104256268"
      unitRef="Pure">14</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:CashIncentiveBonusAward
      contextRef="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-5"
      id="c104256270"
      unitRef="USD">6500000</sava:CashIncentiveBonusAward>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c104256273"
      unitRef="Pure">11</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-5"
      id="c104256274"
      unitRef="USD">74900000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-5"
      id="c104256275"
      unitRef="USD">202300000</sava:PerformancePlanValuationMilestoneAmount>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="d_2023-01-01_2023-09-30_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-3"
      id="c104256276"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <sava:PaymentsForCashIncentiveBonus
      contextRef="d_2023-10-01_2023-11-07_PlanNameAxis-CashIncentiveBonusPlanMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-3"
      id="c104256283"
      unitRef="USD">0</sava:PaymentsForCashIncentiveBonus>
    <us-gaap:LossContingencyDisclosures contextRef="d_2023-01-01_2023-09-30" id="c2493888">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;11.&lt;/em&gt; Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;From time to time, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA, and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assessment can be made as to their likely outcome or whether the outcome will be material to the Company. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; accrual for these matters has been recorded within the condensed consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Government Investigations&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 15, 2021, &lt;/em&gt;the Company disclosed that certain government agencies had asked the Company to provide corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and intends to continue to cooperate with these inquiries. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; government agency has informed the Company that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency &lt;em style="font: inherit;"&gt; may &lt;/em&gt;pursue an enforcement action against the Company or others.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Securities Class Actions and Shareholder Derivative Actions&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Between &lt;em style="font: inherit;"&gt; August 27, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; October 26, 2021, &lt;/em&gt;four putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; June 30, 2022, &lt;/em&gt;a federal judge consolidated the four class action lawsuits into one case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on &lt;em style="font: inherit;"&gt; August 18, 2022 &lt;/em&gt;on behalf of a putative class of purchasers of the Company&#x2019;s securities between &lt;em style="font: inherit;"&gt; September 14, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; July 26, 2022. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; May 11, 2023, &lt;/em&gt;the court dismissed with prejudice plaintiffs&#x2019; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#x2019; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on &lt;em style="font: inherit;"&gt; July 3, 2023. &lt;/em&gt;The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 4, 2021, &lt;/em&gt;a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#x2019;s alleged wrongful conduct. Although the plaintiff in this derivative case does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since &lt;em style="font: inherit;"&gt; November 4, 2021, &lt;/em&gt;four additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, one in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On &lt;em style="font: inherit;"&gt; July 5, 2022, &lt;/em&gt;the three federal court actions were consolidated into a single action.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; August 19, 2022, &lt;/em&gt;a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#x2019;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan in &lt;em style="font: inherit;"&gt; August 2020. &lt;/em&gt;The complaints seek unspecified compensatory damages and other relief. On &lt;em style="font: inherit;"&gt; January 6, 2023, &lt;/em&gt;the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on &lt;em style="font: inherit;"&gt; March 10, 2023, &lt;/em&gt;and moved to partially dismiss the amended complaint on &lt;em style="font: inherit;"&gt; March 14, 2023. &lt;/em&gt;Defendants&#x2019; motion to dismiss remains pending. Although the plaintiffs in this derivative case do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:LossContingencyDisclosures>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c104256292"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c104256293"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c104256294"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsMember"
      decimals="INF"
      id="c104256296"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"
      decimals="INF"
      id="c104256297"
      unitRef="Pure">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember"
      decimals="INF"
      id="c104256298"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-04_2021-11-04_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember"
      decimals="INF"
      id="c104256299"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember"
      decimals="INF"
      id="c104256300"
      unitRef="Pure">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2023-07-01_2023-09-30" id="c2493889">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;a href="#" id="other" title="other"&gt;&lt;/a&gt;Item &lt;em style="font: inherit;"&gt;5.&lt;/em&gt; &lt;/b&gt;&lt;b&gt;&lt;i&gt;Other Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the quarter ended &lt;em style="font: inherit;"&gt; September 30, 2023&lt;/em&gt;, none of our directors or officers (as defined in Rule &lt;em style="font: inherit;"&gt;16a&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;(f) of the Exchange Act) informed us of the adoption or termination of a &#x201c;Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement&#x201d; or &#x201c;non-Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement,&#x201d; as those terms are defined in Regulation S-K, Item &lt;em style="font: inherit;"&gt;408.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

  </ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2023-07-01_2023-09-30" id="c104256306">false</ecd:Rule10b51ArrAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !T2F=76[L8O>T%   +'P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6987.C-A"&_XK&[73:F3A&PG;BN\0S#DEZGM[E<D=Z[;73#PK(-G. 7"'L
MY-]W!38X&;%VF?.7!##[HF>U2*_0Q5JJ;]E""$V>DCC-+CL+K9=O>KTL6(B$
M9Z=R*5+X9295PC6<JGDO6RK!PR(HB7O,<8:]A$=I9WQ17+M7XPN9ZSA*Q;TB
M69XD7#U?B5BN+SNTL[WP.9HOM+G0&U\L^5SX0O^^O%=PUJM4PB@1:1;)E"@Q
MN^Q,Z!O/92:@N.-+)-;9SC$Q*(]2?C,GT_"RXY@6B5@$VDAP^+<2GHACHP3M
M^'<CVJF>:0)WC[?JMP4\P#SR3'@R_B,*]>*R<]XAH9CQ/-:?Y?J=V  -C%X@
MXZSX2];EO?U^AP1YIF6R"886)%%:_N=/FT3L! R&#0%L$\!>!="F)[B; +<
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M%^RV?R##_8/#<#:[SX:?N <_OD'0(^>=!"='IY;FR/AW*N]YJ:"WV8!B<)E
M .3N%'9WHT5E#S+70FM1V,LMHP#;",#[C0#^:V[,V>CA+'SY#U!+ P04
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M[,*?F1I<X$C-AVH<J@50+81J$5034$WN->.<NF^C3*KM2X":=OIK@)J&IHN
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M>O$S!WH%/.)"OZ.P4NM5[7E%2]%0Q$WCQ7QND<]VTR2)Q_GM%!]R*[[U&)\
M2Z7Z'FE5Z1+66P_"*;.]-+YU#W$QS5X%(!HJ.Q3 P/:4PF8:AE'H6!0[%8C<
M*M!),]&/,IT$QX.7?#!"8?_M1L.>Q311MR(:F*;GHV[.0JVIF9U\%5$2_F@^
M1Q' //ZJWX6W5]M/7MZ9#SV^NWX+K];0<CV%5YOZ@Y8.OOZ^Y@/FJEX%*,A6
M#16\3=2L>?W)2GTBV=Y\D_' I&2E.=P1G!.N#=3_MXS)UQ,]0/OAT.H?4$L#
M!!0    ( '1*9U?^(BI0R0,  /T'   8    >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&ULC55M;]LV$/XK!W4H.B"U9#GIFL0V$"?K"[!V7MQN X9]H*FS1(0B
M59*RX_WZWE&RD@&>,<"0^7+WW'.OG.ZL>_ 58H#'6AL_2ZH0FJLT];+"6OB1
M;=#0S<:Z6@3:NC+UC4-11*5:IWF6O4EKH4PRG\:SI9M/;1NT,KATX-NZ%FZ_
M0&UWLV2<' [N55D%/DCGTT:4N,+PM5DZVJ4#2J%J-%Y9 PXWL^1F?+4X9_DH
M\+O"G7^V!O9D;>T#;SX6LR1C0JA1!D80]+?%6]2:@8C&MQXS&4RRXO/U ?U=
M])U\60N/MU;_H8I0S9*W"12X$:T.]W;W 7M_+AA/6NWC%W:];): ;'VP=:],
M#&IENG_QV,?A_RCDO4(>>7>&(LL[$<1\ZNP.'$L3&B^BJU&;R"G#25D%1[>*
M],+\LPT(8W@-[]&@$QJ$*> 7]:U5A0K[:1K(!DNFLL=;='CY?^!=PB=K0N7A
M9U-@\6_]E+@-!/,#P45^$G"%S0@FV1GD63XY@3<9')Y$O,D)AST$"^^4$48J
M<GD51$ JM."/^=O!G1^'XYZY\HV0.$NH*3RZ+2;SER_&;[+K$V3/![+GI]#G
MO[I2&/6/X (^@UMKO-6J$%T]4Z*6;-*$[L!NCOH$=\I+;7WK$/[Z@H\!%MK*
MA[^/^7J2S7%?NP(:P:WP7FP%K*1"(]&?P4<C1Y&E(A*[RFJ]?VUW!@N: &M/
M]45# %Y1 <<.W:+><Y>C<R1!^1&4I0KAY8NW>9Y=W]JZ$68?=^/K'Z$@I^P6
M7310(&G;!AIG&Z<P,'!3"6I:B6U0DN)!5T4K TB2YPAR#50B4"OMX0N9$5)V
M%I0IH36BI?(G'M)2&1O?K?K@TV8SQ-D_Q9GBSX1[IE")+<(:T9!M; 1[I4RT
MXPI21FKT4,5]:P);)>J$V6BB5G;-2!&A>VQ"I\OH7TWD%=/KX54?G?<W-\LA
M-#2I23J@4_4SHLIT$_Q0.DWK?"M,X% SL#(^N#:.2G\X^ZT5CG"(QCTVU@4@
M79Z%,,[X]^<(C"6 RB&"H6*!%7.MUY260\=&"0XR;T:L=8>R%QE'D?QIW,1,
M/,7/$RG9QGKPJC1J0YDDPH:>*JIG3_ZS(P9+P>5#J?45;.B5\23. >9/T[4.
M"Q*>H KS-*\CN(C9:.M6QYS2*%=2!4[C#Y.+R]$EC5NM8[C",<?8*6-AG,.Q
M1D^?C>0:71D?'@\QV=UT'DZ'M^VF&^E/XMW#^$FXDK(#&C>DFHU^NDC =8]-
MMPFVB0-^;0,]%W%9T?N,C@7H?F.I1_L-&QA>_/EW4$L#!!0    ( '1*9U>C
M9<JQ_PP  #XD   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK5I;;]LX
M%OXK1+KHS@".8SO7W@(D:3N;Q4PW:#JS#XM]H"7*YE06-205Q_WU^YUS)%ER
MY'0&V(<XDDB>^UUZNW;^:U@:$]7C*B_"NX-EC.7KHZ.0+,U*A[$K38&5S/F5
MCKCUBZ-0>J-3/K3*CV:3R=G12MOBX/(M/[OSEV]=%7-;F#NO0K5::;^Y-KE;
MOSN8'C0//MO%,M*#H\NWI5Z8>Q-_+>\\[HY:**E=F2)85RAOLG<'5]/7UR>T
MGS?\9LTZ=*X5<3)W[BO=W*;O#B9$D,E-$@F"QK\'<V/RG "!C#]JF <M2CK8
MO6Z@?V3>P<M<!W/C\G_;-"[?'5P<J-1DNLKC9[?^AZGY.25XB<L#_ZJU[#TY
M/5!)%:);U8=!P<H6\E\_UG+H'+B8[#DPJP_,F&Y!Q%2^UU%?OO5NK3SM!C2Z
M8%;Y-(BS!2GE/GJL6IR+EY]<-&JF#M6]710VLXDNHKI*$E<5T18+=>=RFU@3
MWAY%8*,S1TD-^5H@S_9 ?J5^<45<!O6A2$W:/W\$*EM29PVIU[-G =Z;<JR.
M)R,UF\R.GX%WW+)^S/".GV$]J.C41UOH(K$Z5_=11P.3BX/\"KB387#D/:]#
MJ1/S[@#N$8Q_, >7+U],SR9OGB'VI"7VY#GHE]]1C_K/%_,8U77NDJ__':+]
M6>C#M(MIC+]G&>K78)3+U(<0+;P$#[XLC;IQJU(7&YCJ5SPQ[9HN4J4#0D!)
M3AF4+10PEMH32!N#2AS,I0@FI:L '"G.I2IK=11:'=%A;*+(9.,&CA.7ZJ>K
MJ[LQ40"B]F/568:HH"((!7+G"8->$6>!6,%6$^54;O7<YC;:&DIJ0Y*[4'GF
M&=A)%B!F[QG!0DS0 ;K^*QP2N $J"90W#Z:HP*7V!2U@IWDL"3 ))JF\Q].T
M8L%N0=!=:;QUZ;BG)_.@\XIE14K82HX"9X'?A:.3B'\VC A\7J4"V/4$[4W.
MS,"K5KJH,@1=H4 OO.GP1$:F?;*$"/)<SYW7K)@Q#"Q6$ '6$5;)&JJ<A Y]
M>95YMR)6GE/M6-WHL.2G?/'AC\J"M1;QC2L2W @^$N,-Q&2C^FS#UYY ;/$
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M(=H;?-/1^<4$OZ].SNCW^$*!A;.3?K/?0!O$U?.-NN7NEOQ<F>ZG $(PB8;
M^9R120LW&$TUTT70(%USH[^$M^"XH:%#M.I0_;."1;%E''9[88#;#NUN.ZWN
MQST-,//+/2//>$J]H6 LPX,D\95YTK.:;@75;V_J[#S<;*_TACL]^O^YF7+<
M.!HY0 XW+M0M\A6A1:OYI&HPU)^PM2*E/FA$HBILYR5L6ITN(:DAUP.%=A^1
MA)IOMZ;>MJBW/ <A@[MV!3#<Y<C$MP4)6WQSHLZG%_L;@.D$#9P.9N\L8L]
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MT(!SRXS^**BL =TO)#5:O;$.FG]4_ ]02P,$%     @ =$IG5U)AOMK2 @
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M'JBF6S43(RO7(1;24+]Q9DX-'I4-H/6EI*?23NP&W5]&\A=02P,$%     @
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M\-@K" \&5HUZZ\>RH5O62MO-KD$[3/[K;N#]-N]^&Y^9WG)I0."&7*.+Z3@
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MV>B3[S#;]F!K,#6Q[E?$OHOBLO;?%MK@X,_7Y*/OC'!!_Q$6_P!02P,$%
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M;R*P7?_K!MXTH>=DQE,'"Z\5_65 RP:T7AJJ//V -QC^A"S^ U!+ P04
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M<^582KZTAA>A/)?$@B3I5GP&(,X="3;UY;QR&7J>.P3+I#\R7M2"O.@5Y*^
M[W/&=AV0"Q1\XN\48B_H;B'>>I<8 X_"L?]7KTF.SWXZ.YV0A;_99C?B)G+
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MV6@VB<!T*[!3G&["VMEK1TLLB!7]-=!X WI_T#1VO>(##/^A]0]02P,$%
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M/($C.!R&'5JN_H1J@: Q=P#AX(2> ]+04*]^7:_^?ZI7"RX+4R@R=UE?;&G
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M+X:DC6K?C79B9.-Z]4H:ZOQN6-!3B\H:T/Y:4D?J)C9!_WA/OP-02P,$%
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MUZ=J8KQL])</DN6FDWW#I&2IN5TCB9'K >K_)6/RX4$KJ#^WC/\'4$L#!!0
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MP7CUI"]U'G8(:*>;$-2$H$V(/B"$-2'\K(>H)D2?]1#7!"O=K;3;Q$VHILE
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M- 9X?RYP."HV9M8J9^O)?U!+ P04    " !T2F=7Y\HF94D"   _!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6RE55UOVC 4_2M6M(=6VG ^@*XH
M1.)K6A\ZH;)NSX9<B%7'SNP+M/OULYTTHRU4:'LA]O4]Y_A<<F_2O=(/I@!
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M/(G*8)%!%,3%7_^MW!$; 6IW3X!6!FC'!G3*@,YV0&=/0+<,Z&X']/8$],J
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M_G!&_0EE60/Q_C1)^.I)UL'ZCB'7_P-02P,$%     @ =$IG5YEN [9A P
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MZ?,5I&0]TDQM,W";+&(N!_3QL, +F *_+VZHZ.FU2I1DD+.$Y(C"?*1=FH/
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MV\Y^6=B1CLH%V/V5M$W8&2Y!_Y-(_P!02P,$%     @ =$IG5TV@;(4$ P
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MS[H_1_-/4$L! A0#%     @ =$IG5P=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !T2F=7SUS=\^\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ =$IG5PH(_07" @
M<0D  !@              ("!+Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( '1*9U<QA]ZX1P0  -P/   8              " @2<7
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !T2F=7X-]U
M+X,/  !(U0  &               @(&D&P  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ =$IG5Q*;;,)6!@  1"0  !@
M ("!72L  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( '1*
M9U?^(BI0R0,  /T'   8              " @>DQ  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !T2F=7HV7*L?\,   ^)   &
M        @('H-0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( '1*9U?EN5Y% 04  #X,   9              "
M@=I/  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ =$IG
M5Y.&L98Z @  % 4  !D              ("!$E4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !T2F=7>#W7**8#  "0"   &0
M        @(&#5P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( '1*9U?>B'2%3 0  '()   9              " @6!;  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ =$IG5TW:Z-LJ P  ]P8
M !D              ("!XU\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !T2F=74,]UIIL"  "W!P  &0              @(%$8P
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( '1*9U<T>4"X
M6 X  *DM   9              " @19F  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ =$IG5T4.G[C_ @  DP8  !D
M ("!I70  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !T
M2F=7T;RYG<L"  #R!0  &0              @(';=P  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( '1*9U?4E G]F0(  +4%   9
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M970R-BYX;6Q02P$"% ,4    " !T2F=7R+CF\.@$  !Z&0  &0
M    @(&7B0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M '1*9U>A?<#/. 0  ,(2   9              " @;:.  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ =$IG5\B'+7>= @  \P8  !D
M             ("!)9,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " !T2F=7KJ"/T3,"  "=!   &0              @('YE0  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( '1*9U>X)@)$OP(
M !X(   9              " @6.8  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ =$IG5R9L/NY/ @  +P8  !D              ("!
M69L  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !T2F=7
M(@%X X4#  !G#P  &0              @('?G0  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( '1*9U?GRB9E20(  #\&   9
M      " @9NA  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ =$IG5WA1O+/, @  NP@  !D              ("!&Z0  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !T2F=7-2+2_%D"  !F!@
M&0              @($>IP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( '1*9U?(E(%*?@D  #UD   9              " @:ZI  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ =$IG5YEN [9A
M P  FPT  !D              ("!8[,  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " !T2F=7QC)9FB\#  #""P  &0
M@('[M@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( '1*
M9U?S<PFO20(  # &   9              " @6&Z  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ =$IG5TV@;(4$ P  0 H  !D
M         ("!X;P  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " !T2F=7]_R41.0$   ^'0  &0              @($<P   >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( '1*9U<@@D-SD@,  !@4
M   9              " @3?%  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ =$IG5_4!;!,= P  :!$   T              ( ! ,D
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !T2F=7EXJ[',     3 @  "P
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52P4&     #, ,P#<#0  Y=0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>171</ContextCount>
  <ElementCount>186</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - General and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity</Role>
      <ShortName>Note 1 - General and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies</Role>
      <ShortName>Note 2 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets</Role>
      <ShortName>Note 3 - Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Real Property</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-4-real-property</Role>
      <ShortName>Note 4 - Real Property</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment</Role>
      <ShortName>Note 5 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets</Role>
      <ShortName>Note 6 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes</Role>
      <ShortName>Note 8 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-9-commitments</Role>
      <ShortName>Note 9 - Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan</Role>
      <ShortName>Note 10 - 2020 Cash Incentive Bonus Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies</Role>
      <ShortName>Note 11 - Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995463 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995464 - Disclosure - Note 2 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables</Role>
      <ShortName>Note 3 - Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995466 - Disclosure - Note 4 - Real Property (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables</Role>
      <ShortName>Note 4 - Real Property (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-4-real-property</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Note 5 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables</Role>
      <ShortName>Note 5 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995468 - Disclosure - Note 6 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables</Role>
      <ShortName>Note 6 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995469 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995470 - Disclosure - Note 1 - General and Liquidity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual</Role>
      <ShortName>Note 1 - General and Liquidity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995471 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995472 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details</Role>
      <ShortName>Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details</Role>
      <ShortName>Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995474 - Disclosure - Note 4 - Real Property (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual</Role>
      <ShortName>Note 4 - Real Property (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Note 4 - Real Property - Components of Other Income, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details</Role>
      <ShortName>Note 4 - Real Property - Components of Other Income, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995476 - Disclosure - Note 5 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual</Role>
      <ShortName>Note 5 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details</Role>
      <ShortName>Note 5 - Property and Equipment - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995478 - Disclosure - Note 6 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual</Role>
      <ShortName>Note 6 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995479 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995480 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995481 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995482 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995484 - Disclosure - Note 8 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual</Role>
      <ShortName>Note 8 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Note 9 - Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual</Role>
      <ShortName>Note 9 - Commitments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-9-commitments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995486 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual</Role>
      <ShortName>Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sava20230930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Note 11 - Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual</Role>
      <ShortName>Note 11 - Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sava-20230930.xsd</File>
    <File>sava-20230930_cal.xml</File>
    <File>sava-20230930_def.xml</File>
    <File>sava-20230930_lab.xml</File>
    <File>sava-20230930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sava20230930_10q.htm">sava20230930_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>a03.jpg</File>
    <File>a04.jpg</File>
    <File>a1.jpg</File>
    <File>cass01.jpg</File>
    <File>cass02.jpg</File>
    <File>chart_2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="464">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sava20230930_10q.htm": {
   "nsprefix": "sava",
   "nsuri": "http://www.cassavasciences.com/20230930",
   "dts": {
    "schema": {
     "local": [
      "sava-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sava-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sava-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sava-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sava-20230930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "sava20230930_10q.htm"
     ]
    }
   },
   "keyStandard": 170,
   "keyCustom": 16,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 13,
   "hidden": {
    "total": 34,
    "http://xbrl.sec.gov/ecd/2023": 3,
    "http://fasb.org/us-gaap/2023": 25,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 171,
   "entityCount": 1,
   "segmentCount": 36,
   "elementCount": 292,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 464,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 5
   },
   "report": {
    "R1": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
     "longName": "004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2022-01-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
     "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity",
     "longName": "006 - Disclosure - Note 1 - General and Liquidity",
     "shortName": "Note 1 - General and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
     "longName": "007 - Disclosure - Note 2 - Significant Accounting Policies",
     "shortName": "Note 2 - Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets",
     "longName": "008 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets",
     "shortName": "Note 3 - Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
     "longName": "009 - Disclosure - Note 4 - Real Property",
     "shortName": "Note 4 - Real Property",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:RealEstateOwnedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:RealEstateOwnedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment",
     "longName": "010 - Disclosure - Note 5 - Property and Equipment",
     "shortName": "Note 5 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets",
     "longName": "011 - Disclosure - Note 6 - Intangible Assets",
     "shortName": "Note 6 - Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
     "longName": "012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes",
     "longName": "013 - Disclosure - Note 8 - Income Taxes",
     "shortName": "Note 8 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
     "longName": "014 - Disclosure - Note 9 - Commitments",
     "shortName": "Note 9 - Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
     "longName": "015 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan",
     "shortName": "Note 10 - 2020 Cash Incentive Bonus Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
     "longName": "016 - Disclosure - Note 11 - Contingencies",
     "shortName": "Note 11 - Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies",
     "longName": "995463 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables",
     "longName": "995464 - Disclosure - Note 2 - Significant Accounting Policies (Tables)",
     "shortName": "Note 2 - Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
     "longName": "995465 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Note 3 - Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables",
     "longName": "995466 - Disclosure - Note 4 - Real Property (Tables)",
     "shortName": "Note 4 - Real Property (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables",
     "longName": "995467 - Disclosure - Note 5 - Property and Equipment (Tables)",
     "shortName": "Note 5 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables",
     "longName": "995468 - Disclosure - Note 6 - Intangible Assets (Tables)",
     "shortName": "Note 6 - Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
     "longName": "995469 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual",
     "longName": "995470 - Disclosure - Note 1 - General and Liquidity (Details Textual)",
     "shortName": "Note 1 - General and Liquidity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
     "longName": "995471 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)",
     "shortName": "Note 2 - Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
     "longName": "995472 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)",
     "shortName": "Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
     "longName": "995473 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual",
     "longName": "995474 - Disclosure - Note 4 - Real Property (Details Textual)",
     "shortName": "Note 4 - Real Property (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX",
      "name": "us-gaap:NetRentableArea",
      "unitRef": "SquareFoot",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-09-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX",
      "name": "us-gaap:NetRentableArea",
      "unitRef": "SquareFoot",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details",
     "longName": "995475 - Disclosure - Note 4 - Real Property - Components of Other Income, Net (Details)",
     "shortName": "Note 4 - Real Property - Components of Other Income, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual",
     "longName": "995476 - Disclosure - Note 5 - Property and Equipment (Details Textual)",
     "shortName": "Note 5 - Property and Equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
     "longName": "995477 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)",
     "shortName": "Note 5 - Property and Equipment - Components of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual",
     "longName": "995478 - Disclosure - Note 6 - Intangible Assets (Details Textual)",
     "shortName": "Note 6 - Intangible Assets (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
     "longName": "995479 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)",
     "shortName": "Note 6 - Intangible Assets - Components of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
     "longName": "995480 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)",
     "shortName": "Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
     "longName": "995481 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-09-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
     "longName": "995482 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
     "longName": "995483 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual",
     "longName": "995484 - Disclosure - Note 8 - Income Taxes (Details Textual)",
     "shortName": "Note 8 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "d_2022-07-01_2022-09-30",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2022-07-01_2022-09-30",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual",
     "longName": "995485 - Disclosure - Note 9 - Commitments (Details Textual)",
     "shortName": "Note 9 - Commitments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2023-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
     "longName": "995486 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)",
     "shortName": "Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember",
      "name": "sava:CashBonusIncentiveIncrementalAmounts",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:CashIncentiveBonusPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember",
      "name": "sava:CashBonusIncentiveIncrementalAmounts",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:CashIncentiveBonusPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual",
     "longName": "995487 - Disclosure - Note 11 - Contingencies (Details Textual)",
     "shortName": "Note 11 - Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20230930_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ]
    },
    "us-gaap_LeasesAcquiredInPlaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAcquiredInPlaceMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Acquired-in-Place [Member]",
        "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r309",
      "r310",
      "r311",
      "r364",
      "r366",
      "r369",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r396",
      "r406",
      "r440",
      "r480"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities",
        "terseLabel": "Accrued compensation and benefits",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic and diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r120",
      "r121",
      "r123",
      "r124",
      "r125",
      "r127",
      "r250",
      "r251",
      "r280",
      "r292",
      "r389"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r401"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r89",
      "r289"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r426",
      "r427",
      "r469",
      "r481",
      "r483"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of stock options (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)",
        "negatedLabel": "Options exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r45",
      "r67",
      "r191"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 120,000,000 shares authorized; 42,129,798 and 41,735,557 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r285",
      "r402"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r322"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r152"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r45",
      "r322",
      "r340",
      "r483",
      "r484"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Notes 9, 10 and 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r41",
      "r283",
      "r321"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r345"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r77",
      "r80",
      "r81"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r345"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RetainedEarningsAccumulatedDeficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r67",
      "r286",
      "r298",
      "r299",
      "r305",
      "r323",
      "r402"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r271"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r93",
      "r105",
      "r144",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r239",
      "r241",
      "r252",
      "r402",
      "r437",
      "r438",
      "r471"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_DepositContractsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositContractsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract research organization and other deposits",
        "documentation": "Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock upon exercise of stock options",
        "terseLabel": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r15"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net loss per share, basic and diluted (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_OtherAssetsCurrent",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r402"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r22",
      "r67"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r45",
      "r67",
      "r304",
      "r360",
      "r372"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r284",
      "r402"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r128",
      "r277",
      "r302",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r407"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]"
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r402"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r58",
      "r73",
      "r84",
      "r94",
      "r95",
      "r99",
      "r105",
      "r110",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r122",
      "r129",
      "r137",
      "r139",
      "r141",
      "r144",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r251",
      "r252",
      "r291",
      "r342",
      "r358",
      "r359",
      "r391",
      "r412",
      "r437"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r48",
      "r49",
      "r60",
      "r324",
      "r340",
      "r361",
      "r362",
      "r402",
      "r413",
      "r425",
      "r432",
      "r470",
      "r483"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development, net of grant reimbursement",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r221",
      "r479"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r394",
      "r433"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r137",
      "r139",
      "r141",
      "r391"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfCommonStock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r104"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_TX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "TX",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r33"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r87",
      "r386"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r70",
      "r300",
      "r301"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r402",
      "r482"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r309",
      "r310",
      "r311",
      "r364",
      "r366",
      "r369",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r396",
      "r406",
      "r440",
      "r480"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r56"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
        "negatedLabel": "Expiration of restricted stock Performance Awards",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "sava_AtthemarketCommonStockOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "AtthemarketCommonStockOfferingMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-the-market Common Stock Offering [Member]",
        "documentation": "Represents the At-the-Market Common Stock Offering."
       }
      }
     },
     "auth_ref": []
    },
    "sava_AustinTexasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "AustinTexasMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Austin, Texas [Member]",
        "documentation": "Represents Austin, Texas."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation for stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r262"
     ]
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsNet",
        "totalLabel": "Total amortization",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r278"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets",
        "terseLabel": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r31",
      "r35"
     ]
    },
    "sava_PercentageOfCurrentlyLeased": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "PercentageOfCurrentlyLeased",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageOfCurrentlyLeased",
        "terseLabel": "Percentage of Currently Leased",
        "documentation": "Percentage of currently leased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
        "negatedLabel": "Expiration of restricted stock Performance Awards (in shares)",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceAmount",
        "terseLabel": "Government Assistance, Amount",
        "documentation": "Amount of government assistance recognized."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r279"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r56",
      "r103"
     ]
    },
    "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
        "terseLabel": "Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment",
        "documentation": "the percentage of valuation milestone cash bonus award subject to approval and adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r86",
      "r105",
      "r144",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r240",
      "r241",
      "r242",
      "r252",
      "r402",
      "r437",
      "r471",
      "r472"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
        "terseLabel": "Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)",
        "documentation": "The minimum number of days valuation milestone must be achieved and maintained in performance plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
        "periodStartLabel": "Outstanding, performance awards (in shares)",
        "periodEndLabel": "Outstanding, performance awards (in shares)",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8"
     ]
    },
    "sava_PercentageOfOccupancy": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "PercentageOfOccupancy",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageOfOccupancy",
        "terseLabel": "Percentage of Occupancy",
        "documentation": "Percentage of occupancy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
        "terseLabel": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r274",
      "r275",
      "r276",
      "r278",
      "r388"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r161",
      "r162",
      "r163",
      "r177",
      "r178",
      "r207",
      "r208",
      "r209",
      "r272",
      "r273",
      "r294",
      "r312",
      "r313",
      "r363",
      "r365",
      "r367",
      "r368",
      "r370",
      "r383",
      "r384",
      "r393",
      "r395",
      "r397",
      "r403",
      "r406",
      "r434",
      "r439",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "sava_PerformancePlanValuationMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "PerformancePlanValuationMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PerformancePlanValuationMilestoneAmount",
        "terseLabel": "Performance Plan, Valuation Milestone Amount",
        "documentation": "Amount of valuation milestone for performance plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r271"
     ]
    },
    "sava_PrepaidExpensesAndOtherCurrentAssetsTextBock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Text Bock]",
        "documentation": "The entire disclosure of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsDelawareCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "ShareholderDerivativeActionsDelawareCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Delaware Court [Member]",
        "documentation": "Represents shareholder derivative actions in Delaware court."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "ShareholderDerivativeActionsMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions [Member]",
        "documentation": "Represents shareholder derivative actions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance awards granted (in shares)",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "sava_ShareholderDerivativeActionsTexasCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "ShareholderDerivativeActionsTexasCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Texas Court [Member]",
        "documentation": "Represents shareholder derivative actions in Texas Court"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease revenue",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "sava_CashIncentiveBonusAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "CashIncentiveBonusAward",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashIncentiveBonusAward",
        "terseLabel": "Cash Incentive Bonus Award",
        "documentation": "Amount of cash incentive bonus award."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r161",
      "r162",
      "r163",
      "r178",
      "r273",
      "r294",
      "r312",
      "r313",
      "r363",
      "r365",
      "r367",
      "r368",
      "r370",
      "r383",
      "r384",
      "r393",
      "r395",
      "r397",
      "r403",
      "r439",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "sava_ShareholderDerivativeActionsTexasStateCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "ShareholderDerivativeActionsTexasStateCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Texas State Court Member",
        "documentation": "Represents shareholder derivative actions in Texas State Court."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashBonusIncentiveIncrementalAmounts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "CashBonusIncentiveIncrementalAmounts",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashBonusIncentiveIncrementalAmounts",
        "terseLabel": "Cash Bonus Incentive, Incremental Amounts",
        "documentation": "The number of incremental amounts for cash bonus incentive."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Net Settled in Satisfaction of the Exercise Price [Member]",
        "documentation": "Represents stock options were net settled in satisfaction of the exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r161",
      "r162",
      "r163",
      "r177",
      "r178",
      "r207",
      "r208",
      "r209",
      "r272",
      "r273",
      "r294",
      "r312",
      "r313",
      "r363",
      "r365",
      "r367",
      "r368",
      "r370",
      "r383",
      "r384",
      "r393",
      "r395",
      "r397",
      "r403",
      "r406",
      "r434",
      "r439",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r105",
      "r144",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r240",
      "r241",
      "r242",
      "r252",
      "r320",
      "r390",
      "r413",
      "r437",
      "r471",
      "r472"
     ]
    },
    "sava_The2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "The2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2018 Equity Incentive Plan [Member]",
        "documentation": "Represents the 2018 Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
        "negatedLabel": "Performance awards exercised (in shares)",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r219"
     ]
    },
    "sava_The2022RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "The2022RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2022 Registered Direct Offering [Member]",
        "documentation": "Represents the 2022 Registered Direct Offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r161",
      "r162",
      "r163",
      "r178",
      "r273",
      "r294",
      "r312",
      "r313",
      "r363",
      "r365",
      "r367",
      "r368",
      "r370",
      "r383",
      "r384",
      "r393",
      "r395",
      "r397",
      "r403",
      "r439",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "sava_ViolationsOfFederalSecuritiesLawsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "ViolationsOfFederalSecuritiesLawsMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Violations of Federal Securities Laws [Member]",
        "documentation": "Represents the violations of federal securities laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
        "negatedLabel": "Performance awards forfeited/canceled (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_RealEstateOwnedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstateOwnedTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate Owned [Text Block]",
        "documentation": "The entire disclosure for real estate owned (as defined). Generally, the largest component of real estate owned by lenders is assets taken in settlement of troubled loans through surrender or foreclosure. Real estate investments, real estate loans that qualify as investments in real estate, and premises that are no longer used in operations may also be included in real estate owned."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r175"
     ]
    },
    "sava_CashIncentiveBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "CashIncentiveBonusPlanMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Incentive Bonus Plan [Member]",
        "documentation": "Represents the cash incentive bonus plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusAwardExceedsMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "CashIncentiveBonusAwardExceedsMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashIncentiveBonusAwardExceedsMaximum",
        "terseLabel": "Cash Incentive Bonus Award, Exceeds Maximum",
        "documentation": "Amount of cash incentive bonus award if the maximum milestone is exceeded."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r278",
      "r279"
     ]
    },
    "sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-2-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r142",
      "r392"
     ]
    },
    "sava_statement-statement-note-4-real-property-components-of-other-income-net-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-4-real-property-components-of-other-income-net-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Real Property - Components of Other Income, Net (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34"
     ]
    },
    "sava_CashIncentiveBonusPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "CashIncentiveBonusPlanTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Incentive Bonus Plan [Text Block]",
        "documentation": "The entire disclosure for the cash incentive bonus plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-4-real-property-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-4-real-property-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Real Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment - Components of Property and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-5-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-5-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r322"
     ]
    },
    "sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r75",
      "r76",
      "r78",
      "r79"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r322",
      "r340",
      "r483",
      "r484"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-6-intangible-assets-components-of-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets - Components of Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r88",
      "r290"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherNonoperatingExpense",
        "negatedLabel": "Property operating expenses",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "sava_statement-statement-note-6-intangible-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-6-intangible-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "totalLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "sava_EquityOfferingMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "EquityOfferingMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_EquityOfferingMaximumAmount",
        "terseLabel": "Equity Offering, Maximum Amount",
        "documentation": "The maximum amount to be issued in the equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Options forfeited/canceled (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetRentableArea",
        "terseLabel": "Net Rentable Area (Square Foot)",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r72",
      "r287",
      "r402",
      "r425",
      "r432",
      "r470"
     ]
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r281",
      "r290",
      "r402"
     ]
    },
    "sava_IncreaseDecreaseInDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "IncreaseDecreaseInDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_IncreaseDecreaseInDevelopmentExpense",
        "terseLabel": "Accrued development expense",
        "documentation": "Amount of increase (decrease) in development expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sava_EquityOfferingPercentageOfCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "EquityOfferingPercentageOfCommission",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_EquityOfferingPercentageOfCommission",
        "terseLabel": "Equity Offering, Percentage of Commission",
        "documentation": "Percentage of commission in equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property (Square Foot)",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeasePayments",
        "terseLabel": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r268"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
        "negatedLabel": "Operating lease right-of-use assets and liabilities",
        "documentation": "Amount of increase (decrease) in operating lease right of use assets and liabilities, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodStartLabel": "Outstanding, options (in shares)",
        "periodEndLabel": "Outstanding, options (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sava_LeasingCommissionsAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "LeasingCommissionsAndOtherMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasing Commissions and Other [Member]",
        "documentation": "Represents leasing commissions and other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187"
     ]
    },
    "sava_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r175"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual",
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r128",
      "r277",
      "r302",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "sava_OfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "OfficeSpaceMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Space [Member]",
        "documentation": "Represents office space."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r77",
      "r80",
      "r288"
     ]
    },
    "sava_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseCost",
        "terseLabel": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r401"
     ]
    },
    "sava_PaymentsForCashIncentiveBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "PaymentsForCashIncentiveBonus",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PaymentsForCashIncentiveBonus",
        "terseLabel": "Payments for Cash Incentive Bonus",
        "documentation": "Amount of payments for cash incentive bonus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r307",
      "r426",
      "r427",
      "r428",
      "r469",
      "r483"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r91",
      "r105",
      "r129",
      "r138",
      "r140",
      "r144",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r239",
      "r241",
      "r252",
      "r282",
      "r334",
      "r402",
      "r413",
      "r437",
      "r438",
      "r471"
     ]
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r22",
      "r83",
      "r97",
      "r98",
      "r99",
      "r107",
      "r108",
      "r109",
      "r111",
      "r117",
      "r119",
      "r128",
      "r145",
      "r146",
      "r176",
      "r212",
      "r213",
      "r214",
      "r232",
      "r233",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r270",
      "r295",
      "r296",
      "r297",
      "r307",
      "r360"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r107",
      "r108",
      "r109",
      "r111",
      "r117",
      "r119",
      "r145",
      "r146",
      "r212",
      "r213",
      "r214",
      "r232",
      "r233",
      "r243",
      "r245",
      "r246",
      "r248",
      "r249",
      "r295",
      "r297",
      "r307",
      "r483"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive common stock options excluded from net loss per share, diluted (in shares)",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r36"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LossContingencyNewClaimsFiledNumber",
        "terseLabel": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r222",
      "r226",
      "r227",
      "r230",
      "r234",
      "r236",
      "r237",
      "r238",
      "r306"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r344"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r83",
      "r97",
      "r98",
      "r99",
      "r107",
      "r108",
      "r109",
      "r111",
      "r117",
      "r119",
      "r128",
      "r145",
      "r146",
      "r176",
      "r212",
      "r213",
      "r214",
      "r232",
      "r233",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r270",
      "r295",
      "r296",
      "r297",
      "r307",
      "r360"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r223",
      "r224",
      "r227",
      "r228",
      "r229",
      "r231",
      "r303"
     ]
    },
    "sava_AccruedDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20230930",
     "localname": "AccruedDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued development expense",
        "documentation": "Amount of accrued development expense, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "terseLabel": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r82",
      "r118",
      "r119",
      "r130",
      "r225",
      "r235",
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210",
      "r215",
      "r216",
      "r217",
      "r218"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
        "terseLabel": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20230930/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20230930/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20230930/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20230930/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-4-real-property",
      "http://www.cassavasciences.com/20230930/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20230930/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20230930/role/statement-note-9-commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r39"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
        "terseLabel": "2023",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "c(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483081/340-30-45-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483054/340-30-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-20/tableOfContent"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-30/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001437749-23-030502-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-030502-xbrl.zip
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MKK2GJ=?EZIS*NFR!-K>#:AA+X1RB4X7X9'D.P5K?&"=/C?Y[O3[.VCB/:KW
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M1=E-0C2U*RUM:W3E)@L#V#[%6;S )57?.'U%JJ9$KC_37M7_\"%3?NY!L&N
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MD#B#,;#23M+Z/B-T:4.*BP^VW\QK-9(?O_M0$YC7(\JRQ*8;*$Y(W4LAP+O
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M%:^VX_1?5=P5@]Y?]?8\-41&G=K?M#*)H@.8I7VEN8TG8?R^;8//H6W3OF(
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M.N $5WA+H*[@.B],851,24D@_D$6P8$.*/%;;J(S1"Y)0VO:2A07%G'ML:?
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M\;@:R:.R)T'I:\L8TA5>"B=+"[@F.=0VT)#C(VEDXF@*/%Q*5,2#8]_0;G$
MH880%3\F0))9R-M()^;13K83E2>Q>5TETG1 )_#,<H* ]XX'?_/0B1>V%8G-
MAPRK]M:T>G9[>VQ;R-KHTEU9Z$YUC%Y1KS,$O0U^TO4"PDX*T?!#'E-_6G$L
MK7#!0DN_*$- KZ>T-+6JWNS2 %DH_A0S%WX1=I+RDH#<.$78&^H$G9F\UGCG
M(X9];M9"X>7U-<&"@[AN[R<G=TK;E.YE11X>>HO>*FB=4TN90@[6%DL]EW=\
M2KS^(DW0,#K!4-<UQ3^W/E<Y\DJ14ML_&?=X!?OU1Y$,HH&20B(Y)0O+R]HE
MS[0V?VITPTVNW\2"PW$Z1<?@;/A8';^))WZ&BF3W';!!\*;UE+I?789^<+\$
M6<A%7GZYRAKA11E5$ZI0Z+(;#ZP^G16\Y0\VKCC(6B2 ;L!Z7!\%X]S.M/F"
MY3M.-B]2;>&AFG4H$](=LBOI+NYJMUO@#0*5@MP:W A[NW+KX-(J'1#X>U/2
M8]4N-]R9KC-^FIV;W_9;T5S+\7@=F?5TO0<\#>5'=-)VO;HF*!J!:]_193>?
M%\WW.).UG6E6Q@TU[^SKM_3UU@_1&^MY<ON>*:#!7Y$3E8FE=$#37S*':&;)
MQ.P\+="TH9;D4JOMS@BCI[.V+47NL*2EQ?IR%Y?4FJZX[*_/+6+8*=JTGJIA
M;_OFR#6>PS<&X*EN)3/HN@M+M!!G7+3I#Y-W")[TTSW]D9%"AV5"M"I,6YI6
MU("5 ZYL,"IW9.)PT[O0O,C9]0<65RK<9N<475:;:/9(=]7.I7C'33-09BJ)
MY??49=O B<4J:"#9R%>\'2P$?@[A);GA+C65K(109 BI9)_[D7LN;Z=F=7S\
MA)=V_&Z9?8H5?'@)^VGVI.A+7:K 3">P*HS""6D#\89UF%LB.:O@IWS=S"=W
M9N9T/Z8:O,Z8=RYR3HJN_-H>(*2HT/6P^(;8^S-!DNOL<:!RQ]^0$VELV)0#
M7MHIE'T@=C.2#A!I5 .&J8(9TN/,#X'E5#>W3PX"'2FY<;F0ZE2NY+B[DJT
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MLVJKNP14V^;T]EX9:01VW8+DW (^@JJ"!-/$D6WEWW10^+<*-3X\2'NH:H0
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MSAFRB@FI^6E@P0J/<F9VQOOK_=,V=AUB<;Z:.I)S<92:/Y!W[GF8&C6>)FI
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M[SN@T"-X%40L>4*OSXL[;D8F1=7NIB, 8 GCPOQ<GYRT()HGK4;.LR0)V@5
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M,>8[WG? 7(PIQB*P[[29I1G PL("9#-_  8>D#=%>MP$ &MK0 4  $[F9T(
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M7K\UPBVFJ(-7(OTT[3?+_C/#HO]O6?8WP_YNUPS R\K"#!ZK(  #:-3"I$/
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M/F_(.A)X:.AYS&'%(M5] J/S[;GZK AN=,<QV&)M;LAF/\5D'G5DO%4;CQ4
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M 9QKG6R3LR1*;2\NI!8X#=7;AF3TZP1$E)1>J,RD;[.$L!W[&&59E0];S&,
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M,HG@?4+D2/)Y4E>;?CE\UD]:YJ;?J[S:!AH#>.3=4-%B]25>@8UW$H;GBM1
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M/P/]^S;?Y*'X4X41/UY ?CJ]]#<OLOP0QN-$9ZE\M!J8IR[)K0<SLX$76F<
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M0TD2JSKUT9(P;R^,N.8=G#F49]Q86!T;'SA0-_8H]-R<96GOG3>JE.S,58]
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M\1]=%!6J&YCU? /-13VOGU34/&GL%3SB96L7J9-W@3[CSY;N[YE[(MXUN>/
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M*"O*1RV*Q0;R0)DL8'I=A=X+VKY;J;@O4?H.F/G/F?KOEVOQSQ.]Z9ZI"5&
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MKV+'(R7@<Q8$I^#SE\L<-\=FOZ3*3V7(2_>KU,A?+00G#,>_IK5^,1^/\0
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M J^]M3G_7.>[)%*";XOK,26D<<\\VBUY_-[ 1Q\3!\T7ZD_DR"$QCJX'E>/
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M^T,IF0M5_790VV_C]M6A)\HOK'T1.V2\<J2$8_\%V(4!$$ .-IRAU("B:++
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ME;4<>A>8S1O*NK!C/A9:G##0HTI<5AQ37/4XD_"3@&]BN^LLG6PP%G1N]0L
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MCIICVOD(;IHI]RI3\8V9DCWA"B"-&TUS^L^F,WLCCKUTMEGC5,]?VJQ1;NL
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MER!'=> ^LT6P)C3_?/_J&FG$VL9J+ 4$34$4I=\DWY;=N%(.5>$GOHGA=QM
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M*=\HBP#754,30X"&A@:X33T "A;P-(#[> * F1D@!P  ,\!(<P*@H^9HJ =
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M.N.UO%OH"1S'33F@C<F#*I]]9@FH[>HK#V_,<H:>8+V<OR98;D=WYBUY0!?
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M-N1W0DYA0?\4BO,-$5OM)VJ1,D<R^EICQN8O.;X_W&06O>";:OZA(C+K@Q"
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MA?71;MF!=[][6'VQV %^+%>$WBK7D"D?&LJ9=MC?)KZ">15"L\^/ZP2\O[+
MYM(;6O$&%RY\!9ULE7HE86LPEP)XG,D.TN <:7ZPO&2W?4 =PYLC?QX;D26=
M,$0;<^C H)(C.FX+342;L_>]FW4<H@ L,M';;CE;]>?+/I2A(DJ5']V@_6I+
M5W4R_-,#O$R[P.2\8/12A[,0"LSXU(E&<BS/8^3R4RO^MLH=/>ZW-.< @Y]\
M-WNH_,VK<R'NX+!\*K89A+UX?].YUDG;,OO(-#K$?WMB9%+0[D6F'N%*N\FI
MD^/[? 4>7@\M-Q"#1TA2&/$=?G7ITTK:HD.EJ%'A&A*D2+HIU1H3N,V(XPD6
M'<A#_]CP<-F:N<D LS6)7*W@"%Z@0T(OWK0XSB++(RX1)(<WAHE*-A-"_=KR
M2F>'8 QE*OKT <7**MHMO"*?N\?O0ZN11)G>ME?EJDW!1'W\BG&@48CJKW#&
MN9;/=SR"I]-_ZRO+<VE*7=J0=Z( [LE/APB&YL(YT606ZLCL,$6WP.[X<+%-
MOKG*?2;3#[?8$_/PP0NQ=.W".%WKNN,"LC3I(5$\;\U9E."?I"-,>(<>R.%,
M$,<*FVJN,&H6.5F3QV[4A+RMJD>CE.WHG7V?&A8IY[+D(9#$=K76GF3N66@.
MCZ+J0LR!LWS=V$Y/"O8I/E?+5R569^%W7.:)'K;;#$J]L_13XZV\%,"M\@D%
M$"&YM4@2BCJ5:(CY7?*^&>ZWQG\ZA&6ULU;=2;S6[WC*S?C&/19<?NUQ= 0[
M!MZ_U'6/=!;/'KH]^CG-I2+.3^:%CJ' [,S]8,.K=:&1#UX/US&O(::.),E3
M9$TT,:G<'KZQA*NH*ES7!8W]2M*_-M6L\&X6NC<[?S5R?NE:_;#[@P"WS_6F
M9Y^=[)4,J+@T+P=.S,%;@/E]6C2(Z5[YO64^H4YE&9/. LTM^"Z"G6F 3_%T
M>S%](TJ<KRNU?'S1,+$'\J%_]O;2MJRN -QOJJO1KQ8E]@+5D^PN_<H5H7!S
MF]\Z]>3 3*^TQMEK;HDOF/PLX(O6+DD4P"N'AF2,EW06)# ]0:A4P/WF,,8_
MF[;5Y1,TI],G7E[IOW6BVIBEY][VIM&MSI+OD+K"=TM)1MU4Q);3"0'#GW2*
MJ1,D*R1J:T9K9S;9'&3G.+X6(13+EY_KLWY(.G%&0GE U20E(_ 0;&;M$#3[
MY<M;O[. 6[BQB-=Z-YS*;"-]R4-[!O0PO!>V2:$"RQG(AIQC%(^]67_*#U@,
MR Z=0L]@C#QHNT^4!?3D\MVZ+??X$=-H%&\4S*3XHFS>XQQ(Q'PK%\D=?]0N
M)NK/LF$_GR"66]K'6%*\AI+4FBSR8;6;'0"G0>4:/'R6HNZX\D9)>/D_IY.#
M'[0ESX!QX&Y0K MG$.RF)1I=13 LRH?[6^#+'EJ3;\&"L?[;'Y6Z6E7)M[-D
MWTON-:?[EB!1+;7$$OR#]C_CY5RC4I*.QEMBJ8G=Z/K97U#9':S=S9W/?.TT
MT<:?MXS7S%CP+NTC)..8'GEL#J@R06$+6;TT:? "Z6?J-'VDF27<%4(66<(4
MGJ^RK+&NFBCZR7MX%Q!8+K(Z\0=;J$W=J]0X+EB<\M,5F7,@!G>ABJ)_A8B<
M=#"I'=M!.^G?U3Y&#0;1[5OH9-UC;W\!S.GN'5K=7^#3/4&T6?**DA[6\< >
M\W0+G=U)-7%_;V\41*?UNM3WGN%BJ%A>H46#Q$I./*06V;792I226NT&L6SJ
M\E015G(6CY(\*8!%\]AR]E<,U%M*0UH>^4(GS_C5Y8_<3])^*#+X#!!,<=99
M1P%G[;]CT#D=TVK"9DS&IFR#IW'S^_LPE6W0?K'NUX,1W,U3[#*Q-*Q@A92$
MG @P(T),!U+B(],9"MHW+'<7>Q5^QS=??<JZJL?-6#)9V%XM\06K(6VJUJWS
M)";\%0@_!*N5W!$AZB(4GKFE[^C ')W['1 8^%'5ZNV2*;C>>UWN(QI4LZ=]
MLO6=;GYR#!6#_86AOT=HP@_(?$;MNWSPTJU"/-'+J'GBBJ#$UW-Z>[Z?OWOY
MJ:R9P<V*NEKC[06V!?!*5R;4=MGGB#8]*"D2ZGUGH?*&4!3)VO0^. +1<"HI
MBS663??^8#O3.LS?%#T56)H@O FO*-L]#9>)MF)/[=FP2G^\&,E"'RJT3+J(
MU^[4!>,KGA3T%7:^U\<VF:@>J\.NL0UD>4N:GUDZT3 7G<S]^G4Z(#)LZ?4U
MDXJD79(AV*IF@]SYN^58<[JDRS\Z&B4/^"=MK"%^"0;)-QT^+G4X2<^-:;P<
M^WU6PO;+W5$6P]WV2HR+ ]$&G[_$L=I5KN\\N4*\66;"E7ITO3;9MK$&:BP=
M5?BL/6+P:"K]"XR+_K+[C\L- <[#$"]S ,0[4('L$, F;X?4IN2:AF("S50;
MX99Y$R\3:[7O-X&$X>O=-GBFK9%%I:>#>95/2?)Y1,^%SNV'D]:'5M48?1['
MISQOXA[9-:/[3N6\N'6<?6,#,8;/V9\FY'0M$&468G4"BC;FP02;9PHD]P!L
M5,Z5*Y$]W_K*I5Y'.#@"3SOIWUN;7+*^PV@ 4;YYMD4:<8V8@JV,MH]()NAW
MHR!)2LT6(5B87_=/!2'<1.:UQO1?\@F91^(+=2=;OE8[9,&_A^2Y\GK$@JTV
MP'3-@J6VSO;.<)=+C?7C;YO03?%0S>\.+RN^GW"2C]1U57VDO:J=E99F";=9
MW'V*H//(G5F+$!P.?(E0\I&*3A%]]R) \15]EL[G7%;&[O!88T<_C,KH^XN9
MOW*5JH8BOI*U)W2< I9@&G8HX:9*5CAJ\^JS#=FG;BNT*8Y7[/3H0GNU>KK8
M><1"TW+,$I>AF40G_) IT2G?V6[=1'WN,GGI5B/*1Z>O8L<KI2#5!HF3D<L?
ML=);9-UX >,[_PD-Y,7_KWG@_Q4'9/;KVW/P_W(/_G5N?KKBW&8$1&89OQN]
MO_^U2C&  D1 &SSF3);/O.4$'WGA!([96@2IN*6KE>29O)T3Z_)3D>A% 9A.
M4  ":D>GZGB"5*)N1/TLIHLE3Q.CJ)1K-QJ)#U#ZLQ7U[]HW)2L($VWV\@?
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M5 >XF@)T2OESG2.&+#K-RSZ0KD9^*$?B_+ZT]S7\AH1GTK0@EA]=-+SKP:=
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M>-[O_\_YOO^\[SE9ZUYKUDQFYJY[7]?,OO;\'KJ_+EC&);^D7AZ7GCXO=0P
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M_&(7SM&W.$9GS/$P%O#B!=)B=MZ&DE*C9VH^+O_D5_-"7/JY]OF$+VS<YO<
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MK"MJZM7@_]KEK:#VPQG9N/+,EW=V#?<L:0.]]FX,DT]<"!I(WY4*=8G%5\>
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MMY\Q4!%)(=:&WO6*J5E<$A[O=22K?)2P?#34I)#8Y =[@IX\_'-"%-:1H\>
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M2Z0JI 1J3'8,0RH[N54N_;)#M_ Q0*'W?U^B1;__&*!2<  9_ZHV4-12BDI
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M.T]_G#RY0#OO#<FJ7)$$\E#X(9<C02RR7,IG0:D3?_BZ,$8Q\+JT\' <\1B
MOQ)$,VZHAM@]NO%)(;52NB')O88AXS74(&,D!]ZT,A+?*HEJE_4=B<CBGU8
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M7[NZW?Z8J:,DQ,2:N"@4*Z/Q(N+G[N!X#\ZCS1TJ[ZR[%'^A/,<]GX7#HK)
M<[7GV06M'(VY+EI15(N<QII?(HIJ?_]HF_1PU R3[& ,?2IL:]KW<!&S<Z[G
MSNM0X==\!N*:BS,PXDUP7$4S-S$*/;_P8Q<J )S\4IOZ6,7O:[M[@5Z>?Y-#
M<)ON^/>/=P\?1=_PNF>KM%CRESJ8,$D<=Y=N1YR>A?N@C29#_^QP3JD/AE5G
MG)EABK^XH":K=JE'$<TFD'JZ06TE^YX16C@Y,):\#9H.62K5X*5T0<(#Z*V
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M>I8"6BKY-W_]N/)$Z_$Y+%*G(A'A*!V9,GETT+F)X(!O[+6F:8?M*#3QWH^
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MJ5#G='#LS01-"4U)S?Y/B_%@<0,='I0&XR)WX?9\M#)8C=Z/81DY4X>V3^Z
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M5-FPB"<X  !;/P  "@   &-A<W,P,2YJ<&>U>P586]O6;7 I4BANH;BVQ9U
MBY86BKL4*5;<-10M*:ZE6'&'X@[%'8H42G!W=TM>./><^Y_S[CWWO?_)YMO)
MQ]HK<\TQQEQSS@5?X+_@BX"'+V7D90!(2$@ (\0/ #X#> ' 1$?'0$?#Q,#
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M[V80ZM<J,]C^T:W0118B/C=NW_PF4^5_DDG$W5Q56YG+5CW^5S^S*@7J4JV
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MFM8/F$><VXU]U!4,X:C/@ML0CF&"5".L[A(A=">FVE6;)8MO1;-I71<X0L.
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MH ?,7Y)-R7'K1U2$O>^^N>]H-Q!P+K_FBU1U#H0#%M3*!+"<:*L\$EE/T3Q
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MLHL*B8J5R6QOY1BR%Z!I24FBNA70C3;)HP[Q"OMF486G#I=_8Q9-F:H8U5^
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MNH8Z"KD81IY!];0^'% (U%$)8:B7)7=BC]NJ:(^5,DEX=E2K_C;*\N=03M#
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M)C)L2@WT+#^QA%*X;QSOAS>0!RK4VAM]7:NC=3DK,M="D8G88JC]XH&=&<C
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MJF-'3^.JM&ZH3+UYI$.#)%4]\_H;3)29@JV=-QU9TVUT#:&Z[].LLOH',^"
M9G_/\1]\[+)>!7UYG*=O9@:9_ :(&U8%!?O#-M9[=\9RQOD>NVPPU!+8A;<O
M95GH$0IS"VQ*THZWEK_'I.W<;=16Q@FO>3;GBG/;&O22=T _IBCKY5B8:$RY
M6_>S9SW182G&X8!.I4<#H@+!3ROW"65LRA,&7S,G)I#OI#GTH*H?%>CU%.6F
MLH3.#$/'V.+[/T_WD L*Z;D5"5"(A4_8RS*\(D&=INEA4W<7[+U0!P5AR%4S
M&O)@2:79I3#9/:N9:ZHU2#%&9*AFQ<@[XSMIF4_EQ(Y#'\+*^T"J*K*P<M_,
M['?AOS=JM>I/X(#)IV.9(N'QFYF0<LP>[)X?[[[1'=$-%/SZCF,@=93W66NI
M,X;5%&">BP$ZP-[$1'WH21"@1C=:_+;<FC?P(WE =-.&?3>>YU&5K]H/<IM2
M0\EL23!++;AJIH^.+4,_(E\+I6_V&7Z.W)>N5?]573:#CPF<8R]04,A-3I #
MUS[J\2-16QUONK+CQZG(ALF,LC45MQ$W!&V$351:)E0.OC-U8%57V7JL>IQ2
ML'A&TW*9][7ZD4+3C4M2XE#$<^I81WIFQ<&2_MK\HFKBYBK7_ $RNZ1/C3PD
M[TQF8R<FJH*)BBY")F/B?0^OQY!$1F4]60"9$!;DX$H/A[>YHN?1#)4'4E).
M?EV?<<R/BK.6-=+.Z(-6@C&B5;VC>2I\=\O1)+?)C&OW.9<;/LIR[TOT7PX+
MJ6#>210>;?$K&XKMVMO4>7BO&_4DSE2E.&^]UL*&:N2X>#AQ"#PK]GHLCX0M
M^;[2S]X3F8C*A;S$*M1F6;?@R7/8M93:NY$W/)'K5CH EDR(Q._MCTR9+AR0
M;]@=5T.!4>.OO9PFIYP3(JY;X:]*CX%1(ZT>^V+,3"+&LB:BB/4S^_-L##'=
M/-4=S<V"UR7^O:$E7SU64C/"<S\2A_>']^._P7^_J&Z291E,_''K/)=/)ERU
M7P_-)$'/\]&$^C9+XP.ZO'.S8/D;XE9NK,C]GB?H*#X2*[R;O#<BYN&+U<%,
M$2!6;%HT52&H6"6T>%3ZES:Q8K+Q9,4,I1S.(RX/>J[PTL[5&)&4$W73P\D0
MOHY9A:Q?3</R'A1S"EQBC@XZ<:HJ,=-!T>EF&9;"[]>]J+G'H,:-"AW8101;
M46Q>4W)+:#,H;CG:Q7>&,#'-NZ/GMBH3_#K$L'&,VU,XH.<UT#( Y@E>R:TL
MQ&BJA;Q]T$_RXCLJC=)7,9X]74<ZV_=WI<"K;3"]+!2Q4]/RCOF"^&:CK5QK
M,G%Z!+W[=3.44Y#>S&_;F;NM5=<_^^3!Q&U+S@@0D;CU_"+TL-09;!4"\TSO
M'?/)Q;_:@@,BOJQ%%+DR\[=( :VPUF/K=F<J7<6<9L[.2Q0\@KJJ5/,?FTHL
MTDR39T6C#3G7!<:&B@"7>!>JVN  ,=#1N)KQS1!L"Z;^0JTY5FE\M1Z"+Q1+
MKC(C0;X-OIYP?#P[=_,*>#(.!U#S_M=RI=6UU98I[>&HCDWL_FZDZG.G;:+J
M'_(_VY0Q-$I0C/KWK?J_,$5^AC\9(<6>B@\U0F!,O]S*VGL&'E&Z=9[BNVNT
M(BOJL@\CCT*7/!&.PH[P7 NI5FQ(X7QGR_^R+JYC+?YJ8'^FEKS'T%/HH=[\
MOWK07C.1T=C ?]3SY%2OKUX"JX],]*Q7C$<-#JA>/Q'-#3+Y(N]=1Q]-+D]Y
MOL]P1GUY1N1(6__SP6<!_'DWV%9&J1%>Q^#!W;@6U*>OX0.#&?:RC Q@U4PK
M(-*6;0 .* 9?1)YD1>.MP0%_L"3[!XCB[6<^+*N23K*_@QD]_PS:R(,)6PM#
M$*Z._JNKPYD14J2\OG\$AN7,-VMG,R%4>^ODTN >F.A;., U,_M]\.=:VP);
M[0AT6<'B@S\6U>0#71[9Y<-<@J3HG7&_@'Z/J<@_GFM/&$5DED5CKT?^SQ1/
MNN(Y0/ZMFR)Y.O]^'&/L'L XZ<,KTZL44S!6[MT?"#)!$P(W'=?C_QYV&)7Y
M/;E9OP]8_,$ 7VK EBQ]"=7')Q;_M"3^!POF1M?* ;)T#_Z)*9VXD\D465$!
MQSNW8EL7?'G]Z>[H=M->TBF[4&"LAZJ0^MO+:XIF+6CKK7</;..LV*BTW^O!
MORXI;=,;^N]<D?Y;-U06KRD0N'_\+X43>O+XR5?Y"3C >=),_.E9 >P0L9\&
MUM=QTN]#*ON?:Z7Y'EV/*??Z_QM17/Z&*!G\G+_Q3_G/'/U)][_8+Z&4U:S5
M4(T>$2QUK:T:N3Q4*H"Y/ J/&F>S$F?^<?HIPR9_.V%R/!Z'4+.M[4 G?X>.
M/0M=AEP#@S929_%682E<5WWJC+*1U?0#;I@E&9KK[$-=9].4^,4SLAUEIJ#B
M=$(MO1=H0]4IEN\?4_YL&:)@HN$7N4FK4VT4DV&[BZ-25:%/T_RUP^&ME+'M
MUMT_H%:3MHGLG;_ V6/ KE.'2]_^92@Q:/^V:.>C"U9&$EVUXX?'QJO^Q5FT
MT0NBMOG@;]5*=*HD22YX<;9&;F/057(&=0W"AVXF"6P.C:G-E2]R'K1H(Z>4
M%(J10$X^[0'U=5FSJL?VCUQR.*L<[LKUON_0 Y-"R:_D5LW'RJ"6%%VMG_9M
M,VKC.-I?S<[VDZNR(.]!I\UF,7H'>@3YQ/MT;CLV?"):=MY4EGLY-]1'D-1%
M26.Z=E^( 2[R&->:$F.@#+U3#PNKH@/Z@X>QKA>G,$HOK;N$;T>S+_@EBTN&
M^VYC2+2U:\U(7=7RU<G%<TLEQ5M-RH8*@'AZ>CXU8W.F6*+6:\+!LT*BQUZJ
MY\HUD6\VW'Y2HXJS_;#E ^YNNNAJ/WWP^3;>NV9IPF0J0'4;#CC:;CV K/'F
MG[D=I30D9"P5O!$AL\DA[*J /MF5$.+H*;AE+_H)!ZS\!"\0Y1"3,X200-VX
M"NLF.'';:DD?K(<<]Y]<M#:F)9T7$<?PUNONA3-$)M1[+'URQVH$L@J2[QSH
MQ!C41P"%L<QL*GI:^S<*V$>H+XF"^X4F2>H&2\MY3=-0@@'\LBWL*?K8<, Z
MTT-W$:+>5G:R)'FRK1.3V;,=E99/!<*OBJ?-A_7DT,\8[5N:D/;&(ZJ0"IV+
MQ);I.6 >*FY7K4VLX8'F-W7?X8"=27^Z[D\4+.H2Q!*[:$['FY4^N1H/W]&O
M<_CJ0;!9H[5EA[H%19WW="F<G5Z\)7(JY(!@LJ4"^GJV((!&TGF["Z7CP@O^
MH[D9>3L6)B%T2@ST8NF+Y+OQVX*X8)5$^:HT2X9H_<#D3[*-:[.:ED9B#HJP
MP4#H:UN8=?$&=Z/ 8$\$'.!79%+BI&SAIOP\K+!(N(=TF*$/CX$Q<LH2:!#7
M:3FW^4.!4GC-#.^X2(2*G0LU#31'=EIX;J)D\ZR-\3(NR?N$A5'NG7<1*_T4
M@"+D>>C@E/1;4\-*67+CSE &REH:KV.>A<FL$+GF&[&&.!>+I6 !PD$@HZF&
MB \ <.?^%9<3=,,ODL@?>_!%X@4)0V('H1)];(P3)+HJV=QX\*02_^R]:=^G
M];GC:T<,O6OGPIH$M[?OWR804$"'&')?+^X/[P(P2O>=MG2)  -:]#41@B88
M%N]74V+D^QBN8U5:KWO@ '<X0%CJ9N>,J Q6#@?,@X83E>/MH(*G-Z%F8;W1
M&8Y^T8TH@LOU)\1=<=]DCGF((IC"!6JV&,S%WXVGS;J,H%2[$*D2!!5MUS;X
M[# X>$05%M=CI<?N1Y_-:AX6'EM3%#.Y<&4-D)QQ!5$9X:>CI)C&CM#$CXU^
M :RU5AT@BN);1SB@#BEZXPT9ZFPZ/T:_(N*@C6>M*=^<MK81L30I&XGA;/1^
M-0T)J!AHJI%K\16Y@1)X>11R!]THRD X'$D&GBLNW%63._NCONDVI-^ZUTZ
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MTX] 6Q\E"UV#')4J0!71X/=,&!Y$;BBKU2"RUQGIS<K5F!?.%CNE)D+9SW#
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MTY%FV1GSDZZ)Z*KP.0PM\%YW>VJA92U,_R(+QJ@3+W9!M[=[GL:<@XZ&V/=
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ME+@YG)=47AVC@OAD3'A<"G%D'3I<]T-!"C>IKBN;/RBL7@0,AR@;?HM-A!+
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M T0&QVD+@GG-,"O&C.&GC] FHNML*YJ$BWHPH- "L+S>2"Z;[_G565?WC^M
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MC_E;9VX<@Y*Y;H%@1)NR!DCHN5/;QNZIPNDX8OE,LP&[[?NNS(C#6TX?)%)
MN-\RO58([C'G'1UJ@0@<C!#Z4TN.WU&@%\9KG@L7S<.VU^O6(.>#)Z!2I!XP
M?XL1[8\0=P6 M_27;>E)'LZY3#SY4;/+YS\Q7_/?_E'^GY'\/?HO4$L#!!0
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MCST\B^BFN>U\TSOLELSNFXYO[B.O*5#0'GE2)&9)J?(FY9=Q3$,!DWL-"._
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MRM>':K_*N:W-=X@5/T?6]][K4V7_>Z.-G**L4J').&5I#'LK.>B]QE+PT7H
MLVT2DSZ"Z:&>GUVG>E,WR3%%G:J$,@.AY^*#9Z%,20W^-*A'WFQ!S(R?+'[N
MZ&2YO+CSYGB+()=)H@:T_ [_X+ZY[.KJ>03^6]1W&]4*-S5L\]_*FVK8E#E(
M5,-PLQU!RD0/'\&BA2)+<Q4:'_W:'G.>*E^F"%;#!N1@X%5,Z/_KK_W^9SSC
M&$-=[:&Z=?1 L# 'M4?LN#7XGWBH"6,<E73A6J4O]?=;KXCGK&:J$@@7%PIU
M5\X:/'D=7G#FSLVUYR[!W ]O+9BI.//@0\A$$6VZ)J/X3)3+O*PT.<Z@@E9
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MV%G2\KL3ZG1.ROL;]EVGMMC:7M5/7=_'$*9YEG0=;]5&F=-^)E(T))>@_'<
M& E@*,YQ Y%%1J0ULXX'Z./C6U AXP@*6-;7@?6^U%?/)2/[I9J9*945O[_U
M!3/SA>/7%;V4U3V;+_Z51\$,H?#E*2B@M+/Z.,.I3295@SQCLY JB>ED >5C
MMQY"LM $^<(5I@#Z#*:-%W6$Y QC\9C1C\[X&LH-(:KF1PS5G@4$;$Z;+#YF
M@]I90&5?W\GKJV'G3?X"3X(;;F$&Y_&L?5?8H,ZA[16-WXPZ-NA# @%H6H22
M]E"-F;R&LASJ.1_/!DD6LH0@^S"?"TF##)$O&%H2Z ?KFR<;!,TF ,(2;)"$
M\70%8?'7!!NT5X$-(J_D<30_=QMD\S@0Q&'[;0C##0M<0'&8_Q(V'DJ%N;)!
M7<>Y"NDA.0R6 QLT=QG.<(8$<(P"K@_..)C,!B57!?V'!O]3C_X2Q*Z-PS=^
M^[%!#X4QM.#(ICX61@U#5=!@J3<._J?6_E.'HO2@_Q. _PG _X\"  ,NM( Y
M]^?$<6P)K&37BX4,#]I<B-*#_9?#V/MG&"[_YX;Q& !_H. ?M9PS;#+$K;%!
MU\]W+QSG*OJO1H)@"4&YV*#/Q20"I]$(-F@$[&[&!AV4B(;^L*(NLGA6H4 G
M*!CS=W<5_NWDA@Q@VKGFL+NB*(Y*C8X LS2-&8<-#[)!+XR).$#Y#1M$$=TS
MQ/R;#,#^;5 F.'<=!'-:L_RWUB#4*$"1%0L1Q,P5<)@RY0:W\=\%SO#O@N*T
M^)]:^X_]N2 '^;O(+56&>7SA1*=.DG,%G&?IXS+P44=WNSM\D? /,DN#,R7%
M_SXE .=^[E4Z18Z/'-H.385RHV#@#K H2JL5P!\HG&.#TG 2*+<FVY*_&/;4
MA=17,YTDO,2KAS3!G78K;^G!6)0^QK^PC111J6HY4C16Z>"LMU;Q<^(IU6OU
M&?D:F@OIONU&:\!N]FG$YZH_?X$<M*<U$"/MS!MH\0F&)[^AX#3C3I@4TI;>
M+F](A::@1$*IOF;OC2['#8S8Z164D?5M1C<C,2:U;VPX=/P3\V]I&:_'F6)Y
M8ND*&W12C]SRG*05%T.FPV3KWY/@/.<GX@V/ SOMYW!WJ-OY=\L+?X2W82^;
MI+MA3L\']_BWT#.,G'J>)96A+#&_F!BU"Q2,AT9T@0H3]V<94[OA>> )3D@+
M)L2X _30Q =OI+=HRMKF0CN@":T*M ?/^02XVUP.)/A.9(>W.,0GNOH;+L)J
M:?L'"OU(O__ZK#!2>7BW^>_2J9]#A_OG,+NB+=K_>_[^)1\?[F+:CY(^[6+<
M_YG2,-Q+U5DA:0B",:L1_&CTE?LNA]F@V".DLUXT(\99ZO+KL$<KF<@@4T/[
MP8']&Q]N(0U*=;NEM+(<-KVO#-0YW+S=D.607B(V<<N\J';BOJ?.19?[*>([
M3Y[8/E^><I#';:\83CP@I'; A_J/M]9 ?^WXX?P2"+""UN,TV)HE70!YI2C9
MBK;>3F].N$7)F+XP_+QC8N]E'0]-(,)L-*G^OD1@VTH>/S:/8<TQ3\K,E&"$
MI@%T3BVB2^3%'C1Q+E79I"8S)K]!NK^_<N"BB]&7PZ#,C/NJ"V]; MNE4(V!
M*)/,D5Q"HVRD]!@DH^3BZ/.<'2M$Y%F#IM_;YG$/*G-O_\4&9=D]^C[K*:EK
M0E!Z3L>._PN>?N/4G!'3)?-/O'?\.?$6PM!Z&18YVVS0.,KM,IR;#7(3,.XP
M#)OV*_5UB)S?W)_L:N8(8-HGQ(=54X2@]2]<"[1#BCBX4\CBU:<)00!.!=_1
MX(">H+\G?^L#/"?B2QOMV/:>YJ[PE:\!3LP?=Y6@G=_W/'11I>G'J^I[(@..
M#"IM8K=AX 6MI8:QEBOA2">HVB[=&2J2S/3I\T*\'OX4N/, ?K/O;5!R/8MI
M&DR:#U'&9Y>LX:8KV*#%GZ-LT'0'!\;LWHUM-E\^[;SL$%+AGK^C/?ZY2N][
M;<;^KO,K-"=T-Y1Z YX@Q>GH",4NN@7LKZ&&("VYUV4)I;FJSJT+>/]65/+W
M^]TMV\L&G9!3S^'@9W:FG2JT8W!*M<OE<(;YJ^4)TZ$QB3+UM[,K4UVU2@(9
M7.>>R;BO'QA0P8RS5#JGZ1K$KY2L.OJG14CVO&9=1DM9;UTXU3FX4'O2*2OO
MSM8L74/0[;?+<!?Y#7"N?N90B'(DPJ.@/P [C!!E#1-J.*G=,D\S[H+%ZUT?
M9X-6*K[3[F"#2O$-V_Y98_UT[>KIS#2_19@HINTZU ,CB'!$R/D6G$BW2<+'
M&6A4N72K'A_H:&RI>U.W;_-3I@+76-1"(Y27@UJJ!$__/:[^CA8T?/)"POQS
M!YK!>/T&AN#SPG%)LZ3DY^0]'2O5'S@!=!>F>C96V.X:($']G6_H@;,?LNX(
M]?T0(E%P)-.Z<=\.\\=BZ9(Q- DY76STZ/0UT_$@_+,[7Q)6IU%/3CV1J<\.
M--T9FS7F^#J\M\<[R?>-Q4F=-G" M\2<0/P$)#MQQM?$,,R%UZ"@@ 9-L3/S
MS&_+^L+ HA]M>7DG[&L;#<S.<(VJAEE!FNL<DSBXV\ &!2 @CW'\!(^V(J/3
M/^L)-/4<LF-IK@3T9#3%II$:5P!(09OSGZPIYH$P=K7KL02!X"?VM?CX&?[A
MH9O'G?6)>EH9I*L@-NAJ+5:'.RIRF8X$M]FS0>G&Q/B"/4.K,#(TL)L-<L%N
MP5,U<Q?0A]U*K]HN%*9[_$;ON>(,#15Q=EN9H=?Q!DSW!9XL,< C*@/E?/TJ
M[DG*JNW_46(W!;-@]$S_Q&0<Z&;QMM'DDER0-1_@?!7JU1>2Z&U-'MFO32AZ
M(;C$NB]=>A!#J\"-^WM4V2!^8?H-@-:!$R?<95I<>]7^;6E7L)R<;S%SN4O&
MU[P<"+50$KH*,?'07?N YZ3!_Y8A.?$8*LP=RQ3&#F?^T03RK<+4V0:&R>IY
M?9PB862CD'7DE66"S\)D@ZB7Q<Z3,X*'NR-XSJLSX\21WDIL4/;XR&?,<I=@
M8>L9B5SWY@H+UX3OV=,CQ2J!SJL5M<8+@@\Y^?X,$.!3FCD+O*"!NR1XV[YT
MEWE+GSQ]SN3>AR^^$ZZ2!>DNG8=U#;VT-K7C,',XZ%M"W+X(0^FEW-6W40;K
M(@#VUH3VF^YU:;Y*Z]6'B5+MCB_YLVQLR*V-\G_#H ]9]RS_([N'?]$  QJ@
MWV\86EEZSYO>I9SN&D,,U&M.E++N;^C]N/?3.+ZF.(NDGC_Z>MAFH6!G ;]V
M-%)_9O$H"?L(LJ]%_"V8%Z4/(/XR.'(Y5-HKC@'U?]!\X8;YE .S[*E@RH;F
MEM*BX3.Y@7S>@^1WU:D2L=?FH\^"@O=81D>=!W7>_F^EBM@F@)(7X1'C5Y<
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M_W=#*L#_!T0=0!.__3^'+!TVXPRJ! .R,,91C%E[\O6_:T,*L/4/,LM=\K_
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MI2[G0+JM_M&JGRQN\*9;M7SM +4<]7/F'X(\:X%3O_>WD&X?.B5QXXJ@\IX
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M4R.R7 Z%WO!B2D;$BY//O36%76-]-]H=:)QD?$%]AE)<H-)(&>IG2 .,(:)
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MWUR@T$(UK@[Q+/E='8TN_SH[LM&R5LU)M6PHNK$XCZ"9>/+ZZCMRZQ8V"=V
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MVYQ8^74&KKHV]'2B5B]H>H7DT/>[ZR2>0J!A.JASJ50.!9>A[B0C=8F5;)
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M'2B=\&B^]./VGP_K(!).1DK4>!_#9%>YL1@UY"2Z@0_>3UQ.DP.1@@U$16T
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M> ,H["G^<-^LP6R%=5@II,?T'-U7_;*/O;KZ10UHQGYH1 TRRT9Q*BN>^70
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MKKFT%2/^X@U4(K--< 412T4R:<#KK[FRS8%(N8$+/H:^2IGTA4W(6!@*>=V
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MM<511:OQ:B.Q"[C\>/[Y]_EJ*$$_?EKS@5I4Z<=0)^VJ^TW77U!+ P04
M" !T2F=7D%P(KG@%  #\'0  #0   &5X7S4V-C0W.2YH=&WM66USVC@0_MS\
MBCTZ39,9#!@20FS"#'%,RET+%,A-[].-L.58=[;DVB*!^_6WDB$!\M*Y7D)?
M)IED&$MK[:/5/L]J0S.4<=1JAI3XK9U73<ED1%MT]N=AO7YP=%S"V68Y'\39
M7PP#SBFG*9'4A\D<QN&4^S0]$S&%@4@EB<  LU*N'I6KE6H-:I9Y8%4;,/@
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M(*SI U]K]T>#S!1Z*!*,,Y4Q3#TK9]LZK"DL=@,(1.,W3Q0LF9J5M%F=!H6
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M[NZ6%+6VO:J) ZK.'N-[E,VQ0H?HFO5('3=]!<J\62WN:%I#5NWO@P4$OYN
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M^J=VR?# T5RGOEN1%1+=#SG1O4:$^3=?^?X2<W'A&FDZ.ZDN'$Y74B<E>W1
MFW=,U#2.RR4'1RL3.2\:M@^.YJS8"8SROY[>&__CZV?*BCE_]B5%63[-KOE2
M.Y,+\!3G,2/21R[<*M/99LNK>;WM!QJ.3V$%;RA2IBJU&.'P..L^X<# X70V
M(S'6'A0P->N=QK5=]PG3.4/+>Q*C5#G?QK;CH-:Y'&S1VRXM"G5D;-MZ+\R+
M):NH%9]V*.5_?;W]YSY-S[]UF^B,BVNQPP@4R['4'F6&5B&=**03*9V2@X81
MM(S = "U4LB^\=<2<M$.<,WHTF.Z@JK>A,S:O$(*!4Y>!4X&$WT?PN,=+0$@
M//)*RLU:FBIPEG?BVWYG:B6+_J0NA)"M]9H*(=N>0[8Z.VAD@5H[?^?(PK10
M[^E P1GE/<+MHC2VP[H.US2C+\1M#CENT]K/<HJ7#,=$YA4HO"QU38+O*OBN
MO/1=!>0<D//A(6>U"AX(@M7=6=L.?5F,Z!IX69,6,%? 7+KRASMWOTUG^\<(
M%'@!UBG@LH#+ BX+N"S@,C=I^Q9*>2"DUOQNRG9XKO/GND9]/3$0L.$A8T-%
MRO*D*.[Q K&_<'%"%PN:574R9C/,E'F7MOTZ(/-,ROAV>/1(%N6BMG0JM'GG
M1#T+N? I(7G^TG-IW:\#,G<JG^1?<'&#BR(5IUQNN&[(9RBNMHC;>WSVR$DA
M.;YB1%'6M;/Q.F"+/^#=VZ-?JLF\R,0<D@<L#F>I28?VZ8J\=^^N\9SD!68X
M.24,QX5Y95EU=&L=CJ(X_HXZND)LRB1>2OY :8DWAQ(5M%OT=,H1Z)Z^+S1[
MP+DXJ"?>0'Y+"Y3N_B[NZOM"BW^)2/?F%K^GD:I.4Z[3V>T]RM:K6S%/@]-S
M(+._HT>=SW3-LYW.*E]0,\H6XO2XY$I_?X6AM5O*UR6C=!6H:YH,0J.^!O/P
M95@;T#ET6>@8XR07Q]XO\KP4 EFAMO6^H6(!VF\P;G85P@:W[9^DM.[GUH>*
MY%6^@AXA+1R!,L0UH(2C^@*]X(Z'PL^PY8.;5MC8U%6I=H!)6=Q3)O8RU33T
M]9QQS-9Z37[B#8O\(JM*DGQB-%>&0OI[TJAF;%H6HJJ-.!:Q5_OBF3W;TRQ:
M/MVOF?6[:'J8L[$5FF_,4*U*ZF,U=T^!^QF^,VNKNWWVSAZ7A,G&%6>Z^>MR
M_'',CE&7;ZLHG="L8!R:E2@5M93>=3V/[2EQ/^.YL) X&V)5&#QVQO8AZ\1]
MUDD/=')3IGK)IR7;UM>K7OX7_$W^I)YKF\[^\&5CD#<?R"V_Y5V._UUR63I[
MX/]H/7[:MD-2;8A_&%H/3;D>0)K:CY/Z83$LIXHD!+'5CEO&(#_:]B'?+US+
M,]RTF-0;M=8F/G)9&[^AL,B)C_R8E0IM[@X?7;:NI:KUIAY&@Q=$F^>4>)6R
MW),@^U#<I9\7;I^>-[J2-OJ=VM.EZ^C2*E"^A)<K/%QY-IST=)S=.;K"1%8V
MO'^ZQ8BWU2R.1CUT87\<R,U'YF0S[T34H'KLLK.]E$\[R[&5)'9T44PX_AB.
M/Q[>\<<F41^W>*7;&ZO,,5"W^UN7ER[99,ZZU9W=E+,#'U8#,N?+O5D-S[H!
MN?3MUJQ!$O^ <^7;95N#I[, Y^T7S^9M@.- P)GZ^-W,E-41-2AZ<N@E: ^?
M  DE4+Y]@XV6)UN@;'H)&?M,]8=.C&]H<[!\7^B$^0)<>T[PA4Z'+U"W]<*"
MG3F"3HMOV-CZ8/T3HTXK$OT2D8PWPE&!'G';LI&PP5S7#K*A*A0$,CL"QUL0
MJ'5JXX44I%OT>%95ESK&&9?9_7H\P-8A43^4A]SN&SZEBX;X2(B/'%Y\!*2-
M!T)A'T7MP@4II+W5$H2!QG*-P2R("A#LD"&8JB9CF1<DN\6/J+XJDKY1!P14
MET/>+)&N#*"R47MH%.[=#O=N-P;+X@*WZ>SI7L_-G9X*V&QJ[I1V>4/;7NA*
M<UC,U'QPVK4']LP=QDK_H"<.IUQ\$=\:YFOZ<I5%KFXX(+UKIZA*XO6-@Q,A
M.!&\=")\W_?6@[<K:K\YC,X99+=W>Y?"#7@O%&8@>.7TZE9$?3A/%"Z--UP:
M#S"BO1+1<(=\<*D'E[J_+G68(\'M2NN,.9.M"&3+MWPOB#DY4!3DZ*TPX=Y&
MO..]R-FH#L-%=S3CQ"]3E+6,C#0>WW6TI"6A(8+R'4903KBL' L!V9XBY1^8
M%"J.E^31FA>.;-M^'9&Y?9)\KDP&5%&F:=H?,6>/,B-Z?2S)@K3ZCKT0JK_T
M"=*^ [(VN\<Y92^?6$<7J$,7A&T/78F,2YF1^IFD."]HAK<"+U_937GW)XZ+
M6SI9+AE]X"*?)9/D3VXD[6+$9SQT/'8W[&YJG\CWS/<D+G^;!-M3M,I?DOJ9
MDW&,)_$]P0\XX91]1N)B;0X=:A=C3X_HGOF79*COS+/LVGL$<JTXZM>UZO?^
MJ:K>M9JJNM][I^I:Y)<KHK,O?G-#C7*&:G[UAZ)!(W>35#YH]Y#9[C&"=:K6
M%UQ,9[?H417/;C2(4S[##5J#TCEL/=P0->V'SE!;>VC*0VWMD"G@(%/@)9ZC
M!F#E$P?0M1P*28\VL^%P"M+!/4=>A1N;2=\!)2TH3%YOQ$^EK:G1A^"5G$%W
M(Q\DJ\7;4/N91I<V886DO5DN<" 0*MP>4H7;D.1CO>9"DD^/M0SMH\,CR_9I
M'@<:6?Y/_U$\X(3X4L^IQV N<"9\*>74-*4!R*8OI9G@225 QGRK,=HF#@9D
MV9?RH+;9)$-E-!Y% I@0;FEEO%/;T@[0X9SG*UK1%=(3O\/T1*F2[FG*M<@I
M9N0!B84ZD5?KY*<X15P)XQ-:LOHP7ILA>B:^&;U.292'?5I,KJJ_"[+E-M"6
M=M4@'3#P!Z$IJBITS\XQIP"E-S@N&5>R.+]$WS3R8=FU]XRA2_[@>54%FD,'
M16J5NI%C^I0!7$C3,= Z:,[*)<WSD^V6OOJ"OYVDB"SR<VX<K2NW[K'2H&?(
MP@FU"Y3.PD$=\\:,!(T:I#8J:'01;\@>X$T4!?0>:)OMV"MW?#O!'$'($OPN
M;:&W-T[KSKC48W9O?-?=\JO'^=[XISMCVFCUCBZ5)<0_K7?+$/_LUZMN;= ,
MY&O^.1)AN6Q.^,1'O#,N\@@M*"O(WU+/1+CR_T<SRB))$$ZY*DEJNJW=MY;>
MZ?X(<.W/[IN3X $_9 ]X:]/_7$K4I9"HBZU 3:0\37:D<!O/>RQNO^'T 7_F
M6NI>Y=;H9E"/YZ&Z!S$1B0SG)(]1^B^,5$ZJ#D?V>$8$F;??:"=SL#>6+UQ_
MP:I2K[!.P0497)!>NB"#+15LJ<.SI3K?=[UQW/4Y#WHPYHTOK\\IJ(4?WCCT
M.N/\!3(9R)?P(<K%S965VS&/L+S1/D)94GTOKS85-_IL<PNW%K'\/:+R:EC9
M8?F4<AP)9V42H;@@#V*\9FZ&06AS[8$8D,G@G C."5W%'B%"AJH5M6W<UHAY
M$OKJ?F%M=1!#:[=&5^/[E&E6W<A])I7%19;S;4[F1[^XRGW?A'/PR+'/X3EE
M,TR*D@N'NUFL>>C8YU'>%N]2$O<>./;YFY8%API90K*Y-@W/Y:/',:<55[MK
MZB+CBI_0SH71_*11S9A<05L6/C&:=ZX"S4\:U8SUODA-S_%KMG(5&T\X,4M
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MI=G^U)MO*9J=%, >5=YF=S7-?3N VX/3RNR/7W\O_A%IC/R;_P]02P,$%
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MN[._'M_ZM0![;"&2N?H[W-1%8*V'6K>+EJFU<CSTJ"*#ZRN*(R4 $F6Q.!O
M)MZ51':=L?1FX^ILI10:8LP[BZ[K51QO-U%^\%J9>N!4=[4%Z-U1;3%/\NDF
MT#_9.0T^ QO^*&G0!W9$#R5[R 65,,O;9O5Q6^1I18^SQWGR,7UF?QN_\U-_
M -RNY(!=:W*+F6>"-;C#WO9IL)F8\\Y?Y4*2I$R'H^R:=U8^B39I%642F5*,
MAM8V#$-U+4T=6L3ZHBS3',4"<YAJ @5OB2'#O(G0AVV:L5ND46LT/ @H,+O
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MU)U/C 1.\RMP?[!1Z.X[9M;H9RQYN@M @%QUO/<=O;V_2ZML;-_;'S)ASVM
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M]HIMCV)^H=6G>;>&H2,;=72'"ZTYEP?B:Y%=E7L2]M3U(\GEKP/)AD */O=
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M_T9_V/R(_N^>FA_ZD_\'4$L#!!0    ( '1*9U?7[O^-(S$  /AG!  5
M<V%V82TR,#(S,#DS,%]P<F4N>&UL[7U;<]PVMN[[J=K_P<?GF;%EQXD]-=F[
M6C>7ZLAJ'4G)GMDO*8I$MY"PB0XOLI1??P"P;U(3P (O (G&PV1D"0 _?+BM
M&Q;^^5]/B^3-(\IR3-)?WA[]\/[M&Y1&),;I_)>WO]X&D]N3BXNW;_(B3.,P
M(2GZY6U*WO[7?_['__KG_PZ"KRA%65B@^,W]\YN[AS*-479*%NC-OXYO+M\$
M;XZ._O'QY^MO;WZ].WGSX?V'C\'14?#^IR#XSW\F./WS'^P_]V&.WE 0:<[_
M^<O;AZ)8_N/=N^_?O__P=)\E/Y!L_N[#^_<?WZU+OUT59W^-BTV%W<*?WE5_
MW!3=:_K[1U[VZ,N7+^_X7S=%<UQ7D#9Z].Y?WRYOHP>T" .<,D8BAB7'_\CY
M+R])%!:<1F47W@A+L'\%ZV(!^U5P]"'X>/3#4QZ_I:R_>5-1EY$$W:#9&_;_
MO]Y<O/AF%.9Y^!CF$:9#B?(?(K)XQ]A__^7C^W>LPCL*OD +E!9!2@H4? R6
M&5J&. [0TQ*E.<H#.MP!*1Y0%D1EEK&2M%%4Y+3#_/L/&9K]\I9])E@WS2#^
MG_8M%\]+.LERO%@FZ.V[G2[3EG):G'-\27^Q*L\Z9+S[%4CT5" ZY5<#L\:9
MD.@%20Q:OIZ@.8I^F)/'=S'"'!3[@3/(V:/_^/TL+7#Q3%=1B-/UYY+P'B6_
MO!7]N4*3L/E'LA5G':&Y1/,PJ;XY><)Y#2!!"1U,-=.(_N;W*SHX^1TYQRE=
M:CA,;M?#ED_N\R(+H^(5',U:'4"\KB;.V6K>3-)XRF;-235I)GS.W-%I<DRB
M/^O -JG?>+1G87[/=YHR#^9AN*R&'"5%OO[-=NQ7O_C]%.=10O(R0QP&;?]/
M ?D:-<;;@^"#E3YLYC#=]] %_?'U0E07M(/W+KQ/D KKBT(RG+LGP"2+WI",
MRAN_O*4R"_W+#-$U$U]6WQ">KWS_YT#H![F,\ \VUBC^Y6V1E1L481;MG2LO
M&UJ5>+<,^?$0/> D7M>>962AOQL1&#7TPSW14E Q$%T:X08P7TFC!=D?.V8F
MC>Q$)2H)8.R=5TQ_ A XP!0<C94"Z%;ORF2 R!.DM3BU9>N?[VJUC1YTKYA$
M)?^!:1N(3VBJ6,Y(MN!?A:M:P(:,:E9:F'I1I";T\S&#<)Z$\QK%I?;O/:I2
M)VS#RE!X0N+7(I'HSWVBJ=;$.5U=8?)O%&9G:7Q*!Z\.F:)HCRA/5[.H^O8U
MRC")S^GOZA1195EC.!E',)1[)0U@O-BN0I$Z 2UN%FV=,@$I:@!E-=O$2TA:
MS@"^_U>&&17OD^<;M"39:\474-( QKLL3'/,1D\)4E34!$KZ"1FRG3_WB&8E
M_L8Q/;GSU?^QU7DDM!A*RIK"R4ZX:79'OHOMFL*2IC!>$RK")/^#EX)36EW8
M%%(N_T^SZXP\XLH3(<4J*-X[VA.Z*+(PN:#BW=/_1<]"F()R_>,CBP5);PNJ
M$=P^4&4DGY8%]W;AM$YHA%?J'WDEEE4[(/TP&^%:D0-2O'>T0W%H5)\[6Z!L
M3DGXFI'OQ0,=SF68BN>FM'3O6,]Q@J[*Q3W*A #WBQA!E9W0/65.,C%SM:5Z
MQW:11B2CTYR+@GSC.R$EW5Z>I9LZJ)8![%3Z"J,"/R(J(X:K52L!+2O>.]H;
M-,?,%I,65^%"3&U]L=[1W3Z@)%$M[KI"_2-;A$ER7.94#,O%6W9MJ=ZQW85/
M%S&SV,QP%="@V'P4Y<?NG-;%1)CQX8&DXCU;5*1'5+<H*C-*PM&'^SM<U&K1
MHB(&4)T]10]A.D>"/416K$=T5,ED\MSM\^*>)#6P:O_NCOM2MGR<]T2!S$J'
MX(_2(0)N,71T>NSWEH!57$<GBH(2F6 (9N2#&XQ(_%%@*CZZ007,XP1FY4<W
M6 $ZN,"T?'*1%H%'#4S*3VZ1LN^/ #/QLUM,2!U;8%(^NT6*Q!\)IN2+6Y3(
M?8MP,<TIT55D8(;3X938JF$JAC/DB!BK812$<^.(7 MTQ<-Y<42R!3G_X:PX
M(MC"_?=P:AP1;Z%A&'!B')%VQ5&D<"H<D7'E;A8X'8[(MW+_#MS8YHA<*_'>
MP+EP1*A5.]C@E#@EQ4)BIN#4."7$0@)/X-0X)<=*@I[@C#@EPTH"6>",."6Z
M D(*X<PX(KN>*>*QX(0X(L&>:08;V[C$&)$T9I<M8_933A(<LWQ P7V8L/PX
M0?Z 4)%OLJ@LN;TY*-.PC#$K5Y'U@ I,A76-[#*]?-;H!<D>>^#STO00^M<D
M#\;.TKT.LVG&C3CQ;V%2HFN4\=7\"GF#FK9Z5&U&D[)X(!G^&\7JGHAJV.W!
M19Z7</0O2]M%+KZJHE/%:!^NU\=RDT6A5]EBOX!+ U;)>C^D"T1=P3I^]3(!
MUO(YGR!XI[--MJ-K4GG2%0FW=*KZ/%;64]) 1LEZ,BL?)&]^8AQ>>+Q/U]0L
MHUL32<ZYN:+!D%PVA!O&7&6F3N($LS)0OTQ[5@"&PG%&SNM1HVU+ =,S4"=-
M8WHZVF8&ZJEI24NK/6:@+IJ6E S*$\%SN1\%<_XF0<+S#B;XKQ+'5/*$.Q8@
MK9A/40\"Y,W^W9C]1Y".OK5EP^=U'T)>]VDV#U/\-]\O3C9>0'9RI/'USEZR
M8W'9SI^:[@@ZWM=GO#W4VP[E\H7/@>]SX'NCJC>J>J.JB1SX9LY[:[K=AR#'
M\Y3?*&1YY:.(W;FDJF>PI!VDK>@^3@9NS[R^IPG-:WY>\X/*I9/O81:SM! U
M-$K+&$5Y7-+-D$[XB\4R(X\5;=]034(]> 4K^$&8+>+T=H AV '.Z,E"GA'B
MIM7IDATGTHFC+&\4/=WA<($N\2.*+^AAF,XQ%=>JQW:.G[^%?Y#L)*$'H&2_
M:=#"4'JX1<=NS=6>EBU;,=K32Q2RAY.BOTJ<,9C721@AZ5P$U# < 4B6*"N>
M*8ZTH +O&06V9,?!\;/BU-.H.8P>,532&:=1TVB/;A#=;G%4K+S5TODE+6O6
MHL=\7L=TML?L>A)*\Y46F;$[LUS@.'[>EKD.G]GON"BUE:>H D;'0KE5]/DI
MLYQMU9C)1HNY7BDQ*KNU7F5OC?;6:&^-]M9H;XWN?E;HB$:DA?SA"E_U!A1B
M\H!WA<HFNB'I2.ERA4.U)T5B\7/%G:1<DT"KBBO1UDH^ )J7*W-#O4"TC0.N
M4-/PZ)?9MEU902VI4;DJ7*%)O;@:VW]=660MA1RP#=:Y.S$]1L>,Y>Z+CX[1
MBXYI8E6T%O/R8Y"A, F6JY-&,\)%4-M\/(L4B(]>.?#HE3PK=FS8]%];\N@_
M?O]&LF(>SM$E"=-\FM[0F73&Y]<IRJ,,<T6-R5O3V5H@J^&X?4/V^LG,$VM$
M0I]?BQ9Z[]ET1O=;)(V)417K'>,MFK/I_161>18N'UA:-2'/RK+]HUTOQUT,
M@FFO+-MZX\N+95:A93_M(*7_^OWN7Z\QO?SM>*.%QM\#2_%.VXUI^CU%L<H/
MK"KN/;_>\^L]O][SZSV_':X8D.! M.0A%SAIJ4.0#@3UL=.HMF!UI:R-W3S<
MW813JU9CYPHVJX"ZT-C)@._>=;J8^XZG[KP$HW64>"^!U$L TSFM^04^;6SI
M/",06GN>-1T$JF;,>PI@B+S+X,!=!M[D-S*3GS!6!I[&J$D3WC3H38/>-.A-
M@]XT.$[U:J#ZM5>O6JI7S<]R:RK73P'>A&8&(8_-U-2V)"V85[248+R.Y74L
MKV.-2<=Z'3H.5ZTT:GJ-RFM47J/R&I77J+Q&Y36JX6A4VD>X-47JYR!G]XD?
M2$*'(><NGI6WA__^/JP>Q=ZF10C0$_MYPS)0W6K]'?-*64>0O>K6J^HV*8H'
MM BS/U&Q\R3.=$:W$N'U!MUZCFF8 H@[J1;R*U3<HJ)(V 766SJY\QG]%L]2
M??> SIY0%N$<76=8D(^PL_8ZZ!;]P(?W1Y_/^/*]H$N?SL)'Q&Q=8NC0.EW!
M^_#A!LUQ3F5?%)_B#$6%>@)K5?19C;V99)!FDFN4S4BVH-L;JIXQD^:?5)0V
MBWR5[TF6Q+2FB!6,\L2D \A,&29H.N,'!D-"3X4LI$(5/R+DN3G!%7UVTJ%G
M)V4@5\)V=?!27'O(U7E*&S;C3:GF3:G=XRSO<ZJG40QGC_0_TK-$6M8F:H7D
MI"AM&[E\LU*5-XX>QSC,GG>.$07STO+>;>#=!MYM<-AN Y]MMKL%ICCIB/;!
MX@HSM8HE@:ETKG"@/HU)<SW1&9+4'CR84..,2Q,R:YK:5YVYJPDF2=^+XLQ$
M4JXLG\8;:+!U9=D(V>C8'>8*7[##26GK<&4Q-1=W#S.[L-K+XLK,$(G[#7S5
M8$I&FW&YN^B\3V.EP$?GR9-.MW(160O5^QS@E!9"01$^:;^O7E_9?%"=#(>/
ME/.7G'STSIBB=R[X6KX+GW1N-ZFK>%^\O];D_9/>/^G]D^-4G :N3GO%J?&U
M)NC9;4U)^L)NY"QPP8\!31VIMJYY%4D"PVM(_=XE*O,"IW1*A_5AZ/)"CJEH
M HA5\N+;Y=ZC=KN(A(7:2\K^Y9C.7XYIHH6<;+<HN.X'JS1>+7S\/;!D1^!O
M9IZ0E&,HP^0.90M)(*ZJN'7LTB!H=05O__#V#V__\/8/;__H<,7X-W2$*T5Y
MGKY^WAIP>KG"C=I8!)-&7#&>0>8*1 =TA0__Q(W6Y@JPH+@?WNA?O/&6=KFE
M7<=28LW6?O2>:6?O UKQ@87U5)&'P3U):3>62;B1"(#V=W![YFWRFM"\G;Y7
M._T)'85-I.LQ&P-Y.B=(^=Y@B8RB.E4<<RTTLI5_"Y_PHEP('ZRO_7O_J' J
M1U7W]]Y1W;"[Q (_PM[?S* 1,E3SU_':S\?? UMYP'PV+6_1]]F%?'8A6]F%
MQJ56>O^/]_]X_X^NB7)?]"4*&73LO6Y_M]BGTCF 5#K^CK7\CC7<@.0*'7*W
MEL"&,/;.2\\(B25G[!XK>;_%=K6Q]UO#3>43D?A$)/V[<T>;=,.[<VO=N?H^
M'GO.W*,@(A0B/0526DGW[I2HN@57K12)]\P>3(X)T3-'V^POIRC#CR%;EA.>
M?BT_14GXG?[YA)19O7VW31,]@V^&URA$'O/5@EQ1?1.P^:1LBUW42 <=^ V3
MA.^F^71VCB@"NHY05&:XH)O@9?A=,C\TJ_;N,+ZD'YYS0/3L%/FQQ84,XQ/Z
M)2!%Q^LH'G\/;%UV(WE^LI%0GK< A=?=E!6\>]E?&/,.0^\P] [#;HVB$AF#
MZ)SO8^<"YA50261CMX\"9D1C:7KLIG0@-[J:Z-B-QQW0(M=YQVY:[HH@N6(-
M9FF@*9\[8$EIEQK[[FS23S/03=C[:5I>NX-JVEUX:5Y8\U$45_1<I#FFQ-YE
M84Q![+X*]](A4^L38*U4"G$4;_5@=9.MG#1-^]':'U/?6_J/W_<^+K)4P JW
M]M6(D7XK,GZ#/F<ODL7TXZ+;8K#"/2*](NE-F:"C]_>?CNBG)S%9%B@^3\)Y
M#5)QX0YL;MI8[[)%6@"A;LL:00JGU":?8#+;,#FN P:X<Q"]E=N?#&;0G*9'
M#7!>]R>:#989^";:GY8\6')@.TU_VO%@B0&?9S8BC7(\3_$,1R'].8PB4G)1
M.UB2!+-0G<T/+V5=6?"1;HM&XY&:@?,A2KV&*.T,3^.!V@V>Z*(]H_[0R0;0
M]0J&PH6NKF V]7"8/TS2F/T?>[WK,4R86LFA/2LS$.O4-9U0>?,8_ U*Z$R*
M3T@.[I=>;:,].PNSE,Z=_!IEW$ )ZQ&PEM&>G(<X^RU,2O0-A<PJQ-9ZA0O6
M)^WZ=GHWG6TB!*C<0<69Q7:1J'H&J6NT5U_)(\I2AF*2YYANT?34AHV61DVC
M/=J\P@'KAJJX8>R4QCF^3Q#E%!4YG2RX0)?X$<72^06N9SCU-P6#>$9,X#X-
MJ&$VI<E+# I!0%%Z?,AM);O)R!)EQ3.[!U)0<82)(LOM8:":1+K5C?;MAJI1
M5+5D4M8I>D0)X<C.GIAX@J1K7*.FV?C!*AGT#5J2;",$ T]\K;IF>[5Y[W97
M=JS>IZ<C\.(A:?G9WZ(E'[?J0%JD7W,J]9WE!5Y0*").ZPNYXP_HSA3@(V]%
MD;? 0WSLL0L''75K,HIGM(%,AQ;%H]([B+ZMTA5J /TEL%/8E66CQT@#@[ K
M48)Z1#6T78X]@+L960W4OK$'<C<C2MO&.O9([H;SJ:V*#:;M)Y=HT_(A@2GZ
MV26*&CANP$1]=HDH;>LDF*8O+M'4R!$-%SV=DL;!SB X/T[)YLW\''"RG)+/
M-3VD<):<$LQASG ;H9$\=]D'I;FX8+8@W>1LNLV:3]K6#*&/E#0>*=EHM%3A
MDBVF@"E?7/2 XC)AUK-7.@75RG#$A$*<E%38X;9:I5>X76O>:^J UQ0T408P
M_@UPNGC?J^.]RSMY14Y>^50:N]O&^W:];]?[=G>9$!QQI&-IR9I*]S&@7UJ&
M. Y092O,@S"- U(\H"R(RHSS$W*5O9ERU_P#YM6\MEB]PF='X6L^;B#5K^VT
M,"0*GZYV46[0/@F7N @3_#>*KROP=".:,L25_4WR;/LKX;FK9KU:Z-7"(>,\
M/+6PQ;[F%42O('H%T2N(7D%4*XC="E#6-,4?@PR%"3TR*J]W,VU0WHAYC0^"
MQVMU=K0Z^=B -#?(\!IWT?'5?D52ABED9OC*Z[^*U=+TT#5IS&MB7A,;,L[#
MT\04^Y37MKRVY;4MKVUY;4O''==<-+*F8WW:'@',$H?6$<7-E"U@:^:U+BU@
M7OVRHWX!!PFDAVD-N.TL1XWS&WE%RRM:7M$:M*(%W8B\QN4U+J]Q>8W+:UQJ
MC4M7'K*F7?T4X,TMQ%8QC>J&S.M44$Q>G;*C3JG'!Z1)08?9N%=KYT+OZ[N^
MFBXM[9:L])C(<)Z719FAR8*EU_F;K_4FWKTN/^%54:^*#AGGX:FB@)W<:Z%>
M"_5:J-="O1:JX_=K*#^Z,FG@5'4O7UI3[7^FIRM%4STNGW.[[LK$RW]_SW(3
M!M%.\J_UE8=F!H"N/F?>3- M<F],L&-,Z&H402:';J>,<</$&5U<Y!FA6Y0]
MX@C5YRJ=)!P7RUHZNT$1F:<\0A]EF%1Q^QHY<_KYGB7V!/"C C_26:!IV6G2
MF#=<>,/%D'$>GN&BL_/ FS>\><.;-[QYPYLW=,P;S84H5^:-5DZF/J5Q:^:.
MHV".4I2%"3]V$TR/X)@=PC$J0ISD04'QEF&B:=70;-6\\:(10&^CZ-5&<44'
MYHYL'F?8[-BGU9C<O1R278.#7DVC>L -@Y"B>)W1;1)%Y:+DSP6<HAF.L.@A
M7W7%(+7SJ*]7;4<H'S19)]:U*J]$#$""]DK$ )2(P=H7&AQ3UF1==?+J=E)O
MX_:'^ R%EX2])-RI&#:A3,4L?S%^I#IT5&:XH//L["E*2CJ3SNG>PQ3ILEAI
MSZ]3($\6;(H*I+=.VH;9W[OGY7N8Q7?TBS733%K&*,KCDAX4[.;[8IF11SZG
M\F]H<8\R 61U!2OX09@MXMQ8F9@#I'KW4@I96=XH>G$4T*\YFI7))9Z)%#!(
M54LK5!+;=/S\+?R#9"<)/8 EZ[=!"T/IX1;=5;A M:=SRU:,]K3N'5[IT2*N
M8&DV5L\H3J*_2IPQHJ^3,$+2/0)0PV@/KDKVZ>ELNDZGLGI%6K1ZA.4MC< &
M!R?VOQ&>/U!U9T+G23BGV@J;V^L_WJ%L<23HEFXSEGHKO)1Y_*R06C1J#J-'
M#)5TA].H.8P>*8]=0$U+\^X&Y46&([HDN&PCW>&D9<T:F^O=@EE&CT-4S?UM
MD>OPF1\L3+KG__F-]H,]\,G]A:)]H\M/6!I;91=R:1_X[I'&;,XJA9(^/^7=
M+M[MXMTNWNW2W,BN(R*!$F4(Y!!7^*HWA!&3V[TK5#:Q29".E'U7.%2[#"66
M6U?\ILHU";11@OGX,'(^ -J**W-#O4"TC02N4-/PZ)?Y*%Q902VI4;F<7*%)
MO;@:^QU<660MA1RPY1S,U\=A\V4B#.S'L5+@P\"$86!@%TU_&\M@N8%[$/L[
MF 9+3I_&[/XVY<'2V4L@5'\[^V!Y;. 6 [/TR1F6VGJPP93]Y QE3<*<K 5,
MOWY,K%UX-+ U\\'06L!\Z//!A3X+H-)#,V+S<8ZFLY/JC?/DF6]V<1T^2?%F
M7G@ K&D4E4O*Q[,*T*9@EP$!>5;L.(KIO[;3C/[C]V\D*^;TZY<D3/-I>D/7
MX!E?F:<HCS+,[<3,W#.=K4_CFMG8OB%[_63>D34B8>A1BQ9Z[]ET-L,1DH96
MJXKUCG&EB'Y%9)Z%RP<<A8F09V79_M&N=ZU=#()IKRS;^HC(BV56H64_[2"E
M__K][E^O,;W\K=F04E3<L+V,"5/T,'^%3%#*5O"3#^3ITB;F WE\((_%>0':
MB(G6^>(")RUE,M*!X#-V&M4.B:Z$W[%[^[J;<&I1=>Q<P6854+8<.QGPW;M.
MMG4_CJ [I^]H_=[>Z2MV^LK5J0-R]>H:^ [(T0LW-5IS<PB?\FWG[]!MUKSC
MHQE"[P$Y. ](:QO2*:*3F()B4UA@0=HMXBUSWC+G+7/>,C<6[6:@ZJW7;EIH
M-[+SR)JH6O?49SLI5:-%\P*J-C@OFWK95#L!W\[+A-/9ZVLB JE*7LG+KUY^
M]?*KEU^]_.KE5UORJ]X)94VB;?X&7#NYM_/OFI>.>^J"EZ%[E:$G1?& %F'V
M)RI.R&)!TBHMQHSN.<(@6MUZ'< \X[-ITWSXA!?EHC93JJIXI]'M+[_SPN5&
M2<%YOF]@!M?K%.@0524!U)V\+/D5*FY1423L>M(MW33R61A5)\C= SI[HKSA
M'%UG6)!RMK/V.N@6_<"']T>?JY&_2-F XT?$;O2)H4/K= 7OPX<;-,<Y%2)0
M?(HS%!7JC4"KHEE->A2I['=VS^LPFV9\@<6_A4F)UO=@!=@!-2UI_J#'":](
M^HAR=D.3C4%^1XHPV?T[>Z"0;C[_9F$=ZZ<+MRU5E:;T$,KN'L)TM;X%3%G#
MXQS_.WNI<:YWOFTK^33*9B1;L)0)O%_R-R<4I<TB7Z40E.7'KBEB!:,\Y[7]
MU+?7&8D0BG.6O^ BSTLVP)7@MMJ-1=!5]>RE5-_@VEUD:WGH]?U1<#U;=N>0
M/R?,$+&90F6[+*3["A?TY,F9P16'E9Y:E)1DG0:GVGTF9?% ,K:3BKK?]7>&
MFLY;U(_5_/U*"Q;Y15KE<?F:D5SHN.C^2R/E;%H6+)40NZ;P*O'&"ZVJ)QZ!
M7Q\JMSZ]?(><U2ZM/N9D=PALSLM[]:J[?]W!LZ<ESGCAJF\R!KMH?VS\*'>E
M33*B$Y(6&14PRC!A*8D^=,UD<R0V.<^9=$P[PM:&P@8B+.]C'FS&//2 DPKE
MU3"?EMDFR5XU_%?H._^3F&M(96LS1@).1QW3;\A6C\O['/U5TOET]DC_([6A
M2,O:1*VP*RM*VT8N%R)5Y8VCQS$.L^<=]5S!O+2\C]7RL5J'$:OEGZ?I+LA)
ML9\3[>W3%69JW08$9K!WA0/UF4.:6YF=(4D=-@D[NIV)(X7,FJ8Q%LYD P&3
MI!^1YLQ$4JXL_^X7T!WORK(1LM%Q2)PK?,$.)Z5&[\IB:B[N'N9S1.H8&E=F
MADC<;Q"O"J9DM$\T=7<E2ON5CJ%0 /5W'."5J&9NB0/*8Z;MY#N@1&:-@PK[
M.XP'QY'N5:#^#J0Q4 .[A=3?B34XCBQ'IX&9=N<YJ@'$N8!9_]D9UJW<V #S
M_-GSW/4M)##W7YSAOGUP#%SN=D=#T;[A 2?),>VDWTL <%K=46PLQE_#Z1Z_
MCM1[L#:<S/%K5<9N4L%)=4<-:W#=?4N3X31"GP.<TD(H*,(GU#8G)JPQ\PE_
M='#Y+#X^$Z9NY.\%GUUWX=-9E2?J&*5HAE_G^U&4]O= ?.Y+'T_MXZG'XN@=
MN/O?.WH;2*[ H\F:M/J%I65<X()KU2V%55!;YF55#5A>5.TWX629%SBEQVA8
MGSU)7LA165D M7K_\W89RO(;"@NU%R#]8_:=/V;?*)%AAL+I;/N&[/K)6(&8
M+BIN217B;PZ^<KM*[F^JBEO'+KT[JZY@%/^4#CP]3-/Y"E<NTI[W"UJ:+2^!
MK&RCHKE27]BK_%[E]RJ_5_E;S0OP4]QPV6;LG(!/:*)_'KK"C=H^ I-O7+$7
M0>8*1(MQA0_Q_-!0.\9.!GQS!=@"^HOY'\K,Z,ZX//K[==ZXO$<)5-L_P'M#
M:J7V "\,P71F:[Z(H_=,4WT?T(H/++X$\2NDP3U):0>629BV]$\T;M^\SZ(E
M5._'Z-6/<4)'Y9@-Q>:>,_TAX\-'!1E^OVS/L@RMU^G33^R#FV_Q+_-00Q&V
MFJ(FX)P]\4CSU?T\#7 O*_8,5?Y<$Z3\83FPUL?+.<GVR:E#**W0Z>!NKSNR
M$%*^>W_#"<H+DJ+-&N4S[+:\_P-%Q1V9+)<9>:2K-(TG\1]4+6%0:WO14=M=
M=WB=_X9/2YRR!;...#X-G_-]L-\HD&,TH4('>D0QQ?8M9$^@4_FB=O_H^!-]
M=G\?B/@U06#5+OT."E_F:K>KWXI$?^\?537>8E1U?^\=U0T+NA?X>??^9@:-
MD*&:OYKU-"?\0[M7"G=O,*SBEZY0,9W=A4\B_[-6([8>/?(/8GG/Y]"3WOM$
MZ;:1]Y<H?5S^+>\G]WYRD2MG7X@B"FEF[+V&;EX^*_A!9P7WZ2+EZ2+A]C)7
MZ)"[_P7:Z-@[+STC)#:!L7OVY?T66VC&WF\-=[[/J>QS*O<?]C+:_,$^[*4^
M<643'^H!Q;^T<5H<4$2,"9=5?]OT8.GLQ?/9WUX_3!X;!3N 21I_4BB=<!4P
M+>XDTFWG@@,3-OX<N/I!)_8B(X^"B*0L<I-6P*VSBD&;LQ#WJ(7,ASD>7&8Q
M 52^USV0A&Y-IRC#CR%;PQ/^F%5^BI*0G@WHA)19O2.U31,]@V^&URA$?CVG
M!;FB^B9@\YG9%KNHD0XZ\!LF25CEMY^=(XJ +B84E1DNZ.9X&7Z7S _-JKU'
M/UW2#\^K/.94)A$$98D+&<8G# " %#6;IX+D^<GFS'R^0M]/DA O\G.J>ZV2
MRK[J@D9-GT_!YU/P<2(^3J2M+TRRKQ.=/77L7,"<P:I3<.QN,<",:"S!C-V#
M"N1&5_H?N\^P UKD>L;8/8I=$2179OHS,X^&):4M8.R[LTGW_$ W8>^>;^&
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M4B:Z,;L0_OZG9[D?'_4)<81;\BH\6!/%9%]^%*:*I@%S70AUW13JYY)N?A0
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M[T+39 PH9GUD%X]0?OI )I>IO2DW7!\?V-'EX 0NE, )15<*I6]0.C<WJ;)
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M_DML:Y'76 V\YL>MF6W'E>,">CL!W=E60&^%GW6*74YJ_5DN85UI>YCNM%A
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MR&I++I2W;>T[L=GJ'$:A5BU]K-S(2BH.L:FMEA^RFF>7$B#K( E;%=I1*U3
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MQ:E* BJDOU6A&>:^[D>U#&]@E@G=+TIN(\Y,@'"'F]5(H)R,BB+M-^PM.(G
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M51>6WN^9Y/A:F*G-N3>V5)\^'%Q*M_*Q#DZ2C?'6Y1'"=_.Y4<<IBR5!G:M
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MU8T/.]8*.I=_IA[5',YK(G>R\8@91Z:7HPK.$:B"7M_N06>XN=K18>&N9.7
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M_"GV0CT](I(#F@W<B0=Q\;U"1)+# 02J:/MAV*FR_[GCB5X0PK<NP]"A+?5
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M E[E4J4L:R1, QZ0 9!6K^^/,B[)W8,4C"O[ZHFCXK-6*TL8!HU9 H, 5EO
MB&-$N7KPJ)\N*DR2.[^PA\-%D'!LN#HVVV*[MB3(+2-(X&4*F!P#WSH')D<_
MB'5N.3.B:20LN\"A$M/J6>%$> K8=['\_0HU2X)G%78)CT0Z&W;GP<;#$<+@
M#[!2- .Y$9Z/5EM)?=M'?:B*RX#@IQ'?.<>W?#$R*7GCD*,@#/&GJ!6V$=C/
MEW9FMRHG00C'XE\'&FI:8O8!@;TI>'6J-R,H[)*<MHR<K@M.&HD$^0,C7@W
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M\@:B*""IZW60/6(*I589,9G4.$ H_=GD02&V-A;1=##JDFJ4L\EPA&ME3%"
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MPB2J_^HX;HI!Y<I*+(+=:_S4V,_WQPFS_$7VMGPWX)7WH0) -!DIJKC%O'X
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M<\4FV1@M 5[6NKB]6W["!SSABC*').:AT23U^>K9;BL3F? KL7O?N8E"4.7
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M*K[*4@L),0)=D1H<P.XE-T%AC&B8GFU3K?FXAT"_2(BM9A05[1,$=7[##B)
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M#?(7 J^R-3Z0NJY",ZTH3YV'7Y)2*'B!65BJ#%WWJ>.VE?!."\ FK8F47^T
M 74D."0+_H6B!1A[I&H6Y.I"X<2!HZF8 3T$5D6_%7Y@#+P8/P+4+-$'B-]3
MJ0$KRC&EG ?.CZ+FL%0R7#>FM99K5J%!D\^%AD)Q"U"G"7!&<GWB $&PFG2P
M@B(@812.[_V\\==?W@9<P!1709^5UPN>V1&_G,'==^#&$[4D8OH/9&]^FI=-
M@2\"_?>):>Z<.$?48%AE;U[ZR=>UH;JJ=Z]*Y0-*&27,M!6)PCC^/(,OAON
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M4Q/+CH.4&!@%*>4F"=,@1"G'Q"EXL ^4XD=CS-C&I._$U+Q"K5 .3)?L1*:
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M+FIP9U!+ 0(4 Q0    ( '1*9U=4V;"()S@  %L_   *              "
M 2X- @!C87-S,#$N:G!G4$L! A0#%     @ =$IG5Z8_[".S2@  8E    H
M             ( !?44" &-A<W,P,BYJ<&=02P$"% ,4    " !T2F=7><]B
M($OH  #Y%@$ "P              @ %8D ( 8VAA<G1?,BYJ<&=02P$"% ,4
M    " !T2F=7->,I>F0(  !E-P  #0              @ ',> , 97A?-38V
M-#<W+FAT;5!+ 0(4 Q0    ( '1*9U?+YZEM/P@  -HU   -
M  "  5N! P!E>%\U-C8T-S@N:'1M4$L! A0#%     @ =$IG5Y!<"*YX!0
M_!T   T              ( !Q8D# &5X7S4V-C0W.2YH=&U02P$"% ,4
M" !T2F=7T*K.JB,-  !TG0  $0              @ %HCP, <V%V82TR,#(S
M,#DS,"YX<V102P$"% ,4    " !T2F=7YO1%.-T(  "E=0  %0
M    @ &ZG , <V%V82TR,#(S,#DS,%]C86PN>&UL4$L! A0#%     @ =$IG
M5QF9_:2K+@  1@X$ !4              ( !RJ4# '-A=F$M,C R,S Y,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( '1*9U?+FRN7#ST  'IR P 5
M  "  :C4 P!S879A+3(P,C,P.3,P7VQA8BYX;6Q02P$"% ,4    " !T2F=7
MU^[_C2,Q  #X9P0 %0              @ 'J$00 <V%V82TR,#(S,#DS,%]P
M<F4N>&UL4$L! A0#%     @ =$IG5T",4UFG$@$ 8A(- !0
M ( !0$,$ '-A=F$R,#(S,#DS,%\Q,'$N:'1M4$L%!@     /  \ A0,  !E6
$!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
